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ABSTRACT
Glycans are present on the cell surface of mammalian cells. In Dr. Iyer’s laboratories, we
aim to understand the interactions of cell surface glycans with toxins and pathogens at a molecular
level and use that information to develop a point of care diagnostics. This thesis primarily focuses
on the development of new technologies that could potentially be further developed towards the
point of care diagnostics.
Chapter 1, the introduction chapter focuses on the biosensors, different recognition
molecules, various reporters, techniques, testing parameters used in biosensors and point of care
testing (POCT).
In chapter 2, the focus is on the development of a novel electrochemical assay that uses
repurposed glucose meters for the detection of different analytes. Glucose meters have been used
primarily for the detection of blood glucose. The Iyer group has been developing substrates for
enzymes that release glucose when exposed to the enzyme. The released glucose can be detected
using personal glucose meters. While previous research represents a significant advance, one
major concern is that of background glucose present in blood and other matrices. To eliminate the
effect of background glucose, we have developed an electrochemical assay to detect other
molecules such as paracetamol or catechol in the presence of large amounts of glucose. The strips
used for the assay were devoid of glucose oxidase or glucose dehydrogenase, and hence, glucose
cannot get oxidized and will not pose a problem. The paracetamol/catechol gets oxidized directly
on the surface of the strips and can be detected directly making the assay more robust. This assay
was used to detect enzymes, influenza viruses, S. pneumoniae, and E. coli.
The novel assay uses non-glucose bearing sialic acid substrates. The non-glucose analyte
is released when exposed to viral NA or intact viruses. The released non-glucose analyte can be
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detected using repurposed glucose meters. Thus, personal glucose meters that were designed to
assist diabetics and prediabetics monitor blood glucose can potentially be used to detect pathogens.
In chapter 3, the focus was on the detection of influenza virus using an immunoassay-based
detection method. For the immunoassay-based approach biotinylated bivalent Zanamivir analogs
as probes for influenza viruses were designed and synthesized. The compound was used in a
“glycan” based sandwich assay; where glycans were immobilized on glass slides to capture strains
of Influenza A H1N1, A/Brisbane/59/2007 virus and the biotinylated bivalent Zanamivir analoglabeled streptavidin complex was used as a reporter. This study indicated that glycans could be
used for capturing and reporting influenza viruses and the biotinylated compounds could be used
as probes for capturing and isolating influenza viruses from complex mixtures.
The work in chapter 4, we expanded the innovative concept described in chapter 2 to
develop assays for blood disorders. As a first step towards this goal, synthesis of peptide substrates
bearing electrochemically inactive molecules are required. In this chapter, the synthesis and
characterization of novel catechol bearing substrate is described. We have designed a substrate
that can directly measure the amount of thrombin in blood and the doctors can use this to adjust
the dosage of anti-coagulants prescribed for high-risk patients. These compounds will be
eventually used to develop assays that could potentially be used to monitor oral anticoagulant
therapies and patients taking recombinant blood coagulation factors.

INDEX WORDS: electrochemical detection, glucose meter, paracetamol, glycosidase, influenza,
E. coli, assured diagnostics, point of care detection.
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CHAPTER 1
1. INTRODUCTION
1.1

Biosensors

Biosensors can be thought of a sensing device that uses a biological agent. In the past,
biosensors were considered to have only two components, first a biological agent capable of
recognizing the analyte or changes in the analyte and second the transducer which converts the
change into a measurable output. However, with advances in the biosensor field, sample
preparation and output are also considered as unique parts of the biosensor. Some of the steps of
the sample preparation involve filtration, centrifugation, selection using magnetic beads, etc. as
shown in Figure 1. Biosensors can be designed to detect a plethora of biological parameters like
enzymes, nucleic acids, antibodies, pathogens and changes in environmental conditions like
changes in pH. A successful biosensor should be highly sensitive and selective towards the analyte
to be detected, be independent of matrix effects and temperature and other environmental factors.
The signal output should be accurate, reproducible and linear under a significant analytical range
of the analyte. Potential applications of biosensors span from medical diagnostics, drug
development, environmental sample monitoring, food industry, industrial waste control, defense,
and security.
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Figure 1. Different components of a biosensor

1.1.1 Economic impact
The field of biosensors is rapidly growing with new advances every year with an annual
growth rate of ~ 9%. The estimated market for biosensors field is around 16.7 billion worldwide
and is projected to double by 2022. Within the broad field of diagnostics, Point of Care (POC)
testing occupies a niche subfield that has stringent requirements ( discussed in detail later) and is
expected to remain the largest application area for Biosensors reaching a projected US$11.5
billion by 2022 growing at a rate of 8.1% between 2017 (Figure 2) and 2022.2

2

Global clinical diagnosis market
(2017)
17.70%
45.20%

13.10%

24%

POC testing

Diagnostic centre

Research labs/Hospitals

Other testing facilities

Figure 2. Global clinical diagnosis market share 2017
Adapted with permission2
1.1.2 History of biosensors

It has been well accepted that Professor Leyland Clark is widely regarded as the father of
biosensors. In 1956, Professor Leyland Clark published a paper describing an oxygen electrode
that measures oxygen concentration in blood. In 1962, at a New York Academy of Sciences
symposium, he first elucidated the concept of biosensors where the first glucose sensor was
described. He entrapped glucose oxidase enzyme on the Clark oxygen electrode using a dialysis
membrane and then used this setup to measure glucose. This experiment led to increased research
in this field where enzymes were immobilized onto electrodes, and the electrodes were
transformed into powerful analytical tools which can be used to measure a variety of biological
parameters. This laid the foundation for biosensor research.3
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1916
1922
1956
1962
1969
1970
1972
1975

1976
1980
1983
1984
1985

1987
1990
1992
1996
1999
2018
2022

First report on immobilization of proteins: adsorption of invertase on
activated charcoal
pH electrode was developed
Invention of Glass electrode by Clark
Amperometric biosensor for glucose developed by Clark; First
description of biosensor
Potentiometric biosensor: urease immobilized on ammonia electrode to
detect urea
Invention of Ion Selective Field-Effect Transistor (ISFET) (Bergveld)
First commercial biosensor: Yellow spring instrument develops glucose
sensor
Divis first developed a microbial biosensor, detecting bacteria by
measurement of alcohol.
Invention of pO2/ pCO2 optode: a fiber-optic sensor by Lubbers and
Optiz
Glucose biosensor was integrated with artificial pancreas and marketed
by Miles
Fiber-optic pH sensor was developed for in vivo blood gases
Surface Plasmon resonance (SPR) immunosensor was developed
Use of electron mediators: Ferrocene was mediated with glucose oxidase
for detection of glucose
Roche (Switzerland) introduced the Lactate Analyzer LA 640 in which
the soluble mediator, hexacyanoferrate, was used to shuttle electrons
from lactate dehydrogenase to an electrode
Launch of MediSense ExaTechTM blood glucose biosensor
Launch of Pharmacia BIACore SPR based biosensor system
i-STAT launches handheld blood analyzer
Glucocard launched
Use of quantum dots, nanoparticles nanowires, nanotubes, etc in
biosensors
Biosensor market globally accounts for $ 17 billion
It is projected to grow to $25 billion with a robust growth rate of 9%

Table 1. History of Biosensors3,5,7
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1.2

Classification

While a biosensor can be defined in several ways, a biosensor can be typically classified
using 3 major parameters

i.

Based

upon

the

bio-receptor

interaction

involving:

antibody/antigen,

enzymes/ligands, nucleic acids/DNA, cellular structures/cells, or biomimetic
material, etc.
ii.

Based upon the bio transducer: electrochemical, optical, piezoelectric,
thermometric, magnetic, micromechanical, etc.

iii.

Based upon the mode of use: point of care, high throughput.

1.2.1 Bio-receptor interaction
Some of the significant biorecognition molecules are presented below.
1.2.1.1 Antibody/antigen interaction
There are several biosensors that use the antibody/antigen recognition element. The
dissociation constants for antibodies are low around 10-9M, which results in an irreversible
complex formation. An example of a commercially available antigen/antibody-based device is the
pregnancy kit. These types of ELISA based immunosensors are very robust and are used globally
for the detection of a variety of diseases like Malaria, HIV, STDs.5 However, despite their
prevalence in biosensors, there are various drawbacks for using antibodies as biorecognition
element in biosensors due to their high molecular weight, low stability and presence of disulfide
bonds which makes it very difficult to handle. One way to overcome these include the use of
engineered recombinant binding fragments like Fab, Fy scFv or VH or VHH domains. Another
approach involves the engineering of small families of antigen binding proteins (AgBP), which
5

are approximately 100 amino-acid residues which are more stable, disulfide bonds and these bind
specifically to a specific antigen. These molecules are selected using techniques such as phage
display, ribosome display, yeast display or mRNA display.6-10

1.2.1.2 Enzymes/ligands
Enzymes are a very popular bio-recognition element for the development of biosensors
owing to their specificity. The most successful biosensor is the glucose meter, which uses an
immobilized enzyme and an electrochemical output. Almost 80% of the biosensors market is
captured by glucose meters. Glucose meters use glucose oxidase or glucose dehydrogenase for
the detection of glucose. The main reasons for the high use of enzymes are mainly the catalytic
power of enzymes, it can catalyze many reactions, it can detect different types of analytes, can be
used easily with various transducers and mainly since the enzymes are not consumed, it can be
used continuously for a longer time. If enzymes are used as a bio-recognition element, lower
limits of detection can be easily achieved. However, one of the drawbacks, however, is that the
lifetime of the sensor is dependent on the stability of the enzyme.10-15
1.2.1.3 Nucleic acid interactions
Biosensors that employ nucleic acid interactions are referred to as genosensors. The
recognition process is based on the principle of complementary base pairing property of
adenine: thymine (A-T) and cytosine: guanine (G-C). Typically, a complementary sequence to the
target sequence is synthesized and immobilized on the surface of the sensor. If the analyte contains
the complementary target sequence, the binding event triggers a change which is detected by the
transducers and converted into a readable output. The popular, readable outputs for nucleic acidbased sensors is either optical or electrochemical.4, 7, 10
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1.2.2 Transducers
There is an alternate method of classifying biosensors i.e. by their transducers; the
transducers are the detecting or the sensing element of the biosensors. The actual definition of a
transducer is a device that converts one form of energy into another. Therefore, the transducer can
detect a perturbation in the chemical, electrical or physical environment of the analyte and convert
that change into a readable output. The biosensors can be divided into the following based on their
transducers:

1.2.2.1 Electrochemical sensors
These types of sensors are based on redox chemical reactions. They use current flowing
through the system (amperometric), the difference in electrical potential between the two
electrodes (potentiometric) or change in the conductance (conductometric) of the system due to
the presence of the analyte to quantify the amount of analyte. These are fast and highly sensitive
can detect sub-nanomolar or lower concentrations of the analyte. Another significant advantage is
that it can measure samples which are turbid/opaque and provide a quantified output. One of the
most successful biosensors, i.e. the glucose meters fall in this category.4-7
1.2.2.2 Optical sensors
These biosensors employ parameters like light absorption, fluorescence, luminescence,
reflectance, Raman scattering and refractive index to quantify analytes in a sample. Fluorescence
is one of the most measured optical parameters. There are several advances in the detection of
fluorescence and sensors that can detect intensity, decay time, quenching efficiency and
luminescence energy transfer. These optical sensors have been automated and can detect thousands
of samples in a day. Surface Plasmon Resonance (SPR) based sensors are also widely applicable.
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This is a label-free flow-based technique exploiting electron charge density waves called
plasmons. These plasmons are generated when light strikes an electrically conducting surface at
the interface between two media. The resonant angle of these waves depends upon the refractive
index of the medium, this, in turn, is dependent upon the local mass density of the surface. When
the surface of the sensor is modified by the capture of the analyte by the antibodies on its surface,
it changes the resonant angle. This change in the resonant angle can be quantified to the
concentration of the analyte.15-16
1.2.2.3 Piezoelectric sensors
These are sensors that can measure small changes in the mass, the principle of these sensors
relies on the use of piezoelectric materials that can be made to oscillate at a specific frequency by
application of electric signals. The frequency of the oscillation is dependent upon the mass and the
frequency of the electrical signal. When the mass of the crystals changes due to binding with the
analytes that change in mass is directly related to the amount of analyte in the sample. The
piezoelectric immunosensors have been very successful in the detection of HIV in samples.14
1.2.2.4 Thermometric/ calorimetric sensors
These sensors involve the measurement of heat that is generated in an enzymatic reaction.
It utilizes thermistors that transform heat generated (or lost) during a reaction into an electrical
signal. Examples of these types of sensors include enzyme thermistor, thermal enzyme-linked
immunosorbent assay, Isothermal calorimetry-based assays, etc.

8

Global biosensors market share (2016)
4%
9%
23%
55%

Electrochemical sensors

Optical sensors

Thermal Sensors

Piezoelectrical sensors

Figure 3. Global biosensors market share 2016.
Adapted with permission.2
The global market breakdown for these sensors is provided in Figure 3.
1.2.3 High throughput detection technology
Another way that biosensors can be classified is based upon their instrumentation. High
throughput screening techniques for biosensing technology is equipped to screen a large number
of analytes via the methods of automation, multiplexing and involves large-scale data analysis.
These are highly sophisticated high-throughput machines capable of automation that is rapid,
accurate and can measure a huge number of samples in a single day. These technologies are usually
highly expensive and require highly skilled professionals to use. High throughput detection is
mainly useful when the sample contains many non-target micro-organisms and other matrix
effects, which imparts, low specificity and poor detection limit to a biosensor. 16Thus, there is a
need for integrated processes that is able to non-selectively concentrate the target analyte
(amplification techniques like PCR, etc) or separate the target analyte from the non-specific sample
matrix using filtration or employment of antibody-coated paramagnetic beads. These integrated

9

processes also possess the multiplexing capability. Multiplexing is an ability to detect huge number
of analytes simultaneously using either a number of labels at the same time for detection while
using a multichannel detector to detect the various analytes (Label multiplexing) or by the use of
a large number of immobilized probes on separate sites detected using a single channel detector
(Spatial multiplexing). Examples of this include the microarray technology.17-20 The main success
of the high-throughput technology is the ability to detect thousands of targets in a single assay and
is being increasingly used by the pharmaceutical community to isolate potential drug targets. Some
of the most successful HTS techniques are discussed below:
1.2.3.1 Microarray technology
Microarrays consist of a collection of analytes immobilized onto solid support so that each
unique analyte forms a tiny feature, called a ‘spot’ or ‘target.’ These target analytes are then
analyzed using a probe which after recognition gives out an output. Multiple microarray platforms
exist, including printed glycan arrays, protein arrays, double-stranded DNA and oligonucleotide
arrays, in situ-synthesized arrays, high-density bead arrays, electronic microarrays, and suspension
bead arrays. Basic features of a microarray include an immobilized probe onto a solid support
using mainly a chemical reaction in a distinctive pattern as spots. Thousands of probes can be
immobilized on a single microarray plate. The unknown target is fluorescently labeled and then
hybridized with the probes. The hybridization of the probe and labeled target leads to an increase
of fluorescent intensity compared to background and then measured using a fluorescent reader. 21
1.2.3.1.1 DNA microarrays
The principle for DNA microarray is a hybridization between the two strands of a DNA. A
single strand of DNA (cDNA), oligonucleotides, etc are immobilized on the solid support, and
fluorescently labeled targets are added. The hybridization of the complementary sequences results

10

in the increase of fluorescence intensity compared to the background. DNA microarrays are
quantitative. The fluorescence intensity of the probes can quantitatively determine the amount of
hybridization or the DNA. DNA microarray technology can be used for comparing genomic
hybridization, i.e. for assessing genome content in closely related species, gene expression
profiling, by measuring the expression level of thousands of genes in samples exposed to different
pathogens or after undergoing several post-translational modifications or at different stages during
disease prognosis.17-18
Affymetrix GeneChip is one of the successful DNA microarray platforms that are
commercialized; these can be used for gene expression profiling, whole genome transcriptome
mapping, etc.
Manufacture of GeneChip probe array
The GeneChip array is a 5 square inch wafer which is immobilized with DNA samples. At
first, the wafer is modified covalently with a silane reagent, to get a surface layer of hydroxyalkyl
groups. Next linker molecules with photo-labile protecting groups are then attached to these
hydroxyalkyl groups. This layer now can be spatially activated by light. A photolithographic mask
set is next designed which contains the array design and pattern to immobilize the probes at a
specific position by either permitting or preventing the transmission of ultraviolet light. This
ensures the oligonucleotide synthesis at precise locations of the quartz wafer thereby creating the
microarray. Ultraviolet light removes the protecting groups at defined areas, and a single
nucleotide is washed over the deprotected groups and undergoes coupling. This deprotection and
coupling step is repeated until specific full-length probes (25-mers) are immobilized at specific
regions of the quartz wafer. Using algorithms for designing the photolithographic mask ensures
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that significantly less than 100 deprotection-coupling cycles are needed to synthesize the 25-mer
sequences. 15

Figure 4. GeneChip array probe with DNA microarray.
Reprinted with permission14
GeneChip array analysis
The nucleic acid containing the target sample/analyte is selectively amplified and then undergoes
reverse transcription and labeling of the sample. The labeled sample is injected into the GeneChip
probe array and allowed to hybridize overnight. The stained array then is analyzed using
Affymetrix GeneChip scanner, which reads the fluorescent intensity at each spot. To analyze the
fluorescent readout two types of probes are used i) perfect match probe (PM), this probe has a
complete complementary sequence to the target sequence ii) mismatch probe (MM) probes with a
single mismatch to the target. Another set of probes are present which bind to the specific
biotinylated oligonucleotide sequence added to the target labeled sample; these serve as controls.
Based upon the fluorescent intensity pattern for each of the probes in the array the data is analyzed
to give the gene expression studies, Single nucleotide polymorphism (SNP) profiling, gene
mapping etc.14-17
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Figure 5. DNA microarray analysis using Affymetrix GeneChip
Reprinted with permission15
1.2.3.1.2 Protein/peptide microarrays
Protein microarrays were developed in early 1980 for profiling antibody-antigen
interactions. They are now used for proteomic analysis. Protein microarrays have demonstrated
numerous applications for studying biomarker discovery, protein-protein interaction, proteinligand profiling, kinase activity and posttranslational modifications of proteins. Recently protein
microarrays have been widely applied as a promising proteomic technology with great potential
for protein expression profiling, biomarker screen, drug discovery, drug target identification and
analysis of signaling pathways in health and disease. Based on the different detection techniques,
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protein microarray detection techniques can be also classified as being label-based and label-free.
The labeling strategies, such as fluorescent, chemiluminescent and radioactive labeling, have
synthetic challenges, multiple label issues and may exhibit interference with the binding site and
high background interference. Therefore, development of sensitive, reliable, high-throughput,
label-free detection techniques is now attracting significant attention. Label-free detection
techniques monitor biomolecular interactions and simplify the bioassays by eliminating the need
for secondary reactants. These techniques include surface plasmon resonance mass spectrometry
(SPR–MS), backscattering interferometry, UV fluorometry, surface enhanced laser desorption
ionization time of- flight mass spectrometry (SELDI-TOF-MS), etc.14, 20-25
1.2.3.1.3 Glycan microarrays
The glycan microarray was first developed in the early twenty-first century for high
throughput detection of glycan-binding proteins (GPB) and investigation of the biological role of
glycans. The glycan microarray analysis has become one of the most sought-after detection
strategies for host-pathogen interactions. Infectious diseases mainly use a cell surface glycan to
gain entry inside the cell and subsequent invasion and immune response. The use of glycan
libraries to detect and characterize pathogenic GBP is highly predominant. The arrays are created
by immobilizing carbohydrates that are either derived from natural sources or obtained by
chemical synthesis. The immobilization methods include non-covalent methods involving
nitrocellulose and oxidized polystyrene using hydrophobic adsorption methods or by using
covalent ligation methods like thiol coupling, cycloaddition, amine-functionalization, maleimide
functionalization, etc. The detection of the target can be done using labeled or label-free ligands.2425

The labeled ligands include fluorescently labeled lectins and antibodies. Labeled streptavidin–

avidin interactions are also used for binding and further structure elucidation of the glycan. The
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label-free methods for glycan microarray include Surface Plasmon Resonance and Mass
Spectroscopy. The glycan microarray technology has been used to detect infectious pathogens
such as influenza using Hemagglutinin (HA) which bind to glycans containing sialic acid. The
different serotypes of HA bind to the sialic acid-containing glycans differently enabling the
profiling of influenza HA based upon the binding patterns.27 This binding information has led to
the development of several vaccines and other novel methods of therapy and detection. This
method has also been applied to other pathogens where HIV-antibody 2G12, GPI from
Plasmodium falciparum, isolated glycans from Schistosoma mansoni, Closteridum diffile has been
investigated to determine promising glycan based epitopes.28
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Figure 6. Glycan microarrays, generated by different strategies, used for detection of a binding
pattern of pathogens or antibody using fluorescent intensity
The figure is taken from the publisher with permission.23
1.2.3.1.4 Polymerase chain reaction
Polymerase chain reaction (PCR) is a highly sensitive and specific technique that can
amplify and produce millions to billions of copies of a gene of interest in a very short amount of
time. These gene copies can then be further analyzed for sequencing, cloning, and further analysis.
An added advantage of qRT-PCR over PCR is that qRT-PCR can quantitatively measure the
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amount of gene sequence and can be used to measure the gene expression levels in tumors or
amount of gene present in a certain analyte containing a microbe, bacteria or viruses.
The advent of new strains of an infectious virus or detection of uncultivated pathogens or
specific diagnosis of a certain pathogenic strain can be easily done using PCR methods. Owing to
the high level of sensitivity of PCR, detection of the viruses can be done at very early stages of
infection thereby giving physicians enough time to mitigate the disease. Using qRT-PCR, it is also
possible to measure viral load and monitor and adjust the dosage of treatment. This is a very
important part of the HIV treatment regime where the dose of the anti-retroviral drugs are adjusted
according to the levels of viral load in blood.29-30
The essential components of a PCR include
i)

Template DNA: Template DNA containing genomic DNA sample from a
patient can be used in the single or double-stranded form. Closed circular DNA
templates are amplified slightly less efficiently than linear DNAs. Ideally, PCR
requires only a single copy of the target sequence as a template for the
amplification.34

ii)

Oligonucleotide Primers: A pair of synthetic oligonucleotides should be short,
single-stranded, and complementary to the target. Standard reactions contain
0.1 - 0.5μM of each primer, which is sufficient for 30 cycles of amplification.
Higher concentrations of primer increase the chances of mis-priming and may
lead to non-specific amplification.35

iii)

Thermostable DNA polymerase: A thermostable DNA polymerase, which can
withstand the denaturation temperatures (94-95 ºC), is essential to catalyze the
template-dependent synthesis of DNA. Earlier, Klenow fragment of
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Escherichia coli pol I was used17. However, this enzyme being unstable at high
temperature, had to be added after every denaturation step. Now DNA
polymerase, Taq DNA polymerase isolated from thermophilic bacterium
Thermus aquatics which is stable even at higher temperatures are used.
iv)

Deoxynucleoside triphoshates (dNTPs):

•

dCTP, Deoxycytidine triphosphate

•

dTTP, Deoxythymidine triphosphate

•

dATP, Deoxyadenosine triphosphate
dGTP, Deoxyguanosine triphosphate.

These dNTPs are available commercially and supplied as pyrophosphate free mixtures. These
dNTPs are utilized during the amplification steps of PCR to form the target DNA sequences.
Amplification of the target sequence involves the following three steps:
1.

Denaturation of the template at 950C heat.

2.

Annealing of the oligonucleotide primers to single-stranded target sequences.

3

Extension of the annealed primers using thermostable DNA polymerase.

Denaturation
The first stage of PCR involves denaturation to convert the double-stranded DNA sequence to a
single strand. For this process, higher temperatures are required the DNA sequences from their
complementary sequences. PCRs catalyzed by Taq polymerase, the process of denaturation is
carried out at 94-95 ºC, which is the highest temperature the enzyme can withstand for 30 or more
cycles without being damaged. During the first cycle, denaturation is carried out for 5 minutes to
ensure complete denaturation of the long molecules of template DNA. Higher temperatures may
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be required to denature templates containing higher amounts of G+C. In addition, longer the DNA
templates, greater is the denaturation time required.
Annealing
As the temperature is reduced, the single-stranded oligonucleotide sequences then combine to the
available complementary probes (primers) and become double-stranded sequences which can
undergo extension. The design of the primers is essential for successful PCR. Poor primer design
leads to high non-specific amplification of unwanted DNA segments. Annealing temperatures
range from 55-65 ºC depending on the primer sequence and length. The annealing temperature is
also critical. When a high annealing temperature is used the primers will not anneal properly and
the amount of DNA thus amplified will be too low for detection. At low annealing temperatures,
there is a high amount of nonspecific annealing. This results in amplification of unwanted
segments of DNA compared to the target sequence.35
Extension
DNA polymerase catalyzes the extension of oligonucleotide primers and thereby a new strand,
having sequences complementary to template strand is synthesized. The optimal temperature for
DNA synthesis may vary slightly depending on the DNA polymerase used. When Taq polymerase
is used, the ideal temperature for DNA synthesis is about 72-78 ºC. Taq polymerase can insert
about 2000 nucleotides every minute at this temperature. Leading to the formation of a very high
amount of amplified target DNA sequence.34,35
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Figure 7. Basic steps of Polymerase Chain reaction
Reprinted with permission 29
1.2.3.2 Surface Plasmon Resonance Spectroscopy
Surface plasmon resonance (SPR) was first demonstrated by Otto in 1968.19 Biacore® (GE
Healthcare) first commercialized the technology in 199019. Since then SPR has been widely used
for bimolecular interaction applications like binding studies, kinetic analysis of biomolecular
interaction, antigen-antibody interaction, etc.
When a plane polarized monochromatic light strikes the interface of two media one with a
lesser refractive index, then a part of the light is refracted and partly reflected in the same media.
But when the angle of incidence becomes greater than the critical angle, then all of the light is
reflected in the media, and no refraction occurs that is called total internal Reflection (TIR).19,20
SPR consists of a glass prism coated with Au film. This Au film contains free conducting
electrons which oscillate at certain frequency and are called plasmons. The plasmons confined to
the surface is called surface plasmons. These plasmons extend 500nm from the surface and are
referred to as the detection zone. When the incident angle of the light beam is larger than the
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critical angle, and it matches the resonant angle, surface plasmon resonance occurs. So when this
happens, the light is absorbed by the detector at a certain incident angle.21

Figure 8. Working principle of Surface Plasmon resonance
Reprinted with permission21
When there is a change in the composition of the surface Au layer due to any binding by
any target analyte then the resonance does not occur at the same angle of incidence, so there is a
shift in the resonance angle, and this is known as SPR shift. This shift in the resonance is directly
proportional to the binding incident with the analyte or the change in mass at the Au surface due
to binding.

Figure 9. Detection of binding events for Surface Plasmon Resonance.
Reprinted with permission21
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1.2.4 Point of Care (POC) technology
The growth of the population and as the burden of people at the hospitals and clinics
increasing day by day, there has been an urgent need for the development of rapid accurate robust
and easy to use devices at home. These are highly sought after in the health care industry as it
allows the de-centralization of medical treatment from hospitals to the patients, which is ushering
in a new change in the economic landscape of the diagnostic market. Point of care (POC) devices
provide real-time results which are fast, accurate, sensitive at the convenience of home.
Conventional analyses performed in a hospital or clinic are generally expensive, time-consuming
and require skilled professionals to perform them.
In contrast, POC systems are simple easy to use, affordable and can be used in a poor
resource setting, reducing the cost of analysis, and providing privacy of home. This type of devices
are also highly significant for developing countries where though the burden of the disease is high,
but they severely lack modern laboratory or fully automated and sophisticated medical testing
facilities and trained personnel. POC devices require little or no resources and can provide fast and
accurate results which helps a doctor diagnose and save thousands of lives every day in those poor
resource areas.
An immense effort is being made to design and develop POC devices for the diseases that
are of global health importance. The global market for point-of-care diagnostics is expected to
reach $27.5 billion by the end of 2018 at an estimated compound annual growth rate (CAGR) of
9.3% from 2013–2018.3 It is one of the most rapidly growing areas of research and development
and in the past 10 years several new POC devices have been introduced in the market. The design
of each POC is dependent upon the need of the user and the clinical setting, but some of the salient
features include portable, affordable and easy to use. More recently WHO has laid out specific
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design criteria and guidelines for the developers of POC devices and these are called as ASSURED
criteria. For a POC biosensor to meet all the ASSURED criteria it must be Affordable by the
people who are affected by the disease or the consumers who will buy the device or the sensor.
Sensitive, meaning false negatives should be minimal. Specific, the device should only test
positive for the desired pathogen or micro-organism hence low false positives. User-friendly, the
tests must be simple enough that it can be done in a low resource setting, out of a hospital or clinic.
Rapid and Robust, the test should ideally give a result within 15 minutes or less and should be
stable under different environmental conditions. Equipment free such that it does not require any
expensive machine for the output and can be stored in a very low resource setting. Deliverable to
the end consumers in a hassle-free manner. Meeting all these criteria is a tall order, and most often
there are trade-offs, but upon careful design consideration and proper optimization, these criteria
can be achieved.28 A comparison of the different tests available for Influenza virus is done based
on the ASSURED criteria by WHO in the following table (Table 2)
Several prospective label-free biosensors, such as electrochemical, surface plasmon
resonance (SPR), white light reflectance spectroscopy (WLRS), etc., have been developed, and are
being used for improved POC. Complementary technologies, e.g., microfluidics, lab-on-a-chip
technologies, system integration, device automation, and signal readout, are providing the desired
impetus for continuous improvements in POC.17There is also a huge unmet need for quantitative
and multiplex POC.
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ASSURED
Criteria
Affordable

No,
requires laboratory
equipment

Detection methods
Nucleic Acid
Fluoro/
Colorimetric
No,
No,
Cepheid and
an instrument
Biomeriux sell
costs
point of care
thousand and
system but cost
the reagents
thousands of
are
dollars.
expensive.

Sensitive

High

High

High

Selective

High,
can distinguish
between live and
dead virus.

Medium/Hig
h but cannot
distinguish
between live
and dead
viruses.

High, > 90%,
however, cannot
distinguish between live
and dead virus.

Rapid

No,
requires days.

60 minutes.

15 minutes

Robust

No,
requires several
reagents, which are
not stable
No, requires trained
personnel.

High,
however,
requires the
correct primers
and cannot
distinguish
between dead
and live virus
No,
sample
preparation
takes hours, but
newer systems
are integrated to
yield results in
1-2 hours.
Yes/No,
some reagents
may require
refrigeration
Yes/No, newer
systems are
becoming
simpler, but still,
require trained
personnel.
No

No, requires
refrigeration.

Yes/No,
depends on antibody
stability. May require
refrigeration
Yes

No

Yes

No,
requires space

No,
requires
space

Yes,
small footprint, portable

User friendly

Culture

Equipment
free

No

Deliverable to
end users

No,
requires a
laboratory.
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No, requires
trained
personnel.

Antibody
Yes,
however, cost varies.
Typical cost is ~ 18-20 $
per test. e.g., Quidel Flu
A&B test is 450 $ for a
pack of 25. However,
the cost of these tests is
coming lower.
No,
very low sensitivity (2080%), especially at low
concentrations.

Drug
susceptibility

Yes,
however, takes days

Yes,
however, takes
days

Yes,
but requires
hours

No

Table 2. A comparison of different tests for influenza virus based on the ASSURED criteria.

1.2.4.1 Lateral flow Assays
Lateral flow assays (LFA) are simple in-expensive POC devices that can detect the
presence of a target analyte in a sample matrix. These are commonly used for at home testing. One
of the most common and successful LFA is the pregnancy tests. Apart from the pregnancy tests,
Lateral flow assays determine various different infectious pathogens like HIV, Malaria, Influenza.
Some LFA based cardiac marker POC device was recently approved by the FDA.53-55 The Lateral
flow devices are very fast inexpensive and can be used in very low resource settings. These can
detect biological analytes in urine, saliva, sweat serum, blood, plasma, etc.
The principle behind the Lateral flow assay is capillary action. The sample containing the
target analyte moves through the test strip and interacts and binds at the site where the proteins are
immobilized. The binding of the target analyte to the immobilized proteins can be detected
optically.
The main components of a Lateral flow device are the following:
Sample application pad: The sample application pad consists of cellulose and/or glass fiber and
sample is applied on this pad. The sample application pad is to ensure the smooth transport the
sample to other components of the lateral flow test strip (LFTS). Sample pad should be capable of
transportation of the sample in a smooth, continuous and homogenous manner.
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Conjugate pad: The conjugate pad contains the labeled biorecognition component. The conjugate
pad releases the labeled when the solution moves through it. The conjugate pad is mainly made of
glass fiber or cellulose.
Nitrocellulose membrane: The nitrocellulose membrane is the most critical component of the
lateral flow assay. The sensitivity of the LFA is determined by the nitrocellulose membrane. The
control and the test lines are present on the LFA. The proteins are immobilized on the nitrocellulose
membrane, and the pore size of the membrane should be chosen very carefully based upon what
proteins need to be immobilized. The nitrocellulose membrane also should be treated properly to
avoid any nonspecific binding. The sensitivity of the assay is affected by the wicking rate of the
nitrocellulose membrane. Proper dispensing of bioreagents, drying and blocking play a role in
improving the sensitivity of assay.
Adsorbent pad: The adsorbent pad as the name suggests absorbs the excess solution from the
analyte while maintaining the proper flow rate and preventing any backflow. It is usually made of
cellulose.
All these components are fixed or mounted over a backing card. This backing card serves as a
support and makes the strip easier to handle.31

Figure 10. Different parts of Lateral Flow Assay (LFA).
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(Reprinted with permission from MDPI Journal)17

The bio-recognition element of the LFA is either antibodies (lateral flow immunoassay; LFIA) or
amplicons formed during the PCR (Nucleic acid lateral flow immunoassay; NALFA). The LFIA
is an antibody-based technique, specificity and sensitivity may be affected by other chemicals with
similar structures, leading to false positive results. The sensitivity of assays is limited by the Kd
(dissociation constant) of the antibody-antigen conjugate and by the colorimetric read-out. The
colorimetric labels employed for LFIA are usually colloidal gold nanoparticles it can be prepared
in the laboratory at low cost. It has an intense color and requires no extra steps for visualization.
The stability of the gold nanoparticles are high in both liquid and dried forms. Another promising
label is latex, it can be developed in multiple colors, and can be easily used in multiplexed format
Latex based labels can also be tagged with a variety of detector reagents such as colored or
fluorescent dyes, and magnetic or paramagnetic components. Fluorescent dyes or paramagnetic
particles cannot be detected directly by the naked eye and requires fluorescent and magnetic strip
readers. Quantum dots and carbon nanotubes have also shown potential as labels for LFA and has
also exhibited 10-fold lower detection limit than that of gold-based techniques. In recent years,
there have been major advances in LFA development.17,29 This includes novel signal-amplification
strategies, applications of new labels, improved quantification systems, and simultaneous
detection. Some of the new strategies used to enhance the signal from the colloidal gold
nanoparticles (GNPs) have adopted silver enhancement technology or combinations of GNPs with
an enzyme (such as horseradish peroxidase), which results in catalytic amplification of the signal.29
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1.2.4.2 Nucleic Acid-based assays:
Nucleic acid amplification is a precious molecular diagnostic tool for application-based
fields, such as clinical prognosis, infectious diseases diagnosis, gene cloning, and industrial quality
control. Polymerase chain reaction (PCR) was the first nucleic acid amplification method.
Further research led to the development of alternative nucleic acid amplification methods
such as loop mediated isothermal amplification (LAMP), nucleic acid sequence-based
amplification (NASBA), strand displacement amplification, multiple displacement amplification,
rolling cycle amplification (RCA). Mostly all these methods do not require thermal cyclers and
are isothermal based methods. In principle, they are much more complex and require several
different primers than that of PCR, but are faster, more sensitivity and can be used under low
resource setting compared to PCR.10,31-33
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Figure 11. Comparison of the different isothermal nucleic acid amplification methods.
Reprinted with permission.10
1.2.4.3 Electrochemical assays

Biosensors that use amperometric detection methods are gaining prominence since the
development of the highly successful ubiquitous glucose meters. Amperometric biosensors
involve the conjugation of enzymes and the electrochemical reaction for their output. Glucose,
hydrogen peroxide, lactate levels can be determined by using the enzyme coupled electrochemical
setup. The biggest success story of POC biosensors is glucose meters. Glucose biosensors account
for about 80% of the biosensor market.2

Diabetes is a worldwide public health problem, and currently, the diabetes patients are still the
leading driver of the POCD market. The diabetes patient needs to measure the blood glucose
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concentration levels several time one day. Glucose meters play a very important role in this
direction. The normal range of blood glucose is 80-120mg/dL. The insulin deficiency or
hyperglycemia results in higher or lower levels of glucose in blood than normal levels. Home
glucose monitoring of type 1 diabetes was first introduced in the late 1970s, and the first meters
were marketed for home in the year 1981. The two most predominant models available in North
America are Glucometer ones whose trademark is owned by Bayer and the Accu-chek meter
owned by Roche. Current models reflect several decades of innovation since their introduction in
the 1970s, both in terms of strip technology and in meter design. The overall goals have switched
to make them easier to use, with less potential errors, and to minimize the effects of matrixs9. Of
the many different types of strip that have been developed, all are electrochemical biosensors
incorporating an enzyme such as glucose oxidase (GOx) and glucose dehydrogenase (GDH). They
are often termed thick-film sensors because each strip is composed of several layers each with
designated functions such as separation, spreading or support.

Figure 12. Glucose meters for controlling and monitoring diabetes.
Reprinted with permission11
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1.2.4.4 Multiplexed POC devices or x-POCT:
Multiplexed point-of-care testing (xPOCT), involves simultaneous on-site detection of
different analytes from a single specimen. In recent years xPOCT has gained increasing
importance for clinical diagnostics, with ever requiring applications in resource-limited settings.
There has been tremendous research towards the development of xPOCT devices for the detection
of several diseases from one analyte, for point-of-care testing.35
It is highly desirable to screen various analytes simultaneously, enabling a rapid, low-cost,
and reliable quantification. Therefore, in the last decade, multiplexing has become crucial in the
POC testing. In this context, there is an unmet demand for xPOCT devices, which ensure the
quality and also can meet the ASSURED criteria by WHO. This will in future pave the way for
novel home health monitoring systems and add valuable information for personalized medicine.
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Figure 13. Multiplexed Point of Care Testing (x-POCT).
(Reprinted with permission from Sensors Journal)35
1.2.4.4.1 POC MDx devices available in market:
There exists a number of different commercial devices for the simultaneous detection of
several clinical parameters, including blood gases, electrolytes, or immunoassays (e.g.,
Radiometer AQT90 Radiometer, or acute metabolites (e.g., Abbott i-STAT system, Abaxis
Piccolo Xpress, or Nova Biomedical StatSensor), and Mitsubishi PATHFAST analyzer). Some
other xPOCT devices are Atlas io system, Cobas Liat, Alere I, Alere q Analyzer, Genexpert Omni,
Spartan RX, Spartan Cube, Film Array, PanNAT etc.38
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A

B

Figure 14.Multiplexed POC devices available in market.
Reprinted with permission15
A: Abbott i-STAT system; B: Cephid Genexpert Omni;
Some of the more relevant examples of POC biosensors are given in Table 3 and Table 4.
1.3

Summary

As described in this chapter, there are a number of biosensors available in the marketplace.
Some of these biosensors are used primarily in a laboratory environment, and some are used at
point of care settings. Despite a burgeoning market and major advances in the field, there is a
growing need for more accurate, inexpensive and highly accurate biosensors. Biosensors for early
detection of diseases and monitoring of diseases leading to personalized treatment is of paramount
importance. Individualized drug dosing based on patient’s response to drugs is more superior than
the current “one shoe fits all” approach. This self-monitoring strategy had precedent and been very
valuable for diabetic and pre-diabetic patients as daily testing leads to better glucose control
compared to once-a-quarter Ha1C testing.12 Similarly, monitoring several times in a day compared
to weekly or biweekly hospital visits will allow physicians to modify the drug dose and improve
personalized care. This type of personalized care also provides privacy which is critical for certain
diseases.
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The POC biosensors also reduce the morbidity related to a disease and allow the monitoring of
disease progression, response to therapy and post-surveillance tracking for a number of clinically
relevant enzymes, e.g. HIV viral load detection, oral anticoagulant therapy. etc. using glucose
meters at the comfort of home.
The approaches presented in the next 3 chapters represents potential methods to achieve
these goals.
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Table 3. Summary of Recent xPOCT systems38-43

Multiplexing
capability

Detection
Technique

System
flexibility

System
complexity

On-site
applicability

Commercially
available

Paper-based systems
μPADs

2 analytes,
extendable

Colorimetric readout by
naked eye

Low

Low

Yes

–

Triage

Up to 3 analytes

Lateral flow test with
optical detection

Low

Low

Yes

Alere Inc.

Yes

CustomArray
Inc.

Array-based systems
ElectraSense

Up to 12 544
analytes

Optical and
electrochemical
detection

High

Middle

Bead-based systems
xMAP

Up to 500
analytes

Flow cytometry

High

High

No

Luminex Corp.

GeneXpert Omni

Up to 6 analytes

Real-time PCR

Low

Low

Yes

Cepheid

OPKO
Diagnostics

Microfluidic multiplexed systems
MChip

Up to 5 analytes,
extendable

Colorimetric detection

Low

Low

Yes

DxBox

2 analytes,
extendable

Colorimetric detection

Low

Middle

Yes
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MultiLab

1.4

Multiplexing
capability

Detection
Technique

System
flexibility

System
complexity

On-site
applicability

Up to 8 analytes,
extendable

Amperometry
combined with stopflow protocols

High

Low

Yes

Currently available POC, Tabulated list: (Table-4)
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Commercially
available

Company

Product Name

Disease

Alere, Inc.

Clearview HIV ½
STAT-PAK

HIV

Alere, Inc.

Clearview
COMPLETE HIV
½

HIV

OraSure
OraQuick
Technolog ADVANCE HIVies, Inc.
1/2

HIV

Bio-Rad
Multispot HIV
Laborotori
es, Inc.

HIV

MedMira,
Inc.

Reveal G3 HIV-1

HIV

Trinity
Biotech
PLC

Uni-Gold
Recombigen HIV-1

HIV

ChemBio Chembio DPP HIV
Diagnostic 1/2
Systems,
INC

HIV

Format
Gold
labelled
Lateral
Flow Assay
Gold
labelled
Lateral
Flow Assay
Gold
labelled
Lateral
Flow Assay
Gold
labelled
Lateral
Flow Assay
Fluorescenc
e Lateral
Flow
immunoassa
y
Gold
labelled
Lateral
Flow Assay

Required Sample

Detection
time

Sensitivity

Specificty

Whole
15-20 mins
blood/serum/plasm
a5µL

99.7 (98.9100)

99.9(99.6-100)

Whole
15 mins
blood/serum/
plasma
2.5 µL
Oral fluid/whole
20 min
blood/Plasma 5 µL

99.7 (98.9100)

99.9 (99.6100)

99.6 (98.999.8)

99.9 (99.699.9)

serum/plasma
30 µL

20 min

100 (99.9100)

99.9 (99.8100)

serum/plasma
30 µL

<2 min

Serum-99.8
(99.2-100)
Plasma99.8 (99100)
100 (99.5100)

Serum-99.1
(98.8-99.4)
Plasma-98.6
(98.4-98.8)

99.9(99.499.9)

99.9 (99.799.9)

Whole
blood/serum/plasm
a
50 µL
Whole
immunochr blood/serum/plasm
omatographi a or oral fluid
c, in vitro
swab
test for
10 µL
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10 min

10-25 min
for blood
samples
25-40 min
for oral
sample

Approved
US FDA

99.8 (99.3100)

CLIA-waived

Company

Product Name

Disease

Format

Required Sample

Detection
time

Sensitivity

Specificty

the
detection of
antibodies
Alere

Determine HIV 1/2
Ag/Ab Combo Test

HIV (HIV 1
&2
antibodies
and HIV-1
p24 antigen)

Serum/Plasma/wh
ole blood
50 µL

Biolytical

INSTI HIV-1/HIV2 Rapid Antibody
Test
GenoType
MTBDRplus assay
GenoType

HIV

Plasma/whole
blood
50 µL
Pulmonary blood
sample (clinical)
or cultured
material
(solid/liquid
medium

Hain
Lifescienc
e GmbH

Tuberculosis
Detection of
multidrug
resistant TB

Line probe
assay
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20 min

99.9(99.4100)

99.9 (99.5100)
< 2 min
5h

“a limit of
detection of
160
bacteria/ml
was
determined
with both

Serum:
Low risk
subjects
100 (99.6-100)
High-risk
subjects
98.9 (97.799.5)
Plasma:
Low risk
subjects
100 (99.6-100)
High-risk
subjects
99.2 (98.299.7)
100 (99.7-100)

100%

Approved

Company

Product Name

Disease

Format

Required Sample

Detection
time

Sensitivity

Specificty

extraction
methods”
Cepheid,
Inc.

Xpert MTB/RIF
assay

Tuberculosis
Detection of
multidrug
resistant TB

Cepheid,
Inc.

Xpert MTB/RIF
assay ULTRA

Tuberculosis
Detection of
multidrug
resistant TB

Unimed
Internatio
nal
Alere, Inc.

FirstSign MTB test

Tuberculosis

Determine TBLAM Ag

Tuberculosis
(in HIV+
patients)

Automated
cartridge
based
nucleic acid
amplificatio
n test
Automated
cartridge
based
nucleic acid
amplificatio
n test
Serology
based POC
test
Urine LAM
test
Lipoarabino
mannan
LFA

Sputum sample

<2 h

<80 min

Urine

25 mins
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Per CD4
>98%
cell count,
sensitivity
changes:
>200
cells/µL 4%
<200 cells
39.0%
<150 cells
45.7%
<100 cells
51.7%

Approved

Company

Product Name

Disease

Format

Required Sample

Detection
time

Sensitivity

Specificty

Approved

<50 cells
66.7%

Alere

BINAX NOW

Malaria
Plasmodium
Ag

Alere

Panbio dengue Duo
Cassette

Alere/Abb
ott

SD Dengue IgG
capture ELISA

Alere/Abb
ott

SD Dengue IgM
capture ELISA

Dengue
Fever
IgM and IgG
(differentiati
on between
primary and
secondary
infections)
Dengue 1-4
(marker for
secondary
dengue
infection)
Dengue 14(early
diagnosis of
primary
infection)
Malaria

Orchid
Paracheck-Pf
Biomedica
l Systems;
India

LFA
Invitro
immunochr
omatographi
c assay
Immunochr
omatograph
y test
(capture
ELISA)

Whole blood (15
µL)

15 mins

Serum, Plasma,
Whole blood

3-5 days

****
P.
falciparum
99.7%
P. vivax
93.5%
Primary
85.1%
Secondary
98.8%

P. falciparum
94.2%
P. vivax 99.8%

91.6%

ELISA

98.8%

99.2%

ELISA

96.4%

98.9%

Immunochr Capillary Whole
omatographi Blood (5 ul)
c assay
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20 min

Not FDA
approved

Company
Becton
Dickinson

Product Name
ParaSight – F

Disease
Malaria

AmradICT Malaria PF/pv
ICT
Diagnostic
s
ICT
ICT Malaria PF
Diagnostic
s
Accu-tell
Rapid Malaria
Pf/Pv

Malaria

Access
Bio

CareStart Malaria
Pf/Pan

Malaria

Zephyr
Biomedica
ls
Span
Diagnostic
Ltd
MACRO
med
Manufactu
ring LTD
Omega
Diagnostic
s LTD

Parabank

Malaria

ParaHIT-F

Malaria

MAKROmed
Malaria Test

Malaria

Visitect Malaria Pf

Malaria

Malaria

Malaria

Format

Required Sample

Detection
time

Immunochr Capillary Whole
omatographi blood (50 ul)
c assay
(detects >100
parasites/ul)
Immunochr 10 ul
omatographi
c assay

Sensitivity

Specificty

Approved
Not FDA
approved

Not FDA
approved

Immunochr Capillary whole
omatographi blood or venous (5
c assay
ul)
Capillary whole
blood or venous
(10 ul)
Immunochr Capillary whole
omatographi blood (5 ul)
c assay
Immunochr Capillary whole
omatographi blood (5 ul)
c assay
Immunochr Capillary whole
omatographi blood (5 ul)
c assay
Immunochr Capillary whole
omatographi blood
c assay

15 min (>200
parasites/ul)

Not FDA
approved

15 min

Not FDA
approved

20-30 min

Not FDA
approved

20 min

Not FDA
approved

15 min

Not FDA
approved

<20 min

Not FDA
approved

Immunochr Capillary whole
omatographi blood or venous (5
c assay
ul)

15 min

Not FDA
approved
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Company

Product Name

Disease

Omega
Visitect Malaria
Diagnostic Combo Pan/Pf
s LTD
BIO-RAD DiaMed OptiMALIT

Malaria

Cellabs

Malaria

Malaria-Ag
CELISA

Malaria

Zephry
Malascan
Biomedica
ls
PATH
PATH Falciparum
Malaria IC test

Malaria

Abbott

Determine Malaria
Pf

Malaria

Acumen
Diagnostic
s Inc
HUMAN
Diagnostic
s
SD
Diagnosic
s

DiaSpot Malaria

Malaria

Hexagon Malaria

Malaria

SD Malaria
Antigen Bioline

Malaria

Malaria

Format

Required Sample

Immunochr
omatographi
c assay
Immunochr
omatographi
c assay
Enzymelinked
immunosorb
ent
Immunochr
omatographi
c assay
Immunochr
omatographi
c assay
Immunochr
omatographi
c assay
Immunochr
omatographi
c assay
Immunochr
omatographi
c assay
Immunochr
omatographi
c assay

Capillary whole or
venous blood (5
ul)
Capillary whole
blood (10 ul)
Capillary, whole
blood or serum
(100 ul)
Capillary whole
blood (5 ul)

Detection
time

Sensitivity

Specificty

Approved

15 min

Not FDA
approved

20 min (>50100
parasites/ul)
2h

Not FDA
approved

20 min

Not FDA
approved

Capillary whole
blood (5 ul)

Not FDA
approved

Not FDA
approved

Capillary Whole
blood (2 ul)

30 min

Not FDA
approved

Capillary whole
blood (10 ul)

10 min

Not FDA
approved

Capillary or
venous whole
blood (5 ul)
Capillary whole
blood (5 ul)

15 min

Not FDA
approved

15-30 min
(>50/ul)

Not FDA
approved
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Company

Product Name

Zephyr
Biomedica
l Systems
Premier
Medical
Corporatio
n
Abbott
Technolog
ies

Parascreen Rapid
Test for Malaria
Pan/Pf
First Response
Malaria
(pLDH/HRP2comb
o test)
i-STAT analyzer
(BNP)

Disease
Malaria

Malaria

Cardiac
markers
BNP

Alere
Triage BNP test
Technolog
ies

Cardiac
markers
BNP

Response RAMP Myoglobin
Biomedica test
l Corp

Cardiac
markers
NT-proBNP
Acute
Myocardial
infraction

Format

Required Sample

Detection
time

Sensitivity

Specificty

Approved

Immunochr Capillary whole
20 min
omatographi blood (5 ul)
c assay
Immunochr Whole blood (5 ul) <20 min
omatographi
c assay

Not FDA
approved

Immunienzy
matic assay
with
electrochem
ical
detection
Two site
Fluorescenc
e lateral
flow
immunoassa
y
Two site
Fluorescenc
e lateral
flow
immunoassa
y

FDA cleared
for professional
use only

whole blood or
plasma (2-3 drops)

10 min

whole blood or
plasma or finger
prick

15 mins

whole blood

10 min
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Not FDA
approved

Cleared for sale
by FDA

Company

Product Name

Disease

Format

Required Sample

Roche
Cardiac Reader or
Diagnostic cobas h 232 system
s

Cardiac
markers
NT-proBNP

Portable/
Heparinized whole
two-site
blood or finger
gold
prick
labelled
lateral flow
immunoassa
y

LifeSign

StatusFirst CHF
NT-pro BNP

Congestive
Heart Failure

LFA

BTNX,
Inc.

Rapid response
CK-MB test

Myocardial
Infraction
Creatine
kinase
MB(CKMB)

LFA

BTNX,
Inc

RAPID
RESPONSE DDIMER TEST

Venous
LFA
Thromboemb
olism (VTE),
D-Dimer

Detection
time
8-12 min

Sensitivity
60 – 9,000
pg/mL
Cut-off
values:
<125
pg/mL =
Exclusion
of Nonacute heart
failure,
<300
pg/mL =
Exclusion
of acute
heart failure
<75-yearold 92.1%
>75 87.8%

Whole Blood,
Serum, Plasma

10 min

5 ng/ml

Whole Blood,
Plasma

10 min

500 ng/ml
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Specificty

<75-year-old
70.4%
>75-year-old
86.5%
Creatinine
Kinase MB

D-Dimer

Approved

FDA approved
for prescription
use

Company

Product Name

Disease

Format

Required Sample
Whole blood,
Plasma, Serum (75
µL)

Detection
time

Boditech
Med, Inc.

Ichroma CK-MB
test

Myocardial
Infraction
Creatine
kinase
MB(CKMB)

LFA

Trinity
Biotech.

Meritas Troponin

LFA

American
Screening
Corp

Instant View
Troponin

Myocardial
Infarction
Troponin I
Acute
Myocardial
Infarction
(AMI)

LFA

Whole Blood,
15-20 min
Serum 160-200 µL

CTK
Biotech

On Site PSA Rapid
Test

LFA

Whole Blood,
Serum, Plasma

Alere, Inc.

Alere NMP22
BladderChek

Alere, Inc.

Clearview iFOBT

Prostate
Cancer
Prostate
Specific
Antigen
(PSA)
Bladder
Cancer
Nuclear
Matrix
Protein
(NMP22)
Colon
Cancer
Fecal Occult
Blood

Sensitivity

Specificty

Approved

12 min

Not FDA
approved
>98%

95-100%

Invitro
Urine (4 drops)
immunoassa
y

30 min

99%

99%

Antibody
sandwich
assay

5 min

93.6%

99.1%
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FDA cleared
for professional
and
prescription
home use

Company

Product Name

Arbor
Vita Corp

OncoE6 Cervical
Test

Quicking
CA125 rapid test
Biotech
kit
Co., Ltd
Innovation AFP Test
Biotech

Roche
Alere

CoaguChek XS
Plus System
Binax Now
Influenza A and B
test

Becton
Dickinson
& Co

BD Veritor Flu A +
B

Quidel
Corp

Sofia Influenza A +
B FIA

Quidel
Corp

QuickVue
Influenza A + B

Disease

Format

Cervical
Cancer
E6
Oncoproteins
Ovarian
Cancer
CA125 Ag
Hepatocellul
ar Cancer
Alpha
fetoprotein
Ag
Coagulation
monitoring
Influenza A
and B
nucleoprotei
n antigen
based
influenza A
or B Antigen
based

Lateral flow

influenza A
or B antigen
based
influenza A
or B antigen
based

Required Sample
Cervical Swab

Lateral flow Serum
immunoassa
y
Serum/Plasma

Detection
time

Sensitivity

Specificty

Approved

2.5 hours

5 min

CLIA waived
Lateral
Flow Assay

Nasal Swab

10 min

chromatogra
phic
immunoassa
y
Lateral
Flow Assay

Nasal Swab,
nasopharyngeal
swab,

10-15 min

Nasal Swab,
nasopharyngeal
wash
Nasopharyngeal
swab, nasal swab

3-15 min
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<10 min

Influenza A
93.8%
Influenza B
77.4%

Influenza A
95.8%
Influenza B
98%

CLIA waived

CLIA waved

A 90-99%
B 88-90%

A 95-96%
B 96-97%

CLIA waved

CLIA waved

Company

Product Name

Disease

Format

Princetone
BioMedite
ch Corp
Princetone
BioMedite
ch Corp

BioSign Flu A & B

Lateral
Flow Assay

LifeSIgn
LLC

Status Flu A & B

influenza A
or B antigen
based
influenza A
or B
nucleoprotei
n antigens
Influenza A
or B
nucleoprotei
n antigens

OraSure

QuickFly Rapid Flu
A + B test

influenza A
or B antigen
based

Polymedc
o

Poly stat Flu A & B

LABSCO
Advantage Flu A &
B

ImmunoCard STAT influenza A
Flu A & B
or B

Detection
time

Sensitivity

Specificty

Approved

Nasal Swab,
nasopharyngeal
swab
nasopharyngeal
wash

10-15 min

CLIA waved

10-15 min

CLIA waved

LFA

Nasal Swab,
nasopharyngeal
swab,

10-15 min

CLIA waved

LFA

Nasal Swab,
nasopharyngeal
swab,

10-15 min

Nasal Swab,
nasopharyngeal
swab,

10-15 min

CLIA waved

Nasal Swab,
nasopharyngeal
swab,
nasopharyngeal
wash,
nasopharyngeal
wash
Nasal Swab,
nasopharyngeal
swab,

10-15 mi
n

CLIA waved

10-15 min

CLIA waved

influenza A
or B
nucleoprotei
n antigen
based
Sekisui
OSOM ULTRA Flu influenza A
Diagnostic A & B
or B
s
nucleoprotei
n antigens

Meridian
BioScienc
e

Required Sample

LFA
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A = 9798.4%
B = 93.294.4%

A = 94.2CLIA waved
05.8%
B = 93.5-100%

Company

Product Name

Disease

Format

nucleoprotei
n antigens

McKesson Influenza A & B
Consult
Tests
Diagnostic
s

influenza A
or B
nucleoprotei
n antigens

LFA

Remel/Th
ermo
Fisher
Roche

Influenza A
or B viral
antigens
Influenza
A/B
RSV
Strep A

LFA

XPECT Flu A & B

Cobas Liat PCR
System

ZeptiMetri ZeptoMetrix
x
Respiratoryh
Verification Panel

Alere

Binax NOW

RUO panel
(Influenza
A/B, RSV,
Adenovirus,
Rotavirus, &
negatives)
via nucleic
acids
Pneumonia
S.pneumonia
Ag

Required Sample
nasopharyngeal
wash,
nasopharyngeal
wash
Nasal Swab,
nasopharyngeal
swab,
nasopharyngeal
wash,
nasopharyngeal
wash
Nasal Wash

RT-PCR

Urine/CSF
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Detection
time

Sensitivity

Specificty

10-15 min

Approved

CLIA waved

10-15 min

<20 min

Influenza
A/B
100%Strep
A 98.3%
RSV = 97%

A = 96.8%
B = 94.1%
Strep A =
94.2%
RSV = 98.7%

15 min

Urine 86%
CSF 97%

Urine 94%
CSF 99%

CLIA waved

Company

Product Name

Disease

Format

Required Sample

Detection
time

Quidel
Corp

Quick Vue RSV
Test

Infantile
Bronchitis
Respiratory
syncytial
virus (RSV)
Ag

Dipstick
Nasopharyngeal
immunoassa Swab,
y
nasopharyngeal
aspirate,
nasal/nasopharyng
eal wash

15 min

Quidel
Corp

Sofia RSV FIA

Respiratory
syncytial
virus (RSV)
nucleoprotei
n antigen

Fluorescent Nasopharyngeal
Immunoassa swab,
y
aspirate/wash

3-15 min

Thermofis
her

Xpect RSV test

RSV antigen
detection

LFA
Nasopharyngeal
immunochr specimen
omatographi
c sandwich
assay

15 min

Alere, Inc.

Binax NOW
Filariasis

IMMY

CrAg A

Lymphatic
filariasis
Wucheria
bancrofti
Cryptococcal
meningitis
C.
neoformans
C. gattii

LFA

Whole Blood,
Serum, Plasma
(finger prick) (75
ul)
CSF/Serum
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Sensitivity

Specificty

Nasopharyn
geal Swab
92%,
nasopharyn
geal
aspirate
99%,
nasal/nasop
haryngeal
wash 83%
86-92%

Nasopharynge
al Swab 92%,
nasopharyngea
l aspirate 92%,
nasal/nasophar
yngeal wash
90%

Approved

96-98%

10 min

10 min

FDA cleared

Company
Trinity
Biotech

Product Name

Disease

Uni-Gold legionella Legionnarie’
urinary Antigen
s Disease
PLUS
Legionella
Pneumophila
serogroup1
Ag

Format

Required Sample
Urine (4 drops)

Table 4. Tabulated list of current POC diagnostic on market.31-47,61-70
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Detection
time
15 min

Sensitivity
82-91%

Specificty
98-99%

Approved

1.5
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CHAPTER 2
* Most of the work described in this chapter has been published in the following publication and
it is used in this chapter with permission from ACS and RSC:
•

Das, A.; Cui, X.; Chivukula, V.; Iyer, S. S., Detection of Enzymes, viruses and bacteria
using glucose meters. Anal. Chem., 2018, 90 (19), 11589-11598.

•

Cui, X.; Das, A.; Dhawane, A.; Sweeney, J.; Zhang, X.; Chivukula, V.; Iyer, S. S., Highly
specific and rapid glycan based amperometric detection of influenza viruses. Chem. Sci.,
2017, 8, 3628-3634
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2

DETECTION OF VIRUSES, PATHOGENS ENZYMES USING GLUCOSE
METERS
2.1

Introduction

A number of clinically relevant enzymes provide a snapshot of the human condition. For
example, blood tests to ascertain liver enzyme activity is part of regular blood tests to determine
the health of a patient.

1-3

The standard method for diagnosis proceeds from sample collection,

shipping to a centralized laboratory and enzyme assays using fluorescent or chemiluminescent
substrates. These methods, while clearly valuable, are time consuming and expensive. Translating
biochemical assays performed in resource rich clinical or microbiological or biochemical
laboratories by trained personnel to resource poor environments like primary clinics, remote
locations and/or home by patients could arrest the spread of an emerging disease.4 For example,
rapid detection of influenza results in early administration of antiviral drugs, which leads to faster
recovery.5,6 Similarly, detection of environmentally harmful pathogens in food before the products
are shipped to consumers is more valuable than expensive recalls of contaminated food. 7,8 Taken
together, there is a urgent need to develop diagnostics that can be deployed in a variety of settings
for the detection of infectious agents. As described in Chapter 1, these diagnostics should meet
the ASSURED criteria. Hundreds of biosensors have been designed to detect different analytes,
but very few meets all the ASSURED criteria as it is a very high bar to meet and often, there are
trade-offs. For example, point of care PCR tests are extremely accurate, but the instruments are
expensive, and the cost of reagents are expensive and should survive the supply chain. Indeed, the
list price of Alere i Influenza A and B is ~ 9,000 $. Each test is also expensive, the list price at
CVS minute clinic for the 2018 season is 70$, although some portion of the cost may be covered
by the patient’s insurance.9 Despite these costs, the loss of productivity and other economic costs
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far outweigh the cost of the test (especially in the case of emerging pandemics) and these tests are
administered to patients suspected of influenza. If the costs are reduced from thousands of dollars
to a few dollars, more people can avail themselves of the tests and the burden due to influenza can
be decreased. Clearly, if a diagnostic meets the ASSURED criteria, the impact can be
transformative. For example, devices like the glucose monitor, which meets the ASSURED criteria
have assisted millions of type 1 and 2 diabetic patients take more control of their blood glucose
levels, thereby decreasing morbidity and healthcare costs significantly.10,11
2.2

Purpose of the study

We and others have been promoting the use of glucose meters to detect non-glucose
analytes. Liu and coworkers have used glucose meters to detect several analytes that include
cocaine, adenosine, etc.12,13 Their approach was to design assays that release invertase upon target
binding, which converts sucrose to glucose. (Figure 15 A) On the other hand, we and others have
developed substrates that release glucose when exposed to an enzyme.14-17 (Figure 15 B) In both
cases, the released glucose is oxidized by glucose oxidase or glucose hydrogenase, releasing
electrons that can be recorded by a standard glucose meter. Thus, the concentration of the analyte
such as cocaine or the activity of the enzyme such as influenza neuraminidase can be correlated to
the pathogen concentration. Using this approach, we demonstrated the detection of influenza
viruses and measured drug susceptibility for influenza viruses as Relenza and Tamiflu are enzyme
inhibitors. Glucose is not released when the inhibitors are added to the sample containing
susceptible strains. All these assays use glucose meter for the detection of glucose or galactose.
Galactose is detected if the dehydrogenase enzyme is impregnated on the test strips.

18,19

Taken

together, a glucose meter can be repurposed to detect analytes other than blood glucose. This
strategy is expected to have a significant impact in the development of point of care biosensors for
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a variety of ailments as millions of people have adopted glucose meters and there will be minimal
training involved in using the same device for a new purpose. However, one potential concern in
the use of the glucose meters and test strips for detection of analytes is the problem of background
glucose in blood samples. In our previous work on influenza viruses, we used nasal swabs which
is not as complex as blood and does not contain glucose unless the patient is suffering from an
underlying condition.21 Also, we compared the glucose (or galactose level) before and after adding
the substrate; the difference between these two readings allowed us to accurately determine the
presence of influenza virus.15 While this strategy of measuring before and after addition of the
substrate works well, background glucose levels can be an issue if the initial glucose reading is
high especially when measuring blood samples from diabetic patients.21 Glucose meters are
typically calibrated to measure the normal range of blood present in humans (70 -120 mg/dl) and
anything lower or higher beyond this range is met with an error or “low” or “high” message.20 An
alternate method that will overcome the problem of background glucose will allow us to adapt this
strategy to detect analytes other than glucose, especially in blood and other matrices, where the
background levels of glucose can be very high in people suffering from type 1 or type 2 diabetes.
In this chapter, we report novel assays wherein paracetamol or catechol bearing
compounds, when exposed to their respective enzymes, release paracetamol or catechol.
Paracetamol or catechol can be detected using standard glucose test strips and glucose meters.
Paracetamol/catechol oxidation is a two electron and two proton process that has been described
previously.21,22 we demonstrate broad scope of the assays by detecting multiple enzymes and
pathogens. We also demonstrate that strips without glucose oxidase or dehydrogenase can be used
to detect paracetamol, suggesting that this method could be used to develop assays that can detect
enzymes, viruses and bacteria in the presence of high levels of background glucose.
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A

B

Figure 15. Detection of non-glucose analytes using a glucose meter.
15A. DNA-invertase conjugates are immobilized onto magnetic beads. The DNA strands
respond to the target of interest releasing DNA-invertase conjugates from the beads. The released
invertase catalyzes the conversion of sucrose to glucose which can be quantified using a glucose
meter. Because the concentration of DNA-invertase conjugate is proportional to the concentration
of target, the glucose meter reading can be used to quantify the target concentration.
15B. Cleavage of substrate-glucose into substrate and glucose by the target enzyme. The
released glucose and enzyme can be quantified using a glucose meter
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2.2.1

Mechanism of detection
General working of glucose strips and glucose meters. The glucose gets oxidized to

gluconolactone in presence of FAD, which in turn gets converted to FADH2 and oxygen is reduced
to hydrogen peroxide. It also involves the presence of a mediator Prussian white which gets
converted to Prussian blue and releases the electrons that are detected by the glucose meters and
hence detecting glucose present in the analyte.
Paracetamol attached to specific substrate will be added to the sample containing the
relevant enzymes/pathogens. Cleavage of the substrate with the enzyme/pathogen releases
paracetamol which can be quantified using a glucose meter
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A:

.
B:

Figure 16. General working Principle of glucose meters and strips and our strategy to detect
paracetamol.

16A. Glucose is detected by the strips containing the Glucose oxidase using the above
shown mechanism. Glucose is oxidized to gluconolactone. In presence of the mediator Prussian
blue-white the electrons released are detected by the glucose meter.
16B. The specific enzymes release paracetamol from the substrates and the releases
paracetamol is directly oxidized on the surface of the electrodes releasing electrons which are
captured by the glucose meter.
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2.3

Results

Our first step was to demonstrate that paracetamol can be detected using a glucose meter. To
this end, we used a Onetouch glucose meter and standard strips to generate a calibration curve
(Figure 17). The calibration curve and linear range for paracetamol, which ranges from 0.1 mM
to 5mM, demonstrates that it is possible to detect paracetamol using a glucose meter. Since we
could detect paracetamol readily and rapidly using glucose meters, we generated several
compounds that could release paracetamol when exposed to the enzyme or pathogen. The
structures of the figures are given in Figure 18 and the syntheses of the compounds are described
in Schemes 1-4. For the synthesis of SP, the carboxylic acid of the sialic acid is converted to the
methyl ester and then the per-acetylated methyl ester of sialic acid chloride was reacted with
paracetamol to yield the α derivative in reasonably good yield. Deprotection of the acetate and the
ester protecting groups resulted in the desired compound in high yield. For SP(OMe)2, the methyl
ester was treated with anhydrous acetone to protect the 8 and 9 hydroxyl groups as diacetone form
and then the 4 and 7 hydroxyl groups were converted to methoxyl form using BaO, Ba(OH)2 to
generate the oxyanions and then methyl iodide was added to generate the 4,7 methoxy derivative.
Next similar to SP, the 4,7 dimethoxymethyl ester of sialic acid chloride was reacted with
paracetamol to again yield the α derivative in reasonably good yield. For both SP and SP(OMe)2,
the H-3 axial and H-3 equatorial protons resonated at 1.7 and 2.8 ppm in the 1H NMR, respectively
and the C-2 carbon resonated at 100.0 ppm in the 13C NMR, indicating α isomer. Both GP and
GC were synthesized by reacting the galactose imidate with paracetamol/catechol via glycosidic
bond formation using TMSOTf conditions in reasonably high yield to produce the β isomer. Unlike
syntheses that introduces glucose or galactose into the substrates as an output,15 the syntheses of
paracetamol bearing compounds is relatively straightforward.
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Figure 17. Standard curve for Paracetamol.
Calibration curve and linear range for paracetamol using Onetouch glucose meter and Unistrip
strips.

Figure 18. Structure of various glycoconjugates used as substrates for different enzymes.
GP, Galactose-paracetamol cleaved by β-galactosidase; SP, Sialic acid-paracetamol
cleaved by Neuraminidase released by influenza virus and S. pneumoniae; MP, Mannoseparacetamol cleaved by α-mannosidase; SP(OMe)2 – 4,7 methoxy sialic acid-paracetamol cleaved
by influenza virus neuraminidase and GC, Galactose-catechol cleaved by β-galactosidase.
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Scheme 1. Synthesis of SP(OMe)2
Reagents and conditions: a) H+ resin, anhydrous MeOH, reflux, 650C, 72h, 75%, b)Anhydrous
Acetone, TsOH, pH=6.0, 3h, rt, 72%, c) Ba(OH)2, BaO, CH3I, DMF, 45h, rt,66% d)i)NaOMe,
MeOH, 3h, rt, ii) HCl(l),H+ resin, MeOH, 5h, rt iii)Ac2O, Pyridine, DMAP, 15h, rt, 66% (over 3
steps) e)HCl (g), AcCl, Anhydrous CH2Cl2 3h, rt, (crude, not purified) f) N-(4hydroxyphenyl)acetamide, Na2CO3, TBHSO4, anhydrous EtOAc, rt, 3h, 63% b) i.NaOMe,
MeOH, 2h; ii. aq. 0.05 N NaOH, rt, 2h, 92%.
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Scheme 2. Synthesis of SP
Reagents and conditions: a) H+ resin, anhydrous MeOH, rt, 12h, 79%, b) Ac2O, Pyridine,
DMAP, 15h, rt, 66% c) HCl (g), AcCl, Anhydrous CH2Cl2 3h, rt, (crude, not purified) d) N-(4hydroxyphenyl) acetamide, Na2CO3, TBHSO4, anhydrous EtOAc, rt, 3h,58%. b) i. NaOMe,
MeOH, 2h; ii. aq. 0.05 N NaOH, rt, 2h, 94%

Scheme 3: Synthesis of GP:
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Reagents and conditions: a) Acetaminophenol, TMSOTf, DCM, 0 0C, 2h, 76% b) i) NaOMe,
MeOH rt 1h, ii) Pd (OH)2/C/H2, EtOH rt 12 h 1h, 95% (over two steps)

Scheme 4:Synthesis of GC
Reagents and conditions

a) 2-(benzyloxy) phenol, TMSOTf, DCM, 0 0C, 2h, 71%

b) i)

NaOMe, MeOH rt 1h, ii) Pd (OH)2/C/H2, EtOH rt 12 h 1h, 92% (over two steps)
To summarize the synthesis of the compounds, GP, MP, etc. were synthesized in high
yield and in minimal number of steps. All compounds were characterized extensively with NMR
and mass spectroscopies and were obtained in pure form for the biological assays.
2.3.1 Detection of Enzymes and E. coli
The first assay we developed was to detect enzymes such as β-galactosidase and αmannosidase. We chose these glycosidases as they are commonly used in several biochemical
assays to indicate the presence of microorganisms. GP23 was introduced to different concentrations
of β-galactosidase and after different times, a drop of the solution (µL) was used to measure the
paracetamol concentration. When 100 U (1 unit (U) of β-galactosidase will hydrolyze 1umole of
o-nitrophenyl-β-galactosidase to o-nitrophenol and β-D-galactose per minute at pH=7.3 at 370C )
of the enzyme was used, paracetamol was released almost instantaneously, and the reaction was
complete in 15 mins. We determined the limit to be 0.01 U of enzyme in 5 min, however, given a
longer incubation time, the limit of detection can be decreased further as this is an enzyme-based
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detection assay. To demonstrate that we can detect β-galactosidase in different matrices using this
assay system, we spiked GP in different matrices and performed similar experiments. Matrix
effects are not an issue. A similar result was obtained with MP

24

and α-mannosidase. These

experiments demonstrate that we can reliably detect enzymes using paracetamol releasing
substrates.
A

B
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Figure 19. Detection of enzymes and E. coli using Onetouch meters and Unistrips.
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A. Rapid detection of β-galactosidase: 1 mM of GP was incubated with 100 U of enzyme
and monitored at different times. B. Rapid detection of β-galactosidase in various matrices:
Various concentrations of β-galactosidase enzyme was added to artificial urine, defibrinated
glucose-free sheep blood, and phosphate buffered saline (PBS) solutions and paracetamol was
measured. C. Rapid detection of α-mannosidase: 1 mM of MP was incubated with 10 U of enzyme
and monitored at different times. D. Rapid detection of E. coli and limit of detection studies: 1 mM
of GP was incubated with different E. coli concentrations and paracetamol was measured at 15
and 30 min. The y axis, Δ glucose meter reading, represents the difference in current between the
negative control (no enzyme or E. coli) and the sample. All experiments were performed in
triplicate (*p<0.05, **p<0.01, ***p<0.001, ns>0.05).

Building on these results, we performed experiments to detect Escherichia coli. Detection
of E. coli in recreational and drinking water is typically done by culture-based methods and the
disadvantage of these methods is that it requires a microbiology laboratory, trained personnel and
it is time consuming.25-27 Colorimetric methods are available, but those tests rely on a visual color
change, which might be subject to human error, especially when turbid or murky water samples
are being tested.25,28 The assays described here use an electronic output and therefore, are not
subject to the same human errors. Since β-galactosidase is released by the bacteria, we introduced
GP to different concentrations of E. coli and measured the response at 15 min and 30 min.). We
could detect 102 CFU/ml in 15 min; however, a longer time of 1 h is required to obtain a better
linear range because it is an enzyme-based detection method.
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2.3.2 Detection of Influenza
The next set of experiments were designed to demonstrate broad scope and to detect and
differentiate influenza viruses from Streptococcus pneumoniae. Briefly, influenza virus is a deadly
respiratory pathogen that spreads rapidly. Early and accurate detection is important to reduce the
disease burden. 29-31 Of importance is to differentiate between influenza and S. pneumoniae as this
bacterium has been demonstrated to result in severe secondary illness after the initial attack by
influenza viruses.

32-35

Previously, we reported the rapid and specific electrochemical detection

and differentiation of influenza viruses in 15 minutes after sample processing using glucose and
galactose bearing substrates. 15
Here, we use paracetamol bearing substrates to rapidly and specifically detect influenza
viruses. When SP was exposed to a H3N2 strain of influenza virus (A/Aichi/2/1968) or S.
pneumoniae (serotype 1, ATCC 6301), paracetamol was released as evidenced by the increase in
the glucose meter readings, with S. pneumoniae producing a higher value. This is anticipated as
the compound represents the natural substrate present on the termini of the glycocalyx of
mammalian cells and all neuraminidases, viral, bacterial and human, cleave the natural substrate.3639

However, when SP(OMe)2 was used, only influenza virus cleaves the substrate and not the

bacteria because the methoxy groups interferes with the smaller binding pocket of the bacterial
neuraminidase.15,40-42 Therefore, this compound can be used to specifically detect influenza
viruses. The limit of detection studies with two different strains of influenza viruses, a H1N1
(A/SolomonIslands/3/2006) and a H3N2 (A/Aichi/2/1968) strain indicate that we can detect 101
pfu/sample of influenza viruses rapidly. The range of detection for both strains can be improved if
a longer time is used as these are enzyme-based assays. We also note that different strains could
potentially be differentiated using this technique using continuous glucose meters; standard curves
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as a function of time for each strain could be developed and data from an unknown sample can be
fitted to these curves to identify the specific strain.
A

4

B

B

A

C

D

Figure 20. Rapid detection of influenza virus and S. pneumoniae.
A. 1 mM of substrate SP was incubated with 100 µL of 104 pfu/sample of influenza
A/Aichi/2/1968(H3N2) or 106 CFU/ml S. pneumoniae. Readings were taken at 15, 30- and 60-min.
B. 1 mM of substrate SP(OMe)2 was incubated with 100 µL of 104 pfu/sample of influenza
A/Aichi/2/1968 (H3N2) or 106 CFU/ml of S. pneumoniae. Readings were taken at 15, 30- and 60min. C. Limit of detection of influenza virus A/Aichi/2/1968(H3N2): 1 mM of substrate SP(OMe)2
was incubated with different concentrations of A/Aichi/2/1968(H3N2) at 37 °C for 1 h. Readings
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were taken at 15 and 30 min. D. Limit of detection of influenza virus A/Solomon Islands/3/2006
(H1N1): 1 mM of substrate SP(OMe)2 was incubated with different concentrations of A/Solomon
Islands/3/2006 (H1N1) at 37 °C for 1 h. Readings were taken at 15 and 30 min. The y axis, Δ
glucose meter reading, represents the difference in current between the negative control (no virus)
and the sample. All experiments were performed in triplicate (*p<0.05, **p<0.01, ***p<0.001,
ns>0.05).
2.3.3 Matrix effects
To demonstrate that background glucose does not affect the readings, we purchased
commercial screen-printed electrodes without any enzyme imprinted on them. Next, the strips
were connected to a portable potentiostat and the current was measured when exposed to PBS
buffer, which served as our negative control. As expected, there was no current generated as there
is no analyte in solution. (Table 5) When exposed to 2 mM glucose solution, no current was
generated as the enzyme required to convert glucose to gluconolactone is not present. Next, the
strips were exposed to 2 mM paracetamol solution. We observed an increase in the current since
paracetamol is directly oxidized on the surface of the electrodes. Finally, a mixture of 2mM
glucose and 2 mM paracetamol was exposed to the strips. The increase in current was equal to the
increase observed when only 2 mM paracetamol was used. The 2 mM glucose present in the
solution that contained the mixture of 2 mM glucose and 2 mM paracetamol did not affect the
reading, indicating that background glucose is not a problem. We repeated these experiments in
different matrices, such as simulated urine and sheep blood that did not contain glucose to
demonstrate there were no matrix effects. Briefly, either paracetamol or glucose or a mixture of
paracetamol and glucose were spiked into these samples and the readings were taken using strips
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without any glucose oxidase. As seen in Table 5, there are no matrix effects and background
glucose are not an issue when we are detecting paracetamol.

Test solution

Control (no paracetamol
or Glucose).
2mM Glucose solution
added to control.
2mM paracetamol
solution added to control.
2mM paracetamol + 2mM
Glucose solution added to
control.

Current output from i-t curve
(I/ X 10-8 A)
Strips coated with
0.5 % Chitosan (in 2% Acetic Acid)
PBS buffer

Urine

Sheep Blood

0.7+0.1

1.0+0.4

0.8+0.1

0.6+0.1

0.7+0.3

0.7+0.1

141.0+6.8

133.1+11.6

135.4+4.3

138.3+7.0

134.6+14.1

135.3+5.0

Table 5. Studies demonstrating that background glucose is not a problem when glucose oxidase
or dehydrogenase enzyme is absent.
2.3.4 Use of catechol to as an alternate electrochemical signal
The final set of experiments was designed to broaden the scope of the output, i.e., replacing
paracetamol by catechol. This would allow more options for detection if paracetamol bearing
substrates are more complicated to synthesize or the sample contains high levels of paracetamol.
First, we generated a standard curve for catechol. Next, we synthesized a catechol bearing substrate
GC and exposed it to 100 U of β-galactosidase enzyme. The enzyme was detected within 5 mins,
indicating that catechol or paracetamol bearing substrates could be used for the rapid detection of
enzymes and pathogens using a personal glucose meter.
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Figure 21. Calibration curve for catechol using Onetouch glucose meter and unistrip test strips.
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Figure 22. Rapid detection of β-galactosidase using GC.
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2.4

Experimental Details

2.4.1 General
Glycosylation reactions were performed under argon with solvents dried using a solvent
purification system (Innovative Technology Inc., Amesbury, MA, USA). Other chemical reagents
were of analytical grade, used as supplied, without further purification unless indicated. The acidic
ion exchange resin used was Amberlite® IR-120 (H+) resin. Analytical thin layer chromatography
(TLC) was performed on silica gel 230-400 mesh (Silicycle, Quebec City, Canada). Plates were
visualized under UV light, and/or by staining with acidic CeH8Mo3N2O12, followed by heating.
1H and 13C NMR spectra were recorded on Bruker 400 MHz spectrometer. Chemical shifts are
reported in δ (ppm) units using 13C and residual 1 H signals from deuterated solvents as references.
Spectra were analyzed with MNova® (Mestrelab Research, Escondido, CA, USA). Electrospray
ionization mass spectra were recorded on a Micromass QT 2 (Waters) and data were analyzed with
MassLynx® 4.0 (Waters, Milford, MA, USA) software. Reported yields refer to spectroscopically
and chromatographically pure compounds that were dried under high vacuum (10–2 mbar) before
analytical characterization, unless otherwise specified. GP and MP were synthesized as described
previously.23,24
2.4.2 Synthesis and characterization
The synthesis of some of the compounds was performed as described in the literature
with some changes. Therefore, the experimental details are described to reflect these
changes.18,23
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Methyl (5-acetamido-3,5-dideoxy-D-glycero- β-D-galacto-2-nonulopyranosidonate) (2).

A suspension of N-acetylneuraminic acid (1) (10.0 g, 32.4 mmol) was treated with the
Bio-Rad (H+) resin (5.0 g) in anhydrous methanol (400 mL) at room temperature with vigorous
stirring for 12 h. The resin was filtered off and washed with methanol, and then the filtrate was
concentrated and kept at -20 oC overnight for crystallization. The crystals were collected and
washed with cold ethyl acetate: methanol (6:1) to provide white powder 2a (8.2 g, 75%). The
NMR data matched reported literature values 18
1H

NMR (400 MHz, CD3OD) δ 1.68 (dd, 1H, J = 12.7, 11.4 Hz), 2.38 (dd, 1H, J=12.0,

4.9 Hz), 3.31 (s, 3H), 3.54 (d, 1H, J=9.1 Hz), 3.69 (dd, 1H, J = 12.0, 6.0 Hz), 3.82-3.90 (m, 7H),
4.02-4.06 (m, 1H).
13C

NMR (100 MHz, CD3OD) δ 23.17, 52.06, 53.58, 54.20, 65.72, 68.13, 70.60, 71.82,

72.71, 100.81, 171.29, 175.25. MS (m/z): 338.1 [M+H]-. Anal. Calcd for C13H23NO9: C, 46.29;
H, 6.87; N, 4.15. Found: C, 46.13; H, 6.81; N, 4.23.
Methyl (5-acetamido-2,8,9-tri-O-acetyl-3,5-dideoxy-4,7-di-O-methyl- D-glycero-α,β-Dgalacto-2-nonulopyranosidonate) (3a).
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To the suspension of 2a, Ac2O (5 mL, 52.9 mmol), pyridine (5 mL) and DMAP (0.2 g)
was added and the reaction mixture was stirred at room temperature for 15 h. The liquids were
evaporated off and the residue was purified by chromatography on silica gel. The column was
washed with mixtures of hexane and ethyl acetate in the ratio 2: 1 and 1 : 1 respectively, and then
the product was eluted with ethyl acetate to afford 3a (1.5 g, 66%) as a white powder.
1H

NMR (400 MHz, CD3OD) δ 1.76 (dd, 1H, J = 13.2, 11.3 Hz), 2.08 (s, 3H), 2.12 (s,

3H), 2.12 (s, 3H), 2.20 (s, 3H), 2.66 (dd, 1H, J = 13.3, 4.7 Hz), 3.45 (s, 3H), 3.57 (s, 3H), 3.63
(dd, 1H, J = 5.5, 1.3 Hz), 3.75 (td, 1H, J = 10.8, 4.7 Hz), 3.83 (s, 3H), 3.95 (dd, 1H, J = 10.5, 1.0
Hz), 4.11 (t, 1H, J = 10.2 Hz), 4.25 (dd, 1H, J = 12.4, 6.4 Hz), 4.75 (dd, 1H, J = 12.4, 2.3 Hz),
5.09 (td, 1H, J = 6.2, 2.3 Hz).
13C

NMR (100 MHz, CD3OD) δ 20.90, 20.95, 21.25, 23.28, 36.98, 51.53, 53.70, 57.65,

61.74, 63.98, 74.34, 74.81, 77.40, 79.00, 99.32, 169.13, 170.32, 171.99, 172.76, 173.68. MS
(m/z): 478.2 [M+H]-. Anal. Calcd for C20H31NO12: C, 50.31; H, 6.54; N, 2.93. Found: C, 50.43;
H, 6.48; N, 2.89.

Methyl (5-acetamido-8,9-di-O-acetyl-3,5-dideoxy-4,7-di-O- methyl-D-glycero-β-D-galacto-2nonulopyranosyl chloride)onate (4a).

A mixture of AcCl (1.4 mL, 20 mmol) and anhydrous CH2Cl2 (10 mL) containing 3a
(1.2 g, 2.6 mmol) was saturated with dry HCl (g) at room temperature, which was continuously
stirred for 3 h as observed by TLC, resulting in a complete reaction (Rf = 0.49 in CH2Cl2 :
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CH3OH = 92 : 8). Then the reaction mixture was evaporated to dryness in vacuum. The crude 4a
was provided as a white powder which was not further purified and used at once in the next
reaction.

Methyl [4-N-acetamidophenyl-(5-acetamido-8,9-di-O-acetyl-3,5-dideoxy-D-glycero-α-Dgalacto-2-ulopyranosyl)] onate (5a)

To the stirring, solution of 4a (0.30 g, 0.64 mmol) in EA, paracetamol (0.12 g, 0.77 mmol)
was added. TBHSO4 (0.33 g, 0.96 mmol), was dissolved in 1M solution of Na2CO3 and was added
dropwise. The biphasic reaction was stirred vigorously for 3 h. The reaction was monitored with
TLC. On completion of the reaction, it was diluted with 20 ml of EA; washed with saturated
Na2CO3 solution. (X2) The organic layers were collected and dried over Na2SO4 and concentrated
under reduced pressure. The residue was subjected to flash silica gel column chromatography
eluting with EA, to afford 5a (0.25 g, 63%) as white solid.
1H

NMR (400 MHz, CDCl3): δ 8.12 (s, 1H), 7.40 (d, J = 8Hz, 2H), 6.97 (d, J = 8Hz,

2H), 5.92 (d, J = 8Hz, 1H), 5.34-5.34 (m, 2H), 4.93-4.87 (m, 2H), 4.36-4.28 (m, 2H), 4.15-4.05
(m, 2H), 3.59 (s, 3H), 2.67 (dd, J = 20Hz, 8Hz, 1H), 2.10 (s, 3H), 2.09 (s, 3H), 2.07 (s, 3H), 2.01
(s, 3H), 1.99 (s, 3H), 1.85 (s, 3H).
13C

NMR (100 MHz, CDCl3): δ 170.8, 170.5, 170.2, 168.6,167.9, 149.8, 134.5, 120.8,

100.2, 73.2, 69.3,68.9, 67.4, 62.0, 52.9, 49.2, 38.0, 24.3, 23.1, 21.0. ESI-MS: [M+Na]+: Calcd for
C28H36N2O14Na : 647.2167; obtained 647.1951.
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4-N-acetamidophenyl-(5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2ulopyranoside)onic acid: (SP)

Compound 2 (0.05 g, 0.080 mmol) was dissolved in 1 ml of MeOH and treated with 30%
NaOMe in MeOH ((100 µL) and stirred at rt for 1 h. The solution was neutralized with Amberlite
IR 120(H+) resin, filtered and concentrated under reduced pressure. The residue was treated with
aqueous 0.05 N NaOH and stirred at rt for 2 h. The reaction was monitored by TLC, the mixture
was neutralized with Amberlite IR 120(H+) resin, filtered and concentrated under reduced pressure
and subjected to P2 column to obtain pure compound SP (0.034 g, 94%).
1H

NMR (400 MHz, D2O): δ 7.24 (d, J = 12 Hz, 2H), 7.07 (d, J = 12 Hz, 2H), 3.83-3.75

(m, 6H), 3.71-3.65 (m, 2H), 3.57-3.49 (m, 4H), 2.79 (dd, J = 20 Hz, 8 Hz, 1H), 2.65 (s, 3H), 1.95
(s, 3H), 1.85 (t, J = 16 Hz, 1H).
13C

NMR (100 MHz, D2O): δ 175.0, 172.9, 171.8, 150.5, 124.6, 123.2, 122.0, 115.7,

101.6, 73.5, 71.3, 68.1, 67.6, 62.8, 51.6, 40.1, 22.6, 22.0. ESI-MS m/z: [M-H]-: Calcd for
C19H25N2O10: 441.1587; obtained 441.1443.

Methyl (methyl 5-acetamido-3,5-dideoxy-D-glycero- β-D-galacto-2-nonulopyranosidonate)
(2).
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The suspension of N-acetylneuraminic acid (1) (10.0 g, 32.4 mmol) was treated with the
Bio-Rad (H+) resin (5.0 g) in anhydrous methanol (400 mL) and refluxed with vigorous stirring
for 72 h at 65oC. The resin was filtered off and washed with methanol, and then the filtrate was
concentrated and kept at -20 oC overnight for crystallization. The crystals were collected and
washed with cold ethyl acetate: methanol (6 : 1) to provide white powder 2 (8.2 g, 75%).
1H

NMR (400 MHz, CD3OD) δ 1.68 (dd, 1H, J = 12.7, 11.4 Hz), 2.05 (s, 3H), 2.38 (dd,

1H, J=12.0, 4.9 Hz), 3.31 (s, 3H), 3.54 (d, 1H, J=9.1 Hz), 3.69 (dd, 1H, J = 12.0, 6.0 Hz), 3.823.90 (m, 7H), 4.02-4.06 (m, 1H).
13C

NMR (100 MHz, CD3OD) δ 23.17, 42.00, 52.06, 53.58, 54.20, 65.72, 68.13, 70.60,

71.82, 72.71, 100.81, 171.29, 175.25. MS (m/z): 338.1 [M+H]-. Anal. Calcd for C13H23NO9: C,
46.29; H, 6.87; N, 4.15. Found: C, 46.13; H, 6.81; N, 4.23.

Methyl (methyl 5-acetamido-3,5-dideoxy-8,9-O-isopropylidene-D-glycero-β- D-galacto-2nonulopyranosidonate) (3).

A mixture of 2 (7.0 g, 20.8 mmol) and TsOH·H2O (0.2 g) in dry anhydrous acetone
(100 mL) was stirred at room temperature for 3 h, then neutralized with TEA to pH = 6-7. The
solution was evaporated to dryness. The solid was triturated and washed with ether, then purified
by chromatography (CH2Cl2: CH3OH: TEA = 95: 5 : 0.1) to afford 3 (5.6 g, 72%) as a white
powder.
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1H

NMR (400 MHz, CD3OD) δ 1.34 (s, 3H), 1.40 (s, 3H), 1.69 (dd, 1H, J = 12.6, 11.6

Hz), 2.06 (s, 3H), 2.39 (dd, 1H, J = 13.0, 4.9 Hz), 3.29 (s, 3H), 3.52 (d, 1H, J = 8.3 Hz), 3.75
(dd, 1H, J = 10.0, 0.5 Hz), 3.85-3.88 (m, 4H), 4.00 (dd, 1H, J = 8.4, 5.5 Hz), 4.04 (td, 1H, J =
10.6, 4.9 Hz), 4.16 (dd, 1H, J = 8.4, 6.3 Hz), 4.29-4.33 (m, 1H).
13C

NMR (100 MHz, CD3OD) δ 22.85, 25.78, 27.42, 41.72, 51.65, 53.31, 53.83, 67.67,

68.81, 71.68, 72.85, 75.98, 100.55, 110.41, 170.81, 174.90. MS (m/z): 378.1 [M+H]-. Anal.
Calcd for C16H27NO9: C, 50.92; H, 7.21; N, 3.71. Found: C, 50.94; H, 7.31; N, 3.68.

Methyl (methyl 5-acetamido-3,5-dideoxy-4,7-di-O-methyl-8,9-O- isopropylidene-D-glyceroβ-D-galacto-2-nonulopyranosidonate) (4).

A mixture of 3 (4.0 g, 10.6 mmol) was treated with BaO (5.8 g, 37.7 mmol) and
Ba(OH)2·8H2O (0.7 g, 2.2 mmol) in dry DMF (36 mL). After 20 min, CH3I (10 mL, 197.3 mmol)
was added. The reaction suspension was kept stirring for 45 h at room temperature. The solids
were filtered off and washed exhaustively with ethyl acetate. The filtrate was concentrated to about
30 mL by evaporation under diminished pressure, further extracted with ethyl acetate (60 mL) and
5% NaCl solution (30 mL). The organic phase was separated, and the aqueous phase was extracted
with ethyl acetate (60 mL) again. The collected organic phase was dried over anhydrous Na2SO4,
then evaporated to 5 mL under reduced pressure and kept at -20 oC with 20 mL ether overnight to
give the product 4 as a white powder (2.8 g, 66%).
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1H

NMR (400 MHz, CD3OD) δ 1.35 (s, 3H), 1.44 (s, 3H), 1.57 (dd, 1H, J = 12.9, 11.4

Hz), 2.04 (s, 3H), 2.51 (dd, 1H, J = 12.9 , 4.8 Hz), 3.26 (s, 3H), 3.38 (s, 3H), 3.54 (s, 4H), 3.66
(td, 1H, J = 10.8, 4.8 Hz), 3.79 (dd, 1H, J = 10.7, 0.9 Hz), 3.83 (s, 3H), 4.03-4.09 (m, 2H), 4.16
(dd, 1H, J = 8.5, 6.3 Hz), 4.30 (dd, 1H, J = 12.1, 6.4 Hz).
13C

NMR (100 MHz, CD3OD) δ 23.12, 25.67, 27.04, 37.86, 51.38, 51.64, 53.11, 57.31,

61.90, 67.49, 73.48, 77.84, 78.20, 80.00, 100.46, 109.55, 169.84, 173.41. MS (m/z): 406.2
[M+H]-. Anal. Calcd for C18H31NO9: C, 53.32; H, 7.71; N, 3.45. Found: C, 53.43; H, 7.61; N,
3.49.

Methyl (5-acetamido-2,8,9-tri-O-acetyl-3,5-dideoxy-4,7-di-O-methyl- D-glycero-α,β-Dgalacto-2-nonulopyranosidonate) (5).

The product 4 (2.0 g, 4.9 mmol) was suspended in mixture of methanol/water (1 : 1, 20
mL). 1 M NaOH (10 mL) was added and the reaction mixture was stirred for 3 h, the reaction was
neutralized by adding Bio-Rad (H+) resin to pH = 7.0. The resin was filtered off, washed with
methanol and the washing was evaporated to dryness. HCl (30 mM, 33 mL) was added to residue
as well as Bio-Rad resin (2.0 g), then the resulting mixture was heated at 70 oC for 16 h. The resin
was filtered off and washed with water. The solvent was evaporated off and the residue was
dissolved in dry methanol (26 mL). Bio-Rad resin (1.7 g, dried over P2O5) was added and the
reaction mixture was stirred for 5 h at room temperature. The resin was filtered off and the
methanol was evaporated with the addition of 0.5 mL pyridine. The residue was dried under high
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vacuum for 15 h over P2O5. It was then treated with Ac2O (5 mL, 52.9 mmol), pyridine (5 mL)
and DMAP (0.2 g) for 15 h at room temperature. The liquids were evaporated off and the residue
was purified by chromatography on silica gel. The column was washed with mixtures of hexane
and ethyl acetate in the ratio 2: 1 and 1 : 1 respectively, and then the product was eluted with ethyl
acetate to afford 5 (1.5 g, 66%) as a white powder.
1H

NMR (400 MHz, CD3OD) δ 1.76 (dd, 1H, J = 13.2, 11.3 Hz), 2.08 (s, 3H), 2.12 (s,

3H), 2.12 (s, 3H), 2.20 (s, 3H), 2.66 (dd, 1H, J = 13.3, 4.7 Hz), 3.45 (s, 3H), 3.57 (s, 3H), 3.63
(dd, 1H, J = 5.5, 1.3 Hz), 3.75 (td, 1H, J = 10.8, 4.7 Hz), 3.83 (s, 3H), 3.95 (dd, 1H, J = 10.5, 1.0
Hz), 4.11 (t, 1H, J = 10.2 Hz), 4.25 (dd, 1H, J = 12.4, 6.4 Hz), 4.75 (dd, 1H, J = 12.4, 2.3 Hz),
5.09 (td, 1H, J = 6.2, 2.3 Hz).
13C

NMR (100 MHz, CD3OD) δ 20.90, 20.95, 21.25, 23.28, 36.98, 51.53, 53.70, 57.65,

61.74, 63.98, 74.34, 74.81, 77.40, 79.00, 99.32, 169.13, 170.32, 171.99, 172.76, 173.68. MS
(m/z): 478.2 [M+H]-. Anal. Calcd for C20H31NO12: C, 50.31; H, 6.54; N, 2.93. Found: C, 50.43;
H, 6.48; N, 2.89.

Methyl (5-acetamido-8,9-di-O-acetyl-3,5-dideoxy-4,7-di-O- methyl-D-glycero-β-D-galacto-2nonulopyranosyl chloride)onate (6).

A mixture of AcCl (1.4 mL, 20 mmol) and anhydrous CH2Cl2 (10 mL) containing 5 (1.2 g,
2.6 mmol) was saturated with dry HCl (g) at room temperature, which was continuously stirred
for 3 h as observed by TLC, resulting in a complete reaction (Rf = 0.49 in CH2Cl2 : CH3OH = 92 :
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8). Then the reaction mixture was evaporated to dryness in vacuum. The crude 6 was provided as
a white powder which was not further purified and used at once in the next reaction.

Methyl [4-N-acetamidophenyl-(5-acetamido-8,9-di-O-acetyl- 3,5-dideoxy-4,7-di-O-methyl
D-glycero-α-D-galacto-2-ulopyranosyl)] onate (7):

To a solution of 6 (0.40 g, 0.88 mmol) in EA, paracetamol (0.16 g, 1.1 mmol) was added.
TBHSO4 (0.45 g, 1.3 mmol) was dissolved in 1M solution of Na2CO3 in H2O and was added
dropwise to the above stirring solution. The bi-phasic reaction was stirred vigorously for 3 h. The
reaction was monitored with TLC. On completion of the reaction, it was diluted with 20 ml of EA;
washed with saturated Na2CO3 solution. (X2) The organic layers were collected and dried over
Na2SO4 and concentrated under reduced pressure. The residue was subjected to flash silica gel
column chromatography eluting with EA, to afford 7 (0.29 g, 58%) as white solid.
1H

NMR (400 MHz, CDCl3): δ 7.57 (s, 1H), 7.37 (d, J = 8Hz, 2H), 7.01 (d, J = 8 Hz,

2H), 5.56-5.54 (m, 1H), 5.36-5.26 (m, 2H), 4.62-4.59 (m, 1H), 4.25-4.09 (m, 4H), 3.63 (s, 3H),
3.52 (s, 3H), 3.34 (s, 3H), 2.81 (dd, J = 16 Hz, 8 Hz, 1H), 2.14 (s, 3H), 2.10 (s, 3H), 2.08 (s, 3H),
2.05 (s, 3H), 1.95 (t, J= 12 Hz, 1H).
13C

NMR (100 MHz, CDCl3) δ 170.7, 170.6, 170.2, 168.4, 150.2, 134.1, 121.1, 100.7,

73.7, 70.9, 63.1, 61.4, 56.4, 53.5, 50.3, 37.7, 24.8, 23.4, 21.1, 13.9. ESI-MS m/z: [M+K]+: Calcd
for C26H36N2O12 K: 607.2268; obtained 607.2259.
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4-N-acetamidophenyl-(5-acetamido-3,5-dideoxy-4,7-di-O-methyl D-glycero-α-D-galacto-2ulopyranoside)onic acid: SP(OMe)2

Compound 7 (0.03 g, 0.05 mmol) was dissolved in 1 ml of MeOH and treated with 30%
NaOMe in MeOH (100 µL) and stirred at rt for 1 h. The solution was neutralized with Amberlite
IR 120(H+) resin, filtered and concentrated under reduced pressure. The residue was then treated
with aqueous 0.05 N NaOH and stirred at rt for 2h. The reaction was monitored by TLC, the
mixture was neutralized with Amberlite IR 120(H+) resin, filtered and concentrated under reduced
pressure and subjected to P2 column to obtain pure compound SP(OMe)2 (0.022 g, 98%).
1H

NMR (400 MHz, D2O): δ 7.25 (d, J = 8 Hz, 2H), 7.05 (d, J = 8 Hz, 2H), 3.93-3.80 (m,

2H), 3.79-3.57 (m, 2H), 3.46 (s, 2H), 3.45-3.38 (m, 2H), 3.36-3.34 (m, 1H), 3.33 (s, 3H), 3.33 (s,
3H), 3.28-3.26 (m, 1H), 2.91 (dd, J = 12.5, 4.4 Hz, 1H), 2.06 (s, 3H), 1.96 (s, 3H), 1.73 (t, J = 12
Hz, 1H)
13C

NMR (100 MHz, D2O): δ 174.1, 172.9, 172.5, 171.0, 165.9, 151.1, 123.3, 122.1,

102.9, 78.3, 78.0, 73.1, 71.4, 69.6, 62.2, 60.2, 56.7, 49.8, 37.4, 22.6, 22.2. ESI-MS m/z: [M-H]-:
Calc. for C21H29N2O10: 469.1900; obtained 469.1828.

2-benzyloxyphenyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside (4):
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To the stirring solution of galactose imidate 3 (0.20g, 0.40 mmol) in DCM, 2-(benzyloxy)
phenol (0.10g, 0.54 mmol) was added. TMSOTf (1 ml, 0.04 mmol solution in DCM) was added
dropwise at 0 0C. The reaction was monitored using TLC. Et3N was added to quench the reaction
and warmed to rt. The reaction mixture was diluted with DCM, washed with Na2CO3 (X2) and
brine solution (X2). The organic layers were collected and dried over Na2SO4 and concentrated
under reduced pressure. The residue was subjected to flash silica gel column chromatography
eluting with hexane: EA (40:60) to afford 4 (0.15 g, 71%) as white solid.
1H

NMR (400 MHz, CDCl3): δ 7.46-7.39 (m, 4H), 7.35-7.34 (m, 1H), 7.19-7.17 (m, 1H),

7.05-7.03 (m, 1H), 6.99-6.90 (m, 2H), 5.58-5.54 (m, 1H), 5.45 (d, J=4Hz, 1H), 5.11-5.08 (m, 2H),
5.01 (d, J=8Hz, 1H), 4.26-4.13 (m, 3H), 4.00-3.97 (m, 1H), 2.20 (s, 3H), 2.06 (s, 3H), 2.02 (s, 3H),
1.82 (s, 3H)
13C

NMR (100 MHz, D2O): δ 136.9, 128.5, 128.0, 127.4, 121.4, 120.2, 114.9, 101.0, 92.4,

85.4, 72.0, 70.9, 68.7, 66.2, 61.2, 29.7, 29.4, 20.6, 20.4, 17.4, 13.4. ESI-MS m/z: [M+K]-: Calc
for C27H30O11K: 569.1830; obtained 569.3121
2-hydroxyphenyl β-D-galactopyranoside (GC):

Compound 4 (0.05 g, 0.09 mmol) was dissolved in 1 ml of MeOH and treated with a 30%
solution of NaOMe in MeOH (70 µL) and stirred at rt for 1 h. The solution was neutralized with
Amberlite® IR 120 (H+) resin, filtered and concentrated to dryness. The dried compound was
treated with Pd (OH)2/C (0.01 g) in absolute EtOH, was stirred for 12h at rt under H2 at
1 atmosphere. After completion of reaction as monitored by TLC, reaction mixture was filtered
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using celite pad, washed with EtOH and combined solvent was concentrated to dryness and
subjected to P-2 gel column to furnish GC (0.023 g, 92%).
1H

NMR (400 MHz, D2O): δ 7.12 (d, J=8 Hz, 1H), 6.98-6.94 (m, 1H), 6.91-6.83 (m, 2H),

4.94 (d, J=8Hz, 1H), 3.97 (s, 1H), 3.92 (d, J= 4Hz, 1H), 3.80-3.68 (m, 4H), 3.58-3.54 (m, 1H),
3.49-3.45 (m, 1H).
13C

NMR (100 MHz, D2O): δ 144.9, 124.1, 120.6, 116.8, 101.8, 75.4, 72.5, 70.5, 68.5,

62.5, 60.7. ESI-MS m/z: [M-2H]-: Calc for C12H14O7: 270.2530; obtained 270.1854.
2.4.3 Biological Assays
2.4.3.1 Materials:
β-galactosidase from Escherichia coli and α-Mannosidase from Canavalia ensiformis (Jack
Bean) were purchased from Sigma Aldrich, St. Louis, MO, USA. H3N2 (A/Aichi/2/1968), H1N1
(A/Brisbane/59/2007) were obtained from Beiresources (NIAID). S. pneumoniae ATCC 6301 and
E. coli B (ATCC 11303) were obtained from American Type Culture Collection (ATCC). Glucose
meter One Touch Ultra 2 and Unistrip-1 generic blood glucose strips were purchased from
Amazon. Defibrinated sheep blood was purchased from ThermoFisher Scientific (Waltham, MA)
and treated with hexokinase to remove residual glucose. Artificial urine without glucose was
purchased from Carolina Biologicals (Burlington, NC).
Generation and growth of pathogens:
E. coli bacterial growth: The E. coli B (ATCC 11303) samples were grown in Luria-Bertani (LB)
broth for 24 h at 370C, supplemented with a final concentration of 1 mM isopropyl β -Dthiogalactopyranoside (IPTG) for the induction of β-galactosidase enzyme. The cells were
harvested by centrifuging them at 2500 rpm for 5 min and re-suspended in sterile PBS buffer. 1%
Triton was added to the E. coli cells to lyse and release the β - galactosidase enzyme.
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S. pneumoniae bacterial growth: S. pneumoniae (ATCC 6301) was inoculated in Brain Heart
Infusion (BHI) broth which was augmented with 0.16g/L of sialic acid to enhance NA production
by the bacteria. Bacterial concentration was determined as 1.2 X 106 CFU/ml using colony count
method. 100 μL of bacterial solution was lysed using 0.01% SDS and 20μl of chloroform was
added to it. The sample was then lysed by vortexing for 30 sec and incubating at a temperature of
280C for 5 min.
2.4.4 Detection of different pathogens
For all measurements, since the range of glucose meters has been set for testing normal
blood glucose levels, low concentrations of glucose or paracetamol are recorded as “error”. Since
we are detecting low concentrations of paracetamol, a known concentration of paracetamol is
added to all solutions to establish a baseline number, which is subtracted from the assay readings.
Detection of enzymes or E. coli: 100 μL of different concentrations of β-galactosidase or αmannosidase or lysed E. coli was mixed with 100 ul of substrate GP or GC (3 mM) and 100 µl of
paracetamol (3 mM) in PBS or citrate buffer at 370C for 1 h. 2 µL of the solution was used to
measure the release of paracetamol using the Onetouch meter and Unistrips.
Detection of influenza virus or S. pneumoniae: 100 μL of different concentrations of lysed
H3N2 (A/Aichi/2/1968), H1N1 (A/Brisbane/59/2007) or S. pneumoniae was mixed with 100 µL
of substrate SP or SP(OMe)2 (3 mM) and 100 µl of paracetamol (3 mM) in PBS buffer at 370C
for 1 h. 2 µL of the solution was used to measure the release of paracetamol from the substrate.
2.5

Discussion

We have been developing point of care diagnostics using glucose meters for the past several
years. Our previous detection strategy involved the development of glucose or galactose-based
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substrates. Exposure of these substrates to enzymes or pathogens released glucose or galactose,
which was readily detected using a personal glucose meter. However, improvements to this
strategy are required for several reasons. First, glucose is present in blood and in urine and other
body fluids for diabetic and prediabetic patients. High background levels of glucose could cause a
problem in the detection strategy. Second, detecting bacteria using glucose or galactose is
problematic because the released glucose or galactose is used as a food source by E.coli, making
it difficult to detect.43

In our investigations, we discovered that there are a few interfering chemical compounds that
can perturb the glucose meter reading.44 One such compound is acetaminophen or paracetamol,
which can directly get oxidized at the electrode surface, which made us realize that we could
incorporate paracetamol into the substrate. Cleavage of the substrate will release paracetamol,
which can be detected by the glucose meter. Therefore, we have introduced paracetamol or
catechol as an alternate output molecule and demonstrated that this strategy can be used to detect
enzymes, viruses and bacteria. An advantage is the ease of synthesis of these derivatives compared
to more complex synthesis using glucose; the latter has five hydroxyl groups compared to one
hydroxyl group present in paracetamol. A second advantage is that paracetamol and catechol have
higher sensitivity than glucose, the limit of detection for paracetamol is 0.5 mM. In contrast, the
limit of detection of glucose is 2 mM as measured using a Onetouch glucose meter. Thus, the
detection limits of the enzyme in question can be decreased. A third advantage is the strips without
glucose oxidase or dehydrogenase can be used to detect paracetamol. (Figure 16A, B). Thus,
background glucose or galactose will no longer be an issue if glucose oxidase or dehydrogenase is
removed. The cost of producing the strips will also be reduced and the robustness of the strips will
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be increased as glucose oxidase or dehydrogenase is not required. One concern that could
potentially arise is the presence of high levels of paracetamol in the blood or other body fluids.
While paracetamol is not present in bodily fluids such as urine, blood or saliva, paracetamol is a
pain medication. Fortunately, the peak plasma concentration reaches a maximum of ~
20 microgram, which is too low for detection by a glucose meter.

45-47

The concentration in

peripheral blood is negligible and after a few hours, the drug is metabolized and excreted through
urine as predominantly acetaminophen glucuronide.48 Thus, we are not overly concerned with
background paracetamol levels and furthermore, catechol can be used instead of paracetamol. The
assays described here compare very well with other established assays. For influenza viruses, the
diagnostic tests available in the marketplace are rapid influenza antigen detection tests (RIDTs),
direct fluorescent-antibody assays (DFAs) and nucleic acid amplification tests (NAAT). The
commercially available RIDTs for clinical samples provide a qualitative yes/no answer within 1530 mins. However, their sensitivity varies between 60-70% and can be lower, depending on the
sample.49,50 DFAs are more sensitive compared to the RIDTs, but require around 2-3 h and skilled
personnel to analyze the results. NAATs, e.g. Alere-i are highly sensitive and have a low detection
limit of 101 to 103 pfu/ml and can be detected within 15-30 mins but are very expensive.51 The
electrochemical assay described here is inexpensive, user-friendly and can detect 101 pfu/sample
of influenza rapidly. This assay also compares very well for E. coli with established assays.
Fluorescent based enzyme assays for E. coli focuses on the release of 4- Methylumbelliferyl-β-Dglucuronide (MUG) substrate. The hydrolysis of MUG releases fluorescent 4-methylumbelliferone
(4-MU) and the intensity of the measured fluorescent signal is proportional to the amount of E.
coli present in the sample. Using this method it is possible to detect 10-108 CFU/ml of E. coli in
20-120 mins, depending on the bacterial count.52 A hydrogel based, E. coli detection system using
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a plunger-tube assembly, involving a colorimetric substrate can detect 105-106 CFU/ml of E.coli
in 5 mins.53 The assay reported here can detect 102 CFU/ml in 15 mins.
To summarize, we anticipate that this technique will be widely used for the rapid detection of
several clinically relevant enzymes to report acute/chronic infections and human disorders as the
technique meets the ASSURED criteria.
2.6

Summary and Future work

This study demonstrated that we can use reporters other than glucose to detect enzymes. This is an
important advance because, until now, clinically relevant enzymes could not be easily detected in
blood, serum and other matrices using glucose meters because of high background levels of
glucose. In future studies, the Iyer group will be developing assays that can detect a wide variety
of clinically relevant enzymes present in blood or serum for disease diagnosis using repurposed
glucose meters and test strips that do not contain glucose oxidase or glucose dehydrogenase.
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CHAPTER 3.
* Most of the work described in this chapter has been published in the following publication and
it is used in this chapter with permission from Heterocyclic Communication journal:

•

Das, A.; Gurale, B.; Dhawane, A.; Iyer, S. S., Synthesis of biotinylated bivalent zanamivir
analogues as probes for influenza viruses. Heterocycl. Commun. 2017; 23(3): 181–186.
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3

DETECTION OF INFLUENZA VIRUS
3.1

Introduction

Influenza virus is a deadly pathogen which affects the upper and lower respiratory tract
and may cause severe illness in infants and old people. The symptoms of the influenza infection
can vary from mild to very severe and mostly include fever, runny nose, coughing, sore throat,
headaches and muscular pain.1 The symptoms of the influenza viral infection starts to arise usually
after 2-3 days after the exposure and typically last around a week. In severe cases the influenza
viral infection is accompanied with viral pneumonia, secondary bacterial pneumonia, trouble with
breathing, finally leading to heart failure, causing death in many cases. The major risk groups for
influenza infection are children under five years, older people and other immune-compromised
individuals.2 It causes widespread annual epidemics and pandemics every 20 to 30 years.
According to World Health Organization (WHO), it severely affects approximately 3 to 5 million
people per annum and resulting in 250,000 to 500,000 deaths globally.1 The influenza virus is a
highly contagious virus and spreads very rapidly; an infected individual can spread the infection
one day before the onset of the symptoms and 5-7 days after it. Sneezing and coughing during the
viral infection create tiny droplets or aerosols of viruses, which facilitates the spread of the virus.
Close contact or touching a person who has influenza infection can also spread the virus.7 Rapid
and accurate detection is key to mitigate the spread of virus. Consequently, a rapid point of care
kit which can detect the virus accurately is essential. The current U.S. Food and Drug
Administration (FDA) approved method for detection of influenza virus, involves polymerase
chain reaction (rt-PCR). It is considered as the gold standard for detection of influenza virus.3 PCR
involves long hours and qualified personnel with lab expertise. There are several antibody based
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rapid point of care kits that are available in the market, but they are not very sensitive.4 There is a
significant need for a rapid, accurate and sensitive detection method for influenza virus.
3.1.1 History

The first documented use of the word influenza was found in an article in Rome in 1743,
to describe a disease which was similar to the plague and caused a huge economic burden on
people. The word came from the Latin word influentia and the meaning connotes as a disease,
caused due to astrological phenomenon.6 Smith, Andrewes, and Laidlaw were the first to isolate
influenza A virus in 1933, later Francis isolated influenza B virus in 1936, followed by Taylor who
isolated the influenza C virus in 1950.7 The first influenza virus was grown in embryonated hens’
eggs in 1936 by Burnet. This paved the way for the study and characterization of the virus and the
development of inactivated vaccines.12 The first live attenuated influenza vaccine was licensed in
2003.12 There are currently two types of FDA approved anti-viral drugs for influenza virus. The
first type is, M-2 channel inhibitors, Amantadine and Rimantadine. The others are Neuraminidase
inhibitors Zanamivir and Oseltamivir.5
3.1.2 Classification and nomenclature

Influenza virus is part of the family orthomyxoviridae. Influenza virus can be classified
into three genus; Influenza virus A, Influenza virus B, Influenza virus C. The Influenza virus
classification is based mainly on antigenic differences.8, 10 The three main influenza virus antigens
are nuclear protein, hemagglutinin and Neuraminidase. The classification of the Influenza types
A, B and C are based on the internal proteins.10 The influenza virus A is further classified into
different strains based on the surface antigens, Hemagglutinin and Neuraminidase.5 There are three
major types of Hemagglutinin (H1, H2, H3) and two major types of Neuraminidase (N1, N2) that
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cause significant pathogenicity in humans.5,9 All the different types of influenza viruses are
characterized by a segmented negative single stranded RNA genome encapsulated in a viral capsid.
The major differences in the different viruses are given in the following Table 6. Comparison of
characteristics of Influenza Virus A, B, C.

Influenza A

Influenza B

Influenza C

Genome

8 segments

8 segments

7 segments

Structure

11 viral proteins

11 viral proteins

9 viral proteins

Host Range

Mammals, Birds and
Pigs
Both Antigenic shift
and drift

Humans and seals

Humans only

Antigenic drift only

Antigenic drift only

Causes widespread
pandemics. Highest
mortality among the
three genera. Causes
severe illness in young
and old people.

Do not cause
pandemics due to
absence of antigenic
shift. Mutations
occurring are low.
Causes illness in
very young and old
people.

Causes mild illness,
most cases are sub
clinical. Causes
illness in children

Mechanisms of
Mutations
Clinical
features

Table 6. Comparison of characteristics of Influenza Virus A, B, C
The nomenclature of the different isolated human Influenza virus strains are articulated
according to the following standardized order: 1) virus type, 2) geographic origin where it was
first isolated, 3) strain number, 4) year of isolation, and 5) virus subtype. eg: A/California/7/2009
(H1N1).8
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Figure 23. Nomenclature of Influenza virus.
3.1.3 Characteristics of Influenza virus
The influenza virus is a segmented negative polarity single stranded RNA virus from the
family orthomyxoviridae. The influenza virus is an encapsulated virus that can be both filamentous
(20 nm in diameter and 200- 3000 nm long) or spherical (80 to 120 nm in diameter). The influenza
virus isolated from clinical samples are usually filamentous or rod shaped while the viruses which
are cultured in embryonic egg or cells are spherical. It is assumed that the shape of the virus is
directly related to its transmissibility. The filamentous virions are adept at infecting adjacent cells
while the spherical ones are suitable for host transmission through aerosol.9

A
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Figure 24. Images and Structure of Influenza virus.

A. Colorized micrograph showing the spherical morphology of influenza (Image taken from
Public Health Image library (PHIL) at www.cdc.gov, Image ID- 11214, C Goldsmith and
A Balish (2009)).
B. Micrograph showing the filamentous morphology of influenza-A H1N1, (Image taken
from Public Health Image library (PHIL) at www.cdc.gov, Image ID- 7814.).
C. Anatomy of influenza virus. (Image taken from Kulkarni et al., Medicinal Chemistry
Reviews, 2010, 30, 327-393).
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The influenza virion consists of 8 segments of viral RNA. Each linear segment is made of
approximately 2000-2500 nucleotides. In total each virion consists of 14000-15000 nucleotides.9
They contain all the genetic material to produce all the viral proteins. The influenza viral RNA
segments are of negative polarity 3’-5’ and needs to be converted to the complimentary positive
polarity 5’-3’ before the genetic material can be translated to make a protein. Upon entering the
host cell the negative polarity RNA sequence is converted to the complimentary positive polarity
RNA using RNA polymerase enzyme present within the virus. These mRNA serve as a template
for the production of the different viral proteins of the influenza virus. Influenza A, B, C contains
7 linear segmented RNA sequences, which encodes for the viral proteins HA, NA, RNA
polymerase, ribonucleoprotein and M1 matrix protein. The 8th segment in influenza A encodes for
M2 ion channel protein and in influenza B encodes for NB membrane protein. The influenza virus
C only consists of 7 linear segmented RNA strands.11 The re-assortment of the influenza virus is
facilitated by the segmented genome which leads to the development of new strains through
antigenic shift. This re-assortment of the genes causes the pandemics every 20-30 years.

There are two major proteins present on the surface of the influenza virus. The
hemagglutinin (HA) and the neuraminidase (NA). Each viron contains around 300-400 HA which
are evenly distributed over the surface of the virion. There are 40-50 copies of NA which are
present as clusters over the surface of the virion.12 There are approximately 16 different types of
HA and 10 different types of NA, but only H1, H2, H3 of HA and N1, N2 are predominant among
humans.9 After every seasonal outbreak of the influenza virus these two surface proteins
accumulate point mutations (antigenic drift) so that lasting immunity to the virus can never be
achieved. Every 20 to 30 years there is a re-assortment of the genes between the different hosts of
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the influenza virus e.g humans and pigs, resulting in a completely new strain of the influenza virus
(antigenic shift) this strain is usually highly virulent and causes wide spread pandemics.14
3.1.4 Epidemic and Pandemic Spread
The influenza virus infection occurs every season during the cold and temperate climate in
every hemisphere. It affects mainly children and older individuals. The seasonal outbreaks are
caused by strains which have acquired point mutations and are able to escape the acquired
immunity from the past season. Every year it causes approximately 250,000 to 500,000 deaths
globally.1 It also causes widespread illness or pandemics with even higher mortality rates. These
pandemics are associated with the emergence of new strains, to which the population has no
immunity or pre-exposure. So, the vaccines have no effect and thus have very high mortality
rates.17 There are four recorded pandemics till date. The earliest recorded pandemic was the
Spanish Influenza A/H1N1 in 1918. Followed by the Asian flu A/H2N2 in 1957, the Hong Kong
flu A/H3N2 in 1977. The most recent one being the 2009 Mexican flu.14, 18
3.1.4.1 Antigenic drift
The influenza virus undergoes point mutations during every replication. These point
mutations accumulate and evolve into newer strains and finally it is able to escape the acquired
immunity from the pre-existing strain. These acquired mutations render the strain unrecognizable
to the T-lymphocytes and are unable to neutralize it. This is known as antigenic drift.16 The
antigenic drift causes mutations in the amino acid sequence of the surface proteins HA and NA.
The HA of the Influenza virus is mostly affected. The NA of the influenza virus is mostly
conserved.13 These point mutations occur while replication of the virus during the imprecise RNA
polymerase activity.17 Due to change of the amino acids in the HA or the NA the antibodies and
the vaccines that were developed for the older strain and previously effective are rendered futile
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against the newer strain. They need to be developed against the newer strain to be effective. The
point mutations are more predominant in the HA as compared to the NA.13 The antigenic drift is
more prevalent in influenza A than influenza B. Influenza C undergoes a minor amount of
Antigenic drift.13, 17
3.1.4.2 Antigenic Shift
The influenza virus also undergoes abrupt and vast changes in its genome resulting in a
completely new virus with a completely different HA or NA from the previous strains. The
emergence of these new strains cause pandemics as the population has no or little protection from
the virus. This type of a rapid and vast changes occurs due to re-assortment of the influenza virus
genomes between two completely different strains originating from different hosts.5, 14 The new
strain has little or no similarity to the original virus surface antigens. This antigenic shift usually
results when there is a re-assortment of genes between human and avian strains to produce a virus
strain whose surface antigens are completely new.5 H3N2 from humans and H5N1 from avian flu
after re-assortment may result in H5N2. These new strains are highly dangerous and have a high
mortality as the affected population has no previous exposure to this new strain and hence there is
no immunity for it.16 The latest pandemic in 2009 was caused when a previous triple re-assorted
virus from the pig, bird and humans underwent another re-assortment of genes with an Eurasian
pig flu strain.18 The 2009 Mexican flu spread very rapidly but the mortality rate was not as high as
previous pandemics.19
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Figure 25. Antigenic shift and drift.
(Reprinted with permission20)
Antigenic drift and Shift: Antigenic drift creates influenza viruses with slightly modified
antigens, thus the antibodies developed against the original strain become ineffective. Antigenic
shift results after the re-assortment of the genes from different strains to generate a novel strain
with surface antigens HA and NA which have little or no resemblance to the surface antigens of
the original strain.
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3.1.5 Influenza virus proteins

The influenza A virus has in total16 viral proteins. But not all the Influenza viruses have
16 proteins. The major two surface antigens are hemagglutinin HA and Neuraminidase NA. The
other viral proteins include the three different polymerases (PA, PB1 and PB2), matrix protein M1,
M2 ion channel protein, nuclear protein NP and two nonstructural proteins NS1 and NS2 and some
newly identified proteins PB1-F2, N40, PA-X, PA-N155, PAN182 and M42.19
3.1.5.1. Hemagglutinnin (HA)

The HA is one of the major surface antigens present on the surface of Influenza virus. It is
present in a trimeric form.17 It has two parts HA1 and HA2. The major function of the
hemagglutinin is receptor binding, it binds to the receptor Sialic acid present on the surface of the
host cell. It also catalyzes the fusion process with endosomal membrane, when suitably triggered
by proton binding at low pH. Another major function of the HA is that it undergoes point mutations
or variations without compromising the main functions of the antigen and can evolve to escape the
immune response. The HA is presented all over the surface of the virus and each virion contains
around 300-400 copies of the HA on its surface.5 The HA is synthesized as a precursor HAO which
is cleaved into HA1 and HA2, the active forms of the HA. HA1 part of the HA folds into a globular
domain and this contains the receptor binding site for Sialic Acid. This part of the HA is a much
conserved feature of a highly antigenically variable protein.19 The HA2 forms the stalk of the
protein that projects it outward from the surface of the virus. The transmembrane segment present
near the C-terminal end anchors the protein to the viral membrane. The N-terminal end has the
hydrophobic peptide called the fusion peptide. This fusion peptide is hidden inside the HA protein
and at lower pH due to proton binding it undergoes a major unfolding and allows the fusion peptide
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to interact with the target membrane and undergo fusion with the endosomal membrane.20 The
sialic acid utilize two types of glycolipids to enter the host cell. The avain Influenza prefers α-2,3sialic acid-galactose linkages, while the human shows preference to α -2,6 sialic acid –galactose
linkages.21, 22

Figure 26. Structure of Influenza HA.

The HA monomer (A) and trimer (B). The image was generated using Pymol and Protein Data
Bank, code 3HMG.
3.1.5.2. Neuraminidase (NA)
NA is the second major surface glycoprotein present on both Influenza A and B viruses.
NA is a tetrameric protein, that consist of four identical subunits with the molecular weight of
approximately 240kD.23 The Neuraminidase (NA) facilitates the release of the viral progeny by
cleavage of the virus-sialic acid association, prompting further infection.24 NA catalyzes the
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enzymatic cleavage of NeuAα-2-3, and NeuAα 2-6 glycosidic bonds. NA allows viral particles
to move through mucin by cleaving sialic acid from host cells, allowing the efficient spread of
influenza virus progeny from one host cell to the other host cell.12,13 NA can remove both sialic
acid from cellular glycoproteins, glycolipids, and even from both virus surface proteins. Thus,
preventing newly formed viruses from aggregating.25 If NA activity is inhibited, infection is
limited to one round of replication and viral particles are prevented from invading the upper
respiratory airway and spread to other host cell to initiate another round of infection. There is no
amplification of the virus and the infection does not spread any further. 13, 27
There are 10 serologically different subtypes of influenza NA, isolated thus far.26 Influenza
A contains (N1-N9) and one belongs to influenza B viruses (type B NA). Classification of the
subtypes are based on the interaction of NA with the antibodies. The subtypes of NA that illicit a
similar response with antibodies of the same type are classified together to the same subtype.12 The
subtypes N1 and N2 can infect humans. There are two phylogenetically and structurally distinct
groups among neuraminidase. Group-1 contains N1, N4, N5 and N8; while group-2 contains N2,
N3, N6, N7 and N9.13, 25, 28 The structure of group-2 NA of influenza A virus was used to model
and design current drugs (e.g. oseltamivir and zanamivir) using the conserved structure of the NA
active site.5
The active site analysis of neuraminidase shows that it is highly conserved. The highly
conserved nature of Neuraminidase led to it being chosen as a drug target for Influenza virus. The
conserved residues in the catalytic sites that directly bind to the substrate are: Arg118, Asp151,
Arg152, Arg224, Glu276, Arg292, Arg371, and Tyr406. The residues that support the catalytic
residues are Glu119, Arg156, Trp178, Ser179, Asp/Asn198, Ile222, Glu227, His274, Glu277,
Asn294, and Glu425.29-32 The three arginine residues, (Arg118, Arg292 and Arg371) in the active
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site of the Influenza A NA, directly bind to the substrate carboxylate group (Figure 1.5.3). Glu276
and Glu277 forms hydrogen bonds with two hydroxyl groups at carbon 8 and 9 of the NeuAc. Arg
152 interacts directly with the acetamido group of NeuAc.

29, 30

Calcium ion coordinates amino

acids near the substrate binding and it is believed to maintain substrate binding conformation.13
NA is considered an exo-glycohydrolase; it hydrolyzes terminal sialic acid (SA) residues
from glycoproteins and glycoconjugates.33 Cleavage of terminal SA initiate with the binding of SA
the active sites of NA. The stable chair conformation is forced into a less stable boat conformer
due to the highly conserved tri-arginyl cluster (Arg-118, Arg-292, and Arg-371).35 Conformational
changes facilitate the departure of aglycon residue through the formation of an oxocarbocation ion
intermediate (sialosyl cation)34,36 The sialosyl cation undergoes a nucleophilic attack to form a
glycosyl-enzyme intermediate. The glycosyl-enzyme intermediate breaks to form a sialosyl
cation, where it goes under another stereo-selective nucleophilic attack by a water molecule to
form α-Neu5aAc as the first product to release for the active site. The α-Neu5Ac product is further
isomerize into β-Neu5Ac, the more thermodynamically favored product.36
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Figure 27. Visualization of the neuraminidase structure in complex with ligands
(A) Tetramer form of N1 neuraminidase (NA). (The image was generated using Protein
Data Bank [PDB] code 2HU4)
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(B) The active site structure of NA, in complex with N-Acetylneuraminic acid (Neu5Ac).
(The image was generated using Protein Data Bank [PDB] code 2C4L)

(C) Comparison of the N1 NA active site of the wild-type and of H274Y substitution in
complex with oseltamivir. (The image was generated using Protein Data Bank [PDB] codes 2HU0
and 2HU4) Active site residues are displayed in stick form and the backbone is in ribbon form.

Figure 28. Active site structure of NA bound to Sialic Acid.
(The image was generated using Protein Data Bank [PDB] codes 2HU0 and 2HU4)
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Residues that bind to the substrate are highlighted in green. Sialic acid (NeuAc) is shown in pink.
Ca2+ binding site is close to the substrate binding site. The Ca2+ ion is shown as a yellow sphere.
Figure generated using PyMol software (Figure 28).

Figure 29. Mechanism of enzymatic cleavage by NA.
Mechanism showing the cleavage of terminal sialic acids by influenza viral
neuraminidase.36
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3.1.5.3 Influenza viral polymerase
Influenza polymerase is a heterotrimer, which is composed of three subunits call PA, PB1,
and PB2with the molecular weight of approximately 250k Da.37 All three subunits are required for
the transcription and replications of viral RNA. Each unit has a distinct role in the transcription
process. The initiation step for viral RNA transcription is where the PB2 subunit recognizes cap
structure of host pre-mRNA in the nucleus.38 The short capped oligomers (10-13 nucleotides) 39 is
cleaved by an endonuclease subunit of PA and is used to prime viral mRNA by the subunit of
PB1.40 The transcription process ends when the polymerase recognizes the polyadenylation signal,
a oglio-U sequence located near the 5’ end.38 Cusack et. al. was successful in obtaining X-ray
crystals of the complete structure of influenza A and B polymerase including PA, PB1, PB2 and
viral RNA promoter.41, 42
3.1.5.4. M2 Proton Channel
M2 protein of type A and B influenza virus are homotetrameric, type III integral membrane
proteins that are important to the life cycle of the influenza virus.43, 44 M2 proteins are responsible
for the dissociation of the viral particles to release RNA materials. At the later stage of replication,
M2 is responsible for maintaining the high pH of the trans-Golgi network to prevent premature
folding of HA. M2 works as a proton gate where they have an open and close mechanism.
Researchers believe that the open and close mechanism is based on a single trans-membrane
domain residue of tryptophan (Trp 41).43
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3.1.6 Life Cycle of Influenza Virus
The Influenza virus replication cycle is very rapid. It takes approximately 6 hours29 for the
viral replication cycle to complete and release new viral progeny to infect new cells. The
replication cycle starts with the HA binding to the receptor sialic acid on the host cell surface. The
host cell surface has N-glycans which have sialic acid. The globular part of the HA1 binds to the
sialic acid and initiates the endocytosis process of the virus. The exact mechanism for the virus
internalization process is unclear. The major pathways for the endocytosis are Clathrin-dependent
endocytosis,

caveolae-mediated,

clathrin-

and

caveolin-independent

pathway

and/or

micropinocytosis.38
After the virus is internalized the low pH within the endosomal membrane, facilitates a
conformation change in the HA2 domain of the HA. This conformation change projects the
otherwise hidden hydrophobic fusion peptide at the N-terminal end of HA2 towards the endosomal
membrane.45 This fusion peptide then binds to the endosomal membrane. After the binding is
complete the lower part of the stalk of the HA2 starts to contract bringing together the viral and
the host membranes together.47 This contraction leads to the folding of the stalk of the HA2. The
folding is complete with the fusion of the viral and the endosomal host membrane.46, 48 The low
pH inside the endosome also activates the M2 ion channel. The M2 ion channel, facilitates the
entry of protons into the virus bilayer and starts the dissociation of the viral capsid releasing the
viral RNPs, consisting of the viral genome and RNA-dependent viral RNA polymerase and the
nucleoprotein which coats the viral RNA.43 The viral genome and the RNA dependent RNA
polymerase are then imported into the host cell nucleus. Inside the nucleus RNA transcription
occurs. The polymerase acidic component of the RNA dependent RNA polymerase cleaves the
cap of a host pre-cellular m RNA and starts off the RNA replication process. This is called cap
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snatching.49 The viral genome is a negative sense RNA, which gets converted to its complementary
positive sense strand. These complementary positive sense strands are exported outside to the host
cell cytoplasm where they use the host ribosomes to produce the different viral proteins. When a
certain concentration of the viral proteins is achieved. The complimentary positive sense RNA
starts replicating inside the host nucleus to make copies of the negative sense viral genome. After
enough copies of the viral genome is produced the assembly and the nuclear export of RNP occurs.
The viral genome is packaged into RNP complexes, consisting of the viral RNA, NP and
polymerase complex.47 M1 matrix protein is responsible for export of the whole complex from the
nucleus. Simultaneously after production of the viral proteins in the host cell cytoplasm they go
into the endoplasmic reticulum to undergo proper folding, glycosylation and polymerization. The
M2 ion channel at this stage increases the pH, inside the acidic Golgi network to prevent the
activation of the fusion peptide of the HA.40
After all the viral proteins, viral capsid are packaged, the budding process is initiated by
the M1 matrix protein and M2 facilitates the cell membrane split to release the viral progeny.45, 51
After the budding out process of the viral progeny from the infected cell the sialic acid is still
bound to the HA. This HA-sialic acid association is then cleaved by NA to finally release the viral
progeny to infect other cells.47,

52

This cleavage of the sialic acid HA, completes the viral

replication cycle.
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Figure 30. Life Cycle of Influenza Virus.
3.2

Controlling the transmission of influenza viruses

Influenza virus is a lethal pathogen and therefore a number of methods have been employed
to mitigate the spread of this disease. These include proper hygiene, vaccinations, antivirals and
rapid diagnostic tests for appropriate countermeasures. In combination, these different methods
have been shown to arrest the spread of the disease, however as it mutates very rapidly, some of
these methods become in-effective within a very short span and need to be re-evaluated and
regenerated.
3.2.1 Vaccines
Influenza affects millions annually and thus the need for preventions are in high demand.
Antiviral drugs assist in treating the infected cells, and also arrest the spread of the viruses.
However, the excessive use of one kind of antiviral (Oseltamivir) has resulted in a number of
resistant virus strains.50 Annual vaccinations against the influenza virus is a good method to control
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the spread.53 Vaccination generates antibodies that mainly targets HA surface glycoproteins. As
influenza antibodies mainly recognized specific regions on the globular head of the HA surface
proteins, their efficiency relies on the similarities between the HA of the vaccines and the HA of
the currently seasonal strains. If the point mutations caused due to antigenic drift has caused the
virus to escape the acquired immunity the viruses are no longer effective.55
3.2.2 Current Anti-Influenza Drugs
There are currently two types of FDA approved antiviral drugs available against the
Influenza virus. M2 ion inhibitors and NA inhibitors.
3.2.2.1 M2 ion inhibitors
The M2 ion channel is responsible for transporting protons to facilitate the dissociation of
viral particle and the release of viral genome.56 This process is crucial for viral infections and
therefore, was among one of the first proteins targeted for production of antiviral drugs.
Amantadine and Rimantidine are FDA approved M2 ion channel inhibitor Influenza antiviral
drugs. 24 The antivirals work by direct pore-blocking mechanism.43 However, as the influenza
virus mutates, these older antiviral drugs has proven to be ineffective. Over 90% of the influenza
viral A strains has shown resistance to this class of antivirals. A more recent strain of H1N1, 2009
outbreak, have also shown to be resistant to the adamantane-based drugs.55, 56

Figure 31. Structure of M2 Inhibitors.
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Stucture of adamantane based antiviral drugs used against the influenza virus. These class of
inhibitors inhibit the M2 channel present on the influenza virus.
3.2.2.2. NA Inhibitors

FDA approved, anti-Influenza drugs Zanamivir and Oseltamivir, are based on inhibition of
Neuraminidase protein. It is possible to restrict the spread of the infection by stopping the cleavage
of the virus-sialic acid association. The restriction of the virus-sialic acid cleavage prevents the
spread of the influenza virus. 59
These antivirals are more effective as they target a more conserved NA and are less likely
to develop resistantance. Current FDA approved Zanamivir and Oseltamivir are transition state
analog inhibitors of NA. Zanamivir is a sialic acid analog (2-deoxy-α-D-Nacetylneuraminc acid)
that has a guanidine functionality at the 4th position of 2-deoxy-α-D-Nacetylneuraminc acid.
Oseltamivir© is a cyclohexene derivative that contains an amino functionality at the 4th position of
the cyclohexene ring.35 But unfortunately, Oseltamivir resistant strains have been isolated from
patients.57,58 But those strains have not yet developed resistance to Zanamivir.59, 60

Figure 32. Structures of NA inhibitors.
A)

Native sialic acid with numeric system for assigning carbon.

B)

Deoxy form of sialic acid with hydroxy group at the 4th position.
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C)

Zanamivir© is a deoxy form of sialic acid with a guanidine functional group at the

4th position.
D)

Oseltamivir© derivative of clycohexane that mimics the transition state of sialic

acid with an amino functional group on the 4th position.
Peramivir a new NA inhibitor drug was approved recently for the treatment of influenza
virus, in 2014. Peramivir (Rapiacta®, Peramiflu®, BioCryst Pharmaceuticals, Research Triangle
Park, North Carolina, USA) is among one of the drugs that was in phase III clinical trials and was
approved for used during the 2009 H1N1 influenza outbreak under the Emergency Investigational
New Drug (eIND) regulations.61 Peramivir, unlike traditional NA inhibitors, it has a unique
structure differ from known NA inhibitors. This NA inhibitor exhibits high binding affinity that
last up to 24 hours and has a slow rate of dissociation.62Premavir has been approved for the
treatment of influenza in both Japan and South Korea.61 Unlike Zanamivir and Oseltamivir,
Peramivir is administered through IV injections.

Figure 33. Structure of Permavir.
Neuraminidase inhibitor Peramivir was recently approved by the Food and Drug
Administration (FDA) in 2014.
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3.3

Detection of Influenza virus using glycan microarray

Hemagglutinnin (HA) binds to a nine carbon glycan, N-acetylneuraminic acid or sialic acid,
present on the termini of glycolipids and glycoproteins of the epithelial cells of the respiratory
tract.53-54 This is followed by cell entry and infection of the host cell. After utilizing the host cell
machinery for virus propagation, the progeny escapes the host cell to infect neighboring cells and
tissues. Interestingly, sialic acid present on the infected host cell prevents the viral progeny from
escaping. Mucins containing sialic acid also inhibit the virus from propagating.55 Neuraminidase
(NA), an enzyme cleaves sialic acid on the infected host cell and mucins are freeing viral progeny
to infect other cells. We choose to target these glycoproteins for three reasons. (i) They are vital
proteins of the virus and require sialic acids to bind. (ii) There are approximately 300-400 copies
of HA and 50-100 copies of NA on a single viral particle. Hemagglutinnin (HA) exists as a trimer
and NA as a tetramer, and a large number of copies on a single virion provides an adequate amount
of protein targets for synthetic or natural sialic acids to capture.56-57 (iii) This receptor-based
approach is unique in comparison to antibody-based diagnostics. All strains of the influenza virus
are expected to bind to sialic acid analogs and each strain would yield a “fingerprint” pattern of
recognition that can be used to detect the virus.58-59 In previous studies, we developed microarrays
comprised on synthetic sialic acid analogs that could bind to HA and/or NA. After exposure of the
focused microarray to different virus strains, a fluorescently labeled antibody was used as the
readout.58-59 (Figure 34A) These studies were important to establish proof of principle that sialic
acid analogs could be used to detect influenza viruses; however, a limitation of the studies was
that antibody based reporters were required. Following a report by Wong and coworkers,60 we
report the synthesis, characterization and initial binding studies of an “universal” glycan based
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reporter molecule that could bind to all virus strains. Since the capture and reporter molecules are
made of glycans, antibodies are not required. (Figure 34 B)
A

B

Figure 34. Sandwich ELISA assay for detection of Influenza virus.

A. Cartoon representation of the sandwich assay using glycans as capture and labeled antibody as
reporters. B. Cartoon representation of the sandwich assay using glycans as capture and
biotinylated glycan-labeled streptavidin as reporters
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Figure 35. Structures of the four glycans immobilized on glass slides for capturing influenza virus.
3.4

Results

The design and synthesis of the universal reporter is shown in Scheme 5 and it follows our
previous publications.58 We choose to use Zanamivir analogs as the glycan headgroups as the
binding affinity of Zanamivir to NA is in the nanomolar range. The active site of influenza NA is
also highly conserved and furthermore, resistance to Zanamivir is not as high as Oseltamivir. In
fact, very few cases of Zanamivir resistance has been reported.61 We also choose to develop a
dimeric scaffold as dimers improve the avidity effect dimers; 62we designed the molecule such that
the two Zanamivir analogs moieties fit into two active sites of a NA tetramer or two adjacent NA
tetramers.63 We attached biotin at the opposite end of the scaffold because biotin can bind to
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fluorescently labeled avidin yielding our desired reporter. The final construct is expected to
possess eight zanamivir analogs moieties as one avidin binds to four biotin molecules. The azido
compound 1 and the scaffold 2 were synthesized as described previously. 1,3 Dipolar
cycloaddition64 reaction under standard conditions was performed to yield the biotinylated bivalent
compound. Deprotection of the tert-butyloxycarbonyl and methyl ester groups resulted in the
desired reporter molecule AD-R in 60% yield. This compound was purified using size exclusion
Biogel P2 columns to yield a foamy solid. All intermediates and the final compound were
characterized using NMR and mass spectroscopies.
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Scheme 5 Synthesis of the Reporter molecule.
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Reagents and conditions: a) H+ resin, MeOH, rt, overnight 99%. b) Ac2O, py, rt,
overnight, 99%. c)TMSOTf, EtOAc (anhydrous), 500C, 3h. d) TMSN3, t-BuOH, reflux, overnight,
60% (over two steps). e) PPh3, THF: H2O (1:1), rt, 4h, 60%. f) Boc2O, Et3N, THF, cat DMAP, rt,
overnight, 90%. g) NaOMe, MeOH, rt, 2 h , h) H+ resin, CH3COCH3, rt, 5 h, 80% (over two steps).
i) 4-nitrophenylchloroformate, py, DMAP, rt, 16h, 80%. j) 6-azidohex-1-amine, NEt3, DCM,
(pH=8.5), rt, overnight, 70%. k) DCM: TFA (1:1), rt, 2h, 1,3-Bis(tert-butoxycarbonyl)-2-methyl2thiopseudourea, HgCl2, NEt3, DCM, rt, overnight, 50%. l) t-BuOH: H2O (7:3), CuSO4, Lascorbate, rt, 12h, 70%. m)TFA: DCM (1:1), rt, 1 h, NaOMe, MeOH, rt, 1 h, 60% (over two steps)

Next, we used the biotinylated compound as a reporter in microarray studies. We printed
four bivalent compounds on glass slides for these exploratory studies. 58-59 (Figure 35) These
compounds have been shown in our previous studies to capture different strains of influenza
viruses. 58 After incubating with Influenza A H1N1, A/Brisbane/59/2007 virus at rt for 1 hour, the
slides were washed extensively, and exposed to AD-R. This step was followed by extensive
washing and addition of labeled streptavidin. While we choose a two step procedure of adding the
biotinylated compound followed by the labeled streptavidin, an alternate method of premixing the
avidin with the biotin could also be used with the caveat that the latter method requires purification
of the avidin-biotin complex. The slides were scanned using a Genepix400B scanner at 557 nm. It
was gratifying to observe that all four printed compounds capture the virus when the labeled
streptavidin-AD-R conjugate is used as the reporter; non-specific binding to PEG is negligible.
(Figure 36) The increase in Relative Fluorescence Units (RFU) from background is not as high in
comparison with antibody based reporters, 58 presumably because we are using capture and reporter
ligands that primarily bind to NA. The number of NAs on a single virion is not as high as the
number of HAs. 56-57 Secondly, NAs have been shown to be present in clusters or scattered on the
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virus surface, 56-57 which may limit the number of available sites for the reporter to bind when the
virus is captured by the glycans on the glass slides. This may lead to a lower RFU. We plan to
develop the use of ligands that capture HA, which should give us a higher RFU. We also

% Relative Fluorescence Intensity

determined the limit of detection of this virus to be 104 PFU (plaque forming units).
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Figure 36. Influenza virus (A/Brisbane/59/2007) binding studies.
Fluorescence detection of H1N1 (A/Brisbane/59/2007) influenza A virus using synthetic
glycans as capture and biotinylated glycan-label streptavidin as reporter. Glycans and PEG
(negative control) were printed at 200 μM. Virus concentration was 105 PFU. Fluorescence
intensity was measured by the Genepix400B scanner using tetramethylrhodamine (TRITC) labeled
streptavidin and scanned at 557 nm. All experiments were performed in triplicate (*p<0.05,
**p<0.01, ***p<0.001, ns>0.05)
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3.5

Experimental section

3.5.1 General
All reagents and solvents were reagent grade or were purified by standard methods before
use. All reactions were performed under argon with solvents dried using a solvent purification
system (Innovative Technology). All chemical reagents were of analytical grade, used as supplied
without further purification unless indicated. Tetramethylrhodamine (TRITC) labeled streptavidin
was purchased from Thermo Scientific as a lyophilized powder. Compounds AD1-4 were
synthesized as described previously.58 The acidic ion exchange resin used was Amberlite® IR 120
(H+) resin. Analytical thin layer chromatography (TLC) was performed on silica gel 230-400 mesh
(Sicicycle). Plates were visualized under UV light, and/or by staining with acidic CeH8Mo3N2O12
followed by heating. Column chromatography was performed on silica gel (230-400 mesh). 1H
and

13

C NMR spectra were recorded on Bruker 400MHz spectrometer. Chemical shifts are

reported in δ (ppm) units using 13C and residual 1H signals from deuterated solvents as references.
Spectra were analyzed with MestreNova® (Mestrelab Research). Electrospray ionization mass
spectra were recorded on a Micromass Q \T 2 (Waters) and data were analyzed with MassLynx®
4.0 (Waters) software. Reported yields refer to spectroscopically and chromatographically pure
compounds that were dried under high vacuum (10–2 mbar) before analytical characterization,
unless otherwise specified.
3.5.2 Synthesis and Characterization
(1S,2R)-1-((1R,2S,3S)-2-acetamido-3,5-diacetoxy-5-(methoxycarbonyl)cyclohexyl)propane1,2,3-triyl triacetate (2).
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Compound 1 (10.0 g, 32 mmol) was dissolved in 300.0 mL of methanol and 1.0 g of H+
DOWEX 50WX8-200 ion-exchange resin was added. The reaction mixture allowed to stir
overnight. The resin was filtered, and the filtrate was concentrated under reduced pressure to give
a white solid (10.2 g, 99% yield). The white solid was dried under vacuum. The dried solid (10.0
g, 31 mmol) was dissolved in 300 mL of anhydrous pyridine, acetic anhydride was added dropwise
(35 ml) at 0oC. Reaction mixture was allowed to stir overnight. The reaction mixture was washed
with excess of 1.0 M hydrochloric acid solution and extracted with DCM (50ml, 3x), organic layers
were collected and further washed with saturated NaHCO3, extracted with DCM, dried over
Na2SO4 and concentrated under reduced pressure to yield a white foam 2 (16.5g, 99% yield). NMR
obtained was similar to the literature.
(1S,2R)-1-((2R,4S)-3-acetamido-4-azido-6-(methoxycarbonyl)-3,4-dihydro-2Hpyran-2-yl)propane-1,2,3-triyl triacetate (3).

To a solution of compound 2 (11.0 g, 20 mmol) in anhydrous EtOAc at 50oC, TMSOTf
(11ml, 61 mmol) was added dropwise. The reaction mixture was allowed to stir at 50oC for 3 h.
The reaction was washed with saturated NaHCO3 solution, in small portions (50 ml, 3x). Organic
layers were collected and dried with Na2SO4 and concentrated under reduced pressure, to give a
solid (8g, 75% yield). The solid was dried under reduced pressure and used immediately for the
successive reaction without purification. The resulting solid (7g, 16 mmol) was dissolved in 50
mL of t-BuOH, TMSN3 (3ml, 26 mmol) was added dropwise and allowed to stir overnight at 800
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C. The reaction mixture was concentrated under reduced pressure. The crude product was purified
using column chromatography with n-hexane: acetone (2:1) to yield a pale golden solid (5.4g, 60%
overall yield for 2 steps).
1H

NMR (400 MHz, CDCl3): δ ppm 6.21 (d, J = 8.8 Hz, 1H), 5.97 (s, 1H), 5.47 (d, J =

2.0 Hz, 1H), 5.32 (s, 1H), 4.67 (d, J = 12.4 Hz,1H), 4.50 (d, J = 10 Hz, 1H), 4.42 (d, J = 8.8 Hz,
1H), 4.20 (dd, J = 6.4, 12.2 Hz, 2H), 3.81 (s, 3H), 2.13 (s, 3H), 2.06 (s, 3H), 2.05 (s, 3H), 2.00 (s,
3H).
5-Acetylamino-4- N-tert-butyloxycarbonyl-6- (1,2,3-triacetoxy-propyl) -5,6-dihydro4H-pyran-2-carboxylic acid methyl ester (4).

Compound 3 (5g, 10 mmol) was dissolved in a mixture of THF: H2O (5ml, 1:1), PPh3
(4.3g, 16 mmol) was added and reaction was allowed to stir at 400C for 12 hours. Tetrahydrofuran
(THF) was removed under reduced pressure and the crude product was purified by column
chromatography to obtain the intermediate amine as an oil. The purified amine intermediate was
immediately used for the subsequent reaction. To the amine intermediate (2.3g, 0.53 mmol) in
THF (10.0 ml), Et3N (1.86 ml 13 mmol ), was added and the reaction mixture was allowed to stir
for 30 min at rt. Boc2O (4.0 g, 18 mmol) was added and the reaction was allowed to stir for 12 h
at rt. THF was removed under reduced pressure and the crude was washed with HCl (1M, 50 ml),
extracted with DCM (50 ml 3X). The organic layers were combined and washed with NaHCO3
solution and dried over Na2SO4. Product was purified by column chromatography with hexane:
acetone (3:1), to yield a white solid. (3.18g, 60% yield over two steps).
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1H

NMR (400 MHz, CDCl3): δ 6.46 (d, J = 9.0 Hz, 1H), 5.94 (s, 1H), 5.43 (s, 1H), 5.27

(s, 1H), 4.63 (d, J = 12.4 Hz, 1H), 4.44 (d, J = 10.0 Hz, 1H), 4.35 (d, J = 8.9 Hz, 1H), 4.15 (dd, J
= 12.3, 7.1 Hz, 1H), 3.95 (d, J = 9.2 Hz, 1H), 3.77 (s, 3H), 2.14 (s, 9H), 2.10 (s, 3H), 2.03 (s,
3H), 2.02 (s, 3H), 1.95 (s, 3H).
13C

NMR (100 MHz, CDCl3): δ 170.9, 170.6, 170.3, 170.0, 161.8, 156.2, 144.6, 111.0,

80.2, 71.4, 67.8, 62.2, 60.4, 52.4, 50.1, 47.3, 28.2, 23.1, 21.0, 20.9, 20.8.
HRMS(ESI): Calculated for C20H32N2O9: 444.2108; Found: 445.2180 (M+H).

5-Acetylamino-4-N-tert-butyloxycarbonyl-6- [(2,2-dimethyl-[1,3] dioxolan-4-yl)- (4nitro-phenoxycarbonyloxy)-methyl]-5,6-dihydro-4H-pyran-2-carboxylic acid methyl ester
(5).

The compound 4 (0.6g, 1.3 mmol) was dissolved in MeOH and NaOMe (0.05 eq) was
added and the reaction was allowed to stir at rt for 2h. The reaction was monitored by TLC. After
completion the reaction mixture was neutralized with H+ DOWEX 50WX8-200 ion-exchange
resin to pH 7. The resin was filtered, and the filtrate was concentrated and dried under reduced
pressure to give a colorless solid. The dried solid was then dissolved in dry acetone and the H+
resin was added to the reaction mixture to adjust the pH to 4. The reaction mixture was stirred
overnight at rt. The reaction was filtered and then the filtrate was washed with saturated NaHCO3
solution and extracted with DCM (20 ml, 3X). The organic phases were combined and dried over
Na2SO4. The crude product was purified by column chromatography with hexane: acetone (4:1)
to give a white solid. The solid (0.5 g, 0.11 mmol) was then dissolved in pyridine (10 ml) and
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DMAP (0.68g, 0.56 mmol) was added. The reaction mixture was allowed to stir at rt for 30 min.
4-nitrochloroformate (0.7g, 3.3 mmol) was added to the reaction mixture and it was allowed to stir
for 16 h at rt. The reaction was monitored by TLC and upon completion, the reaction mixture was
washed with HCl (1M, 30 ml) and extracted with DCM (30 ml, 3X). The combined organic layers
were washed with saturated NaHCO3 and dried over Na2SO4. The crude was purified by column
chromatography with hexane: acetone (3:1) to give 5 (0.4 g, 60% overall yield for 2 steps).
1H

NMR (400 MHz, CDCl3): δ 8.27 (d, J = 8.9 Hz, 2H), 7.50 (d, J = 8.9 Hz, 2H), 5.97 (d,

J = 9.6 Hz, 1H), 5.90 (s, 1H), 5.31 (t, J = 5.7 Hz, 1H), 4.81 (d, J = 9.6 Hz, 1H), 4.54 (t, J = 9.7 Hz,
1H), 4.47 – 4.29 (m, 2H), 4.24 (dd, J = 8.9, 5.7 Hz, 2H), 4.17 – 4.05 (m, 1H), 3.79 (s, 3H), 1.95
(s, 3H), 1.42 (s, 9H), 1.41 (s, 3H), 1.38 (s, 3H).
13C

NMR (100 MHz, CDCl3): δ 171.3, 161.6, 156.4, 155.7, 152.5, 145.6, 144.8, 125.2,

122.3, 110.5, 108.9, 80.6, 75.1, 74.2, 65.5, 52.5, 49.5, 48.1, 28.2, 26.4, 25.5, 23.2.
HRMS(ESI): Calculated for C27H35N3O13: 609.2170; Found: 632.2057 (M+Na).
5-Acetylamino-4-N-tert-butyloxycarbonyl-6-[(6-azido-hexylcarbamoyloxy) -(2,2-dimethyl[1,3] dioxolan-4-yl)-methyl]-5,6-dihydro-4H-pyran-2-carboxylic acid methyl ester (6).

To a solution of 6-azidohex-1-amine (0.55g, 0.39 mmol) in CH3CN (20 ml), Et3N (0.4 ml,
0.29 mmol) was added and the reaction mixture was allowed to stir for 30 min at rt. Solution of 5
(0.6 g, 0.98 mmol) in CH3CN was added to the reaction mixture and stirred at rt for 3h. The reaction
was monitored by TLC. Upon completion CH3CN was removed under reduced pressure and the
crude was washed with HCl (1M, 30 ml) and extracted with DCM (30 ml, 3X). The organic layers
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were collected and washed with saturated NaHCO3 solution and dried over Na2SO4. The product
was purified by column chromatography with hexane: EtOAc (1:1) to give 6 (0.42g, 70%).
1H

NMR (400 MHz, CDCl3): δ 6.15 (d, J = 9.4 Hz, 1H), 5.90 (s, 1H), 5.24 (d, J = 3.7 Hz,

1H), 5.01 – 4.83 (m, 2H), 4.51 (t, J = 8.9 Hz, 1H), 4.33 (dd, J = 13.6, 7.8 Hz, 2H), 4.19 – 4.04 (m,
2H), 4.04 – 3.92 (m, 2H), 3.76 (s, 3H), 3.73(s, 1H) 3.24 (t, J = 6.9 Hz, 2H), 3.11 (m, 2H), 1.93 (s,
3H), 1.66 – 1.53 (m, 2H), 1.48 (m, 2H), 1.41 (m, 2H), 1.39 (s, 9H), 1.34(s, 3H), 1.23(s, 3H).
13C

NMR (100 MHz, CDCl3): δ 170.8, 162.1, 156.2, 155.5, 144.4, 111.4, 108.9, 80.1,

74.9, 69.7, 65.9, 52.4, 51.3, 50.0, 47.6, 41.1, 29.6, 28.7, 28.3, 26.4, 26.3, 25.4, 23.2.
HRMS(ESI): Calculated for C27H44N6O10: 612.3119; Found: 635.3006 (M+Na).

5-Acetylamino-4-[2,3-bis(tert-butoxycarbonyl)guanidine]-6-[(6-azido-hexyl
carbamoyloxy)-2,3 dihydroxy propyl]-5,6-dihydro-4H-pyran-2-carboxylic acid methyl ester
(7).

To a solution of compound 6 (0.1g, 0.16 mmol) in DCM (3.0 ml), TFA (3.0 ml) was added.
The reaction mixture was stirred at rt for 1 h. DCM was removed, and the crude product was dried
under reduced pressure. The dried compound was dissolved in DCM and Et3N (68 µl, 0.48 mmol)
was added. The solution was stirred at rt for 30 min. HgCl2 (0.06g, 0.24 mmol) and 1,3-Bis(tertbutoxycarbonyl)-2-methyl-2-thiopseudourea (0.07g, 0.24 mmol) was added. The reaction mixture
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was allowed to stir at rt for 12 h. The reaction was monitored by TLC. Upon completion the
reaction mixture was washed with HCl (1M, 25ml) and extracted with DCM (20 ml, 3X). The
organic layers were collected and washed with saturated NaHCO3 and dried over Na2SO4. The
product was purified by column chromatography with DCM: MeOH (25:1) to give the product 7
(0.058g, 50%).
1H

NMR (400 MHz, CDCl3): δ 11.40 (s, 1H), 8.54 (d, J = 8.7 Hz, 1H), 7.39 (s, 1H), 7.28

(s, 1H), 6.85 (s, 1H), 5.89 (s, 1H), 5.32 (s, 1H), 5.20 (t, J = 9.5 Hz, 1H), 5.03 (t, J = 5.7 Hz, 1H),
4.82 (d, J = 9.4 Hz, 1H), 4.49 (d, J = 10.5 Hz, 1H), 4.37 (m, 1H), 4.14 (dd, J = 14.2, 7.1 Hz, 1H),
4.05 (d, J = 9.2 Hz, 1H), 3.80 (s, 3H), 3.68 (m, 1H), 3.27 (t, J = 6.8 Hz, 2H), 3.17 (m, 2H), 1.95
(d, J = 10.0 Hz, 3H), 1.60 (dd, J = 13.8, 6.8 Hz, 2H), 1.50 (s, 18H), 1.38 (m, 4H), 1.27 (dd, J =
7.7, 6.5 Hz, 2H).
13C

NMR (100 MHz, CDCl3): δ 171.0, 162.8, 162.4, 162.2, 162.1, 157.1, 152.5, 144.9,

110.5, 83.7, 79.7, 69.4, 68.7, 62.4, 53.5, 52.31, 51.26, 49.4, 47.1, 45.7, 41.2, 29.4, S-14 28.7, 28.3,
28.2, 28.1, 27.9, 26.3, 26.2, 22.7.
HRMS(ESI): Calculated for C30H50N8O12: 714.3548; Found: 715.3627 (M+H).

136

Compound 3: 7 (0.03g, 0.05 mmol) was dissolved in t-BuOH/ H2O (1.0 ml, 7:3) and 8
(0.01g, 0.02 mmol) were added. CuSO4 (0.004g, 4.6 mg, 0.03 mmol) and sodium L-ascorbate
(0.007g, 7.3 mg, 0.02 mmol) was added to the reaction mixture and stirred at rt for 12 h. Reaction
was monitored by TLC. Upon completion, solvent was removed under reduced pressure and
product was purified by column chromatography with DCM: MeOH (10:1) to yield 3 (0.06g, 60%
yield).
1H

NMR (400 MHz, CDCl3): δ 11.40 (s, 2H), 8.62 (S, 1H), 8.62 (s,1H), 8.48 (d, J = 4.0

Hz, 2H), 8.20 (s, 1H), 8.05 (s, 1H), 7.80 (s, 1H), 7.39 (s, 2H), 6.90 (s, 1H), 6.52 (m, 3H), 5.90 (s,
2H), 5.42-5.33 (m, 3H), 5.14 (s, 1H), 5.10-5.08 (m, 1H), 5.02-4.99 (m, 1H), 4.75-4.51 (m, 9H),
4.38- 4.22 (m, 10H), 4.03-4.01 (m, 3H), 3.77 (s, 6H), 3.70-3.66 (m, 3H), 3.58-3.50 (m, 3H), 3.37
(s, 1H), 3.20-3.05 (m, 6H), 2.99-2.84 (m, 5H), 2.33-2.15 (m, 16 H), 1.92-1.78 (m, 10H), 1.66-1.59
(m, 8H), 1.47 (s, 18H), 1.27 (s, 18H).
13C

NMR (101 MHz, CDCl3): δ 170.9, 166.9, 164.2, 164.2, 163.0, 162.5, 156.9, 152.6, 144.9,

139.4, 122.9, 110.6, 100.1, 83.6, 79.6, 73.9, 73.0, 71.7, 69.9, 68.6, 62.6, 60.4, 55.9, 52.5, 50.1,
46.9, 31.9, 29.7, 29.7, 29.8, 29.6, 29.4, 29.1, 28.9, 28.3, 28.0, 25.6, 25.6, 25.5, 22.9, 22.7, 14.1,
1.0.
HRMS (ESI): Calculated for C91H140N22O29S: 2038.29; Found: 1020.00 (m/z; m = M+2H; z=2).
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AD-R: 3 (0.01g, 0.004 mmol) was dissolved in DCM: TFA (1ml, 1:1) and stirred at rt for 1 h. The
reaction mixture was neutralized with H+ DOWEX 50WX8-200 ion-exchange resin to pH 7. The
resin was filtered and washed with MeOH and the product was concentrated under reduced
pressure. The solid was re-dissolved in MeOH and NaOH (50 mM, 1 ml) was added and the
reaction mixture was allowed to stir at rt for 2 h. The reaction was neutralized to pH 7 with H+
DOWEX 50WX8-200 ion-exchange resin. The resin was filtered, and the product was purified
with Bio-Gel P-2 Gel with DI water to give AD-R (0.005g, 5.2 mg, yield 80%).
1H

NMR (400 MHz, D2O): δ 7.91-7.85 (m, 5H), 5.55-5.51 (m, 2H), 4.79-4.77 (m, 4H),

4.57 (s, 3H), 4.41-4.40 (m, 1H), 4.39 (d, J = 8Hz, 1H), 4.36-4.35 (m, 1H), 4.31-4.28 (m, 5H),
4.03-3.90 (m, 4H), 3.61 (s, 3H), 3.54-3.44 (m, 3H), 3.36-3.34 (m, 1H), 3.08-2.99 (m,3H), 2.882.86 (m, 3H), 2.63 (s, 1H), 2.30-2.26 (m, 2H), 2.12-2.06 (m, 2H), 2.01-1.99 (m, 1H) 1.90 (s, 1H),
1.84 (s, 6H), 1.77-1.73 (m, 2H), 1.67-1.64 (m, 2H), 1.55-1.53 (m, 2H), 1.48-1.45 (m, 2H), 1.391.37 (m, 2H), 1.31-1.29 (m, 4H), 1.23-1.20 (m, 6H), 1.15-1.12 (m, 6H), 0.80-0.78 (m,2H).
13C

NMR (100 MHz, D2O): 175.8, 171.2, 168.4, 163.5, 163.2, 162.9, 156.2, 135.8, 134.9,

129.3, 123.9, 122.5, 115.3, 110.0, 104.8, 100.0, 78.7, 75.2, 71.9, 69.6, 68.5, 62.5, 51.8, 50.0,47.3,
35.0, 29.1, 28.4, 28.0, 27.8, 27.5, 26.0, 25.6, 25.1, 21.8, 20.0.
HRMS (ESI): Calculated for C69H104N22O21S: 1609.7639; Found: 1610.7600 (M+H).
3.5.3 Biological Assays
A. Immobilization of Glycans: Synthetic glycans were covalently immobilized onto
Nexterion NHS slides using a DIGILAB OmniGrid Micro printer in 300 mM phosphate buffer
with 0.005% Tween-20 at pH 8.5.[58] Each glycan was printed 20 times in quintuplicate at 200
μM concentration. Following printing, the glycans were allowed to react for 30 min at 60%
humidity. After overnight desiccation, the slides were blocked for 60 min with 50 mM
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ethanolamine in 50 mM boric acid buffer (pH 9.5), washed 3 times with deionized (DI) water,
dried and stored at −20 °C.
B. Binding studies: A serial 10-fold dilution of A/Brisbane/59/2007, starting with a
concentration of 2.4 X 106 plaque forming units (PFU) was prepared in a buffer consisting of PBS,
2% BSA and 0.05% Tween-20. 200 μL of this solution was applied to the microarray for 60 min.
Following virus incubation and wash (three times with PBS and 0.05% Tween-20 and two times
with PBS), 200 μL of 20 mM of AD-Reporter was applied to the microarray for 60 min in the
same buffer. TRITC labelled streptavidin (1mg) was re-suspended into 1 ml of the buffer. A
20,000-fold dilution of the fluorescently labelled streptavidin was applied to the microarray after
the slides were washed as extensively and incubated for 60 min. The slides were washed as
described followed by a rinse with DI water (three times). The slides were dried and scanned using
GenePix4000B scanner at a wavelength of 557 nm. All experiments were performed in triplicate.
3.6

Discussion

Influenza virus affect millions worldwide annually. Therefore, it has been extensively studied and
still being studied for more effective diagnostics and treatments. It is well known that influenza
viruses has several surface proteins that are good targets for therapeutics. The adamantane based
antiviral drugs, which block M2 protons pump proteins have been rendered inadequate in the
recent years. The viruses mutated and have shown total resistance to these adamantine based drugs
for both influenza A and B viruses. The NA inhibitors, as a result of overuse of Oseltamivir,
several strains of Oseltamivir resistant influenza virus has been isolated. Thus, there is a need for
both effective and less resistant antivirals. Surveillances of influenza viruses are required for a
more effective treatment and arrest the spread of this deadly disease. However, detections methods
currently on the market haveom poor sensitivity and low accuracy. The gold standard for influenza
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detections are PCR which require expensive requirement and lab expertise. The limitation for the
PCR is the lack of availability of specific primers and probes and the inability to use this method
in low resourse setting. Methods of detection involving cell cultures require long turnaround time
(4-7 days) and cannot differentiate types of influenza viruses. Therefore, it is not useful for doctors
to use as a diagnostic methodology to prescribe anti-viral medications. Antiviral medications have
an effectiveness window of 24-48 hours after onset of infection, therefore diagnostic tools must
have fast turnaround times with accurate diagnosis that can be used by doctors to prescribe
medications. Thus, there is an urgent need to develop both diagnostic tools which are highly
accurate and time sensitive along with antiviral drugs which are effective and less likely to develop
antiviral resistance.
3.7

Summary

In summary, we have synthesized a biotinylated bivalent Zanamivir analog for the specific
capture of influenza viruses. We used this molecule as a reporter in our microarray studies and
demonstrated that this compound could be used as a reporter in a sandwich assay with an influenza
A H1N1 virus strain. While we used it as a reporter in our assay, the biotinylated molecule could
be used as probes to capture influenza viruses as the biotin can readily be attached to streptavidin
coated magnetic beads,65 nanoparticles66 or surfaces.62 This technology will become very useful
to detect high volume of samples in less amount of time.
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CHAPTER 4
* Most of the work described in this chapter will be published in a manuscript that in under
preparation.
Das, A., Dinh, H., Howard, J, H., Iyer, S. Electrochemical monitoring of Thrombin, Factor VIII,
and Factor Xa using repurposed glucose meters. (Manuscript under preparation)
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4

TOWARDS POC DETECTION OF THROMBIN
4.1

Introduction

Detection of pathogens in bodily fluids using glucose meters has always been challenging due to
the high background interference from glucose. To overcome this problem, as described in chapter
2 we have devised new strips which can detect paracetamol in the presence of high background
glucose. Using this method, we have successfully detected pathogens in blood and urine. Building
on these results we wanted to detect thrombin in blood. Thrombin is a very important enzyme of
hemostasis and is essential for blood coagulation.1
4.2

Blood coagulation cascade

The blood coagulation occurs through two pathways, the extrinsic and intrinsic pathway.
The intrinsic pathway is activated when blood reaches the sub-endothelial connective tissues due
to tissue damage. Quantitatively it produces or activates more thrombin of the two pathways but
acts much slower compared to the extrinsic pathway. The Factor XII (Hageman factor), Factor XI,
prekallikrein, and High molecular weight kininogen (HMWK) are involved in this pathway of
activation.2-5
Activation leads to the cleavage of the native Hageman factor into two subunits (50 and 28
KDa). The smaller subunit forms the activated Hageman factor (factor XIIa). Once triggered this
pathway is self-amplifying. This factor XIIa then activates prekallikrein to kallikrein. This
kallikrein further activates the activation of factor XII to factor XIIa. Presence of Ca2+ ions is
essential for this step. HMWK, binds to factor XI and aids in the coagulation cascade.
The common pathway starts with the formation of Factor X. Factor X is formed by the
complex of molecules consisting of activated factor IX, factor VIII, calcium, and phospholipid.
The factor X is also synthesized from the extrinsic pathway.5
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The extrinsic pathway activated instantaneously in response to injury and produces
activated factor X in seconds compared to an intrinsic pathway which requires minutes. The
primary function of the extrinsic pathway is to augment the intrinsic pathway as mentioned earlier
the intrinsic pathway is self amplifying once triggered, so the extrinsic pathway helps in triggering
the intrinsic pathway. Once there is an injury to the endothelium, tissue factor is released. The
activated tissue factor then binds to factor VII. This complex containing the activated tissue factor,
factor VII, calcium and phospholipid forms the activated factor X.6
Activated factor X then converts the prothrombin to Thrombin. The thrombin then converts
the soluble fibrinogen to insoluble fibrin and ultimately together with aggregated platelets forms a
clot. This is known as the common pathway.6

Figure 37. Coagulation cascade.
Reprinted with permission6
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4.3

Background on Thrombin

Thrombin or blood coagulation factor IIa, is a serine protease that is encoded by the F2
gene and plays a pivotal role in the blood clotting cascade to promote hemostasis following an
injury to the endothelium.7 The word Thrombin comes from the greek word thrombus meaning
clot. Thrombin is synthesized by the liver as inactive zymogen prothrombin in the blood.
Prothrombin or coagulation factor II is proteolytically cleaved to form the active enzyme thrombin
only at the site of vascular injury following an upstream activation of the coagulation pathway.
Prothrombin is activated by Factor Xa, Factor V, phospholipid, and calcium to form the thrombin
enzyme, which in turn converts the soluble plasma glycoprotein, fibrinogen, to insoluble fibrin,
forming the clot.1-2 Thrombin in the presence of calcium activates factor XIII, which promotes the
cross-linking of fibrin polymers. The cross-linked fibrin then acts a hemostatic plug to stop blood
loss. The thrombin plays the crucial role in the coagulation cascade by activating the platelets,
Factor V, Factor VIII and also by the conversion of fibrinogen to fibrin. At the site of vascular
damage, the coagulation cascade is activated by the binding of tissue factor (TF) to factor VII. The
complex of TF-FVIIa initiates a complex cascade reaction which leads to the formation of
prothrombinase complex consisting of FVa, FXa, calcium and phospholipid ions, which aid to the
proteolytic cleavage of prothrombin to release Thrombin.8-10

151

Figure 38. Active and Inactive forms of Thrombin generated using PDB.
The inactive form of the protein is depicted on the left. To generate the active form of the
protein the strand between the yellow and the red strands must be cleaved. After this cleavage, the
two ends separate and undergoes relaxation and produces the active form of the enzyme depicted
on the right. In the active form, the key catalytic residue containing the serine amino acid (bright
red depicts the oxygen atom of serine) is facing outwards unlike the inactive form.
4.4

Drugs to modulate coagulation

Anti-coagulant drugs are used to maintain the balance between hemostasis and bleeding.
The targets of anti-coagulants are mainly the different clotting factors in the coagulation cascade
they were first introduced in 1930. Heparin was the first anticoagulant to be approved by FDA.11
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The anticoagulant drugs can be classified as follows:

Figure 39. Classification of anti-coagulants along with FDA approval times in parenthesis.11-13
The oldest anti-coagulants in clinical use are the heparins, [unfractionated heparin (UFH)
and low molecular weight heparin (LMWH)] and vitamin K antagonists (VKA) like warfarin. The
heparins are parenteral or injectables while warfarin is an oral anticoagulant. Unfractionated
heparin catalyzes the inhibition of Thrombin by the natural anti-coagulant antithrombin (AT). By
catalyzing AT, it inhibits the activation of FIXa, FXa, FXIa, FXIIa along with Thrombin. The
LMWH heparins inhibit FXa to a greater extent than thrombin. VKA inactivates the vitamin K
dependent coagulation factors II, VII, IX, and X. they also inhibit the activation of anticoagulants
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protein C and S.9 The drug targets for the classical anti-coagulants (heparins and VKAs )are
depicted in the following Figure 40.

Figure 40. Drug targets of the classical anti-coagulants Heparin and Vitamin-K antagonists.
Reprinted with permission9
Recently, a new class of direct oral anticoagulants (DOAC) were approved by FDA; these
include the direct thrombin or direct Factor Xa inhibitors. In 2010, Dabigatran a direct thrombin
inhibitor, (Pradaxa, Boehringer Ingelheim), and in 2011, rivaroxaban, direct factor Xa inhibitor
(Xarelto, Johnson and Johnson, and Bayer Healthcare AG) were approved. Followed by, apixaban
(Eliquis, Bristol-Meyers Squibb and Pfizer Inc) in 2012 and edoxaban (Savaysa/Lixiana, Daiichi
Sankyo) in 2015. Both apixaban and edoxaban are direct factor Xa inhibitors. These directly inhibit
the function of thrombin, thereby preventing the formation of fibrin and activation of platelets.16
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These oral anticoagulants are much easier to take than the injectables like heparin and has
proven to be safer than oral warfarin with fewer bleeding episodes and as of 2016, the DOAC
prescriptions exceeded than those of warfarin.33

DOAC

Dabigatran

Mechanism

Direct Thrombin
inhibitor

Rivaroxaban Factor Xa inhibitor
Apixaban
Factor Xa inhibitor
Edoxaban

Factor Xa inhibitor

Typical
doses
110, 150, 75
mg
2.5, 5 mg
10, 15, 20
mg
30, 60 mg

Renal
HalfElimination
life
(%)
(h)
80
12-14

Reversal agent

25
33

8-15
9-13

Idarucizumab 5g
dose (dose can
be repeated)
Andexanet.alfa
Andexanet.alfa

35

8-10

No

Table 7. Summary of new DOACC and their doses and available reversal agents.12
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Figure 41. FDA approved direct oral anti-coagulant drugs (DOAC).

These new age DOAC cannot be monitored using the routine coagulation assays like
prothrombin time (PT) and activated thromboplastin time (aPTT). There are no FDA approved
methods to reliably monitor the DOACs. 33-34
Unlike the widely available reversal agents for heparin (Protamine), warfarin (4-factor
PCC) there is currently only one FDA approved reversal agent for Dabigatran (Idarucizumab) and
for the reversal agents for FXa, Andexanet.alfa (Andexxa) was recently approved by FDA in May
2018, while another reversal agent for FXa, Ciraparantag is still under clinical trials.33
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Thus, there is a huge need to monitor the level of thrombin in blood for the people who are
prescribed with these new age anti-coagulants.
4.5

Need for monitoring oral-anti-coagulants

Thrombin plays an important part in the coagulation pathway. It is related to a number of
blood clotting disorders. Some of these disorders are hereditary like hemophilia, von Willebrand
disease, etc. and other cardiovascular diseases like Deep Vein Thrombosis, arteriosclerosis,
hemorrhage etc.4,9 Thrombin enzyme is a key component in thrombus formation, and maintains
the finer balance in coagulation, anticoagulation and fibrinolysis. Anti-thrombotic treatment relies
on the prevention of thrombosis while maintaining hemostasis.7 It is very critical to maintain this
balance otherwise there is a very high risk of either bleeding out or formation of clots that can
cause thrombosis or embolism. Thrombin generation is dramatically reduced in patients with
bleeding tendencies, while it is increased in patients with risk of venous thromboembolism. It is
therefore used as a marker for deep vein thrombosis. Thrombin inhibitors like warfarin etc. are
used to treat and prevent various diseases such as venous thrombosis and stroke. Excessive
thrombin production can also lead to Disseminated intravascular coagulation (DIC). This causes
the formation of huge lumps of clot throughout the body, resulting in depletion of clotting factors
and platelets. This leads to bleeding in other areas, and the body is overwhelmed and is unable to
stop the bleeding.6,8
Some of these anti-coagulant drugs have very high renal elimination rates. Dabigatran has
a renal elimination rate of 80%.33 This issue is further aggravated with patients with kidney failure,
as they are taking these drugs and they are eliminated in the whole dose, making it very difficult
to measure the amount of active drug in blood. Since there are no FDA approved ways to detect
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the level of drug in blood coupled with the failure of PT and aPTT time to correctly detect the level
of these DOAC drugs, it becomes essential to detect the amount of thrombin in blood.

Figure 42. Anti-coagulation therapy.
4.6

Current detection methods of Thrombin

Thrombin is undoubtedly a pivotal component in multiple disease conditions as the enzyme
directly affects blood circulation. Therefore, the ability to monitor thrombin activity in whole
blood and in real time will allow researchers to elucidate the relationship between the thrombin
and disease further. Current platforms to detect Coagulation activity Current methods to assess
thrombin levels and coagulation activity include prothrombin time (PT), activated partial
thromboplastin time (PTT), thrombin clotting time (TCT), bleeding time, platelet count, platelet
function testing, aptamer-based assays, immunoassays.15-18 The prothrombin time assay strictly
looks at the extrinsic and common pathways of coagulation. Blood is drawn into a vacuum tube
loaded with citrate (1:9 anticoagulant: blood), which chelates to the calcium ions in the sample.
The blood is then centrifuged to separate the plasma from the red blood cells.1,2,12, 24 Excess
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amounts of calcium is introduced into the plasma sample to help in coagulation. Tissue factor II is
added and the clotting time is measured optically. The prothrombin time (PT) falls within a range
of 10-13 seconds.10,24 The activated partial thromboplastin time (aPTT) assay strictly evaluates the
intrinsic and common pathways of coagulation. Again, the blood sample is drawn into a vacuum
tube loaded with citrate (1:9 anticoagulant: blood) phospholipids, silica activator, and calcium,
which activates the intrinsic pathway. Thrombus formation time is then measured. In the presence
of coagulation factors, I, II, V, VIII, IX, X, XI, and XII will normal PTT times range from 25 to
39 seconds.24

Figure 43. Mechanism for measuring prothrombin time (PT) and activated partial
thromboplastin time (aPTT).
Reprinted with permission 12
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Prothrombin time (PT)
Normal

Activated Partial Thromboplastin time
(aPTT)

11-13 seconds

25-30 seconds

Table 8. Detection methods of coagulation.3
4.7

Chromogenic/Fluorogenic substrates for detection of Thrombin

There are several other chromogenic and fluorogenic substrates for direct detection of
Thrombin. There are several chromogenic substrates that are available. These substrates contain a
specific peptide sequence attached to o-nitrophenol (chromogenic) or resorufin (fluorogenic). The
thrombin cleaves the peptide to release either, a chromogenic substrate o-nitrophenol (absorbs at
405nm)11, or fluorogenic substrates like resorufin (Eex/Eem=573-582 nm)12 and 7-Amino-4-methyl
coumarin (AMC) (Eex/Eem=480-550 nm)23 to indicate the presence of Thrombin. Several substrates
that currently used for the detection of Thrombin are given in Table 8.
But these assays are qualitative in nature and does not quantify the amount of Thrombin present
in the blood. Detection using chromogenic substrates is difficult because of the dark color of blood
which makes it difficult to observe any color change. The fluorogenic substrate requires a
fluorescent reader. Thus, the test can no longer be done at home or in a POC setting. Thus, there
is a huge unmet need for quantitative detection of Thrombin in a POC setting. We were interested
in developing an electrochemical assay that would use existing, ubiquitous glucose meters for the
rapid detection of protease activity. Amperometric approaches are not subject to visual change in
color but detect electron released upon oxidation of the electroactive substance (glucose,
paracetamol, catechol, etc.). The use of glucose meters is very attractive for point of care
diagnostics because glucose meters meet the ASSURED (Affordable, Sensitive, Selective, User-
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friendly, Rapid and robust, Equipment free and Deliverable to end users) guidelines, established
by the World Health Organization. Glucose meters are very affordable as the meters are a onetime
cost and the disposable strips are inexpensive.
We thus devised the use of substrates that can be detected using a glucose meter. Out of the
substrates available in the market we choose the tripeptide sequence with the highest Kcat/Km
value (Entry-6, Table-8) and then coupled it with catechol. Catechol is absent in blood and can
be detected with glucose meters in blood with a high background interference of glucose,
(demonstrated in Chapter-2) making it the perfect candidate for detection of thrombin using
glucose meters.

Entry

Substrate

Km(mM)

Kcat (S-1)

Kcat/Km(S-1/mM)
X 10-3

1

Fibrinogen11
(Natural substrate for FIIa)

0.012

71

6.5

2

Phe-Pip-Arg-pNA
(Chromogenic substrate S-2238)

0.007

180

26

3

PyroGlu-Pro-Arg-pNA
(Chromogenic substrate S-2366)

0.15

330

2.2

4

H-β-Ala-Gly-Arg-pNA
(marketed by Siemens healthcare)

1.95

1.91

0.98

5

Gly-Gly-Arg-AMC
(marketed by Technoclone)

0.31

1.86

6

6

H-D-Phe-Pro-Arg-Resorufin12

0.001

29

29

Table 9. Commercially available substrates for Thrombin or Factor IIa.11,21-22
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Figure 44. Strategy for detection of thrombin using chromogenic/Fluorogenic substrates.
4.8

Strategy to detection of Thrombin (FIIa)

The Factor IIa and Factor Xa are both serine proteases, and they cleave the substrate at specific
sites to convert the zymogen to the activated form.10 We have designed a tripeptide sequence that
can be cleaved by the Factor IIa to release a unit of catechol that can be detected using a glucose
meter. Successful probes for biomolecular applications need to fulfill several requirements:
increase in cleavage efficiency, upon reaction with the enzyme, efficiency, and stability. We chose
the model of a self-cleavable linker as a spacer between peptide substrate and the catechol.
Katzenellenbogen reported for the first time the prodrug linker p-aminobenzyl alcohol (PABA).19
The use of the spacer PABA made is very easy to conjugate peptides to catechol. The spacer is
also beneficial to prevent steric hindrance around the cleavage site. We synthesized the prodruginspired substrate for thrombin (D-Phe-Pro-Arg-PABA-catechol) and will evaluate their
effectiveness in the presence of thrombin (Figure 45). The synthesis of the building block 6,
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started from NHFmoc-D-Arg (Pbf)- OH (Scheme 6). It coupled to PABA under standard
conditions, affording the benzylic alcohol 2 in almost quantitative yield. The bromination of the
alcohol was carried out by the PBr3 under CH2Cl2 conditions to produce 3, which was then coupled
to catechol to give the first building block. As shown in Scheme 6, the synthesis of the second
building block started with the coupling of NHFmoc-D-Phe-OH with H-Pro-OMe to provide the
methyl ester 6 in good yield. The ester was hydrolyzed in THF/H2O mixture with AcOH under
refluxing conditions, providing the free dipeptide 8 in good yield. The coupling of dipeptide 8 and
building block 6 worked better with HATU as activator than with other agents. The reaction
afforded better yields, and the product could be easily isolated from the byproducts. The Pbf and
Fmoc deprotection with TFA/DCM mixture and C18 silica chromatography afforded D-Phe-ProArg-PABA-catechol as TFA in good yields.

Figure 45. Design strategy for the substrate for detection of Thrombin.
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Scheme 6 Synthesis of Phe-Pro-Arg-PABA -catechol
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Phe-Pro-Arg-PABA-catechol

Scheme 6 Synthesis of Phe-Pro-Arg-PABA-catechol
Reagents and conditions: a) p-amino-benzyl alcohol, HATU, DIEPA, DMF 00C, 12 h, 78% b)
PBr3, CH2Cl2, 00C, 45 mins. c) 4, K2CO3, Acetone, 12 h, rt, 68% (two steps). d )20% Piperidene,
DMF, 00C, 45 mins, 85% e) HATU, DIEPA, DMF, 00C, 12 h, 71% f) TFA:DCM (1:2), 00C, 2 h,
87% g) HATU, DIEPA, DMF 00C, 12 h, 65% h) i)20% Piperidine, DMF, 00C, 45 mins ii)TFA
(92.5%) Isopropyl silane (2.5%) H2O (5%),00C, 3h iii) NaOMe, MeOH, rt, 2h (72%, over three
steps).

165

4.9

Experimental section

4.9.1 General
All reagents and solvents were reagent grade or were purified by standard methods before
use. All reactions were performed under argon with solvents dried using a solvent purification
system (Innovative Technology). All chemical reagents were of analytical grade, used as supplied
without further purification unless indicated. The acidic ion exchange resin used was Amberlite®
IR 120 (H+) resin. Analytical thin layer chromatography (TLC) was performed on silica gel 230400 mesh (Sicicycle). Plates were visualized under UV light, and/or by staining with acidic
CeH8Mo3N2O12 followed by heating. Column chromatography was performed on silica gel (230400 mesh). 1H and 13C NMR spectra were recorded on Bruker 400MHz spectrometer. Chemical
shifts are reported in δ (ppm) units using 13C and residual 1H signals from deuterated solvents as
references. Spectra were analyzed with MestreNova® (Mestrelab Research). Electrospray
ionization mass spectra were recorded on a Micromass Q \T 2 (Waters) and data were analyzed
with MassLynx® 4.0 (Waters) software. Reported yields refer to spectroscopically and
chromatographically pure compounds that were dried under high vacuum (10–2 mbar) before
analytical characterization unless otherwise specified.
4.9.2 Synthesis and Characterization
Compound 2:

Add 1 (400 mg, 0.66 mmoles) and HATU (300mg, 0.78 mmoles) and dissolve in 10 ml of DMF
(dry) at 00C and stir for 30 mins. Next add B (76 mg, 0.66 mmoles) to the above mixture and then

166

add DIEPA (0.128 ml, 0.74 mmoles) dropwise. The reaction mixture was allowed to stir at room
temperature for 12 h. DMF is removed under reduced pressure and then the compound is purified
by column chromatography. Pure compound 3(388mg, 78%) elutes at hex: EA (10: 90).
1H

NMR (CDCl3, 400 MHz): δ 1H NMR (400 MHz, CDCl3) δ 7.72 (d, J = 6.8 Hz, 2H), 7.51 (d,

J = 10.9 Hz, 4H), 7.34 (s, 2H), 7.18 (d, J = 8.1 Hz, 4H), 6.19 (s, 3H), 4.54 (s, 2H), 4.33 (d, J = 5.8
Hz, 2H), 3.18 (d, J = 5.1 Hz, 2H), 2.87 (s, 2H), 2.56 (s, 3H), 2.48 (s, 3H), 2.07 (s, 3H), 2.04 (s,
2H), 1.85 (s, 1H), 1.66 (s, 2H), 1.54 (s, 1H), 1.41 (s, 4H).
Compound 7:

Add C (200 mg, 0.30 mmoles) and HATU (136 mg, 0.36 mmoles) and dissolve in 10 ml of DMF
(dry) at 00C and stir for 30 mins. Next add C (62 mg, 0.36 mmoles) to the above mixture and then
add DIEPA (0.26ml, 1.5 mmoles) dropwise. The reaction mixture was allowed to stir at room
temperature for 12 h. DMF is removed under reduced pressure and then the compound is purified
by column chromatography. Pure compound 7 (170 mg, 74%) elutes at hex: EA (30: 70).
1H

NMR (CDCl3, 400 MHz): δ 1H NMR (400 MHz, D2O) δ 7.89 – 7.86 (m, 1H), 7.52 (s, 2H),

7.35 (s, 2H), 7.15 (s, 4H), 5.78 (s, 2H), 5.49 (s, 2H), 4.16 (s, 3H), 3.88 – 3.80 (m, 1H), 3.56 (s,
2H), 2.68 (d, J = 22.5 Hz, 3H), 2.35 (s, 2H), 2.29 (s, 3H), 1.85 (s, 3H), 1.22 (s, 9H), 0.58 (s, 7H).
Compound 8

Compound 7 (120 mg, 0.14 mmoles) was dissolved in 20 ml of a mixture of DCM: TFA (2:1) at
00C. The reaction was allowed to stir for 2h. TLC was done to check completion of the reaction.
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After completion, the reaction was concentrated under reduced pressure and dried under vacuum.
The compound 8 was used in the next step without purification.
Compound 5

Dissolve 2 (130mg, 0.17 moles) in 10 ml of DCM (dry) and add PBr3 (0.008ml, 0.08mmoles) at
00C. The reaction mixture was allowed to stir for 45 mins. Then TLC was checked to determine
the completion of reaction. After completion, the reaction was concentrated under reduced
pressure and dried under vacuum. The compound 3 was then dissolved in 20 ml of acetone dry
(with CaCl2) and then K2CO3 (141 mg, 1.0 mmoles) (dried in oven overnight) was added and then
allowed to stir for 30 minutes. Next 4 (46 mg, 0.20 mmoles) was added to the reaction mixture.
TBAI (5.4 mg, 0.017 mmoles) was added and the reaction was allowed to stir overnight at room
temperature. The reaction mixture was filtered to remove K2CO3 and then concentrated under
reduced pressure and then the compound is purified by column chromatography. Pure compound
elutes at hex: EA (20: 80) to give 5 (84 mg, 52%).

1H

NMR (400 MHz, CDCl3) δ 7.75 (d, J = 7.4 Hz, 2H), 7.61 (dd, J = 29.3, 7.7 Hz, 4H), 7.40 –

7.32 (m, 3H), 7.25 (s, 4H), 6.91 – 6.75 (m, 5H), 6.24 (s, 2H), 6.07 (d, J = 7.5 Hz, 1H), 5.14 (s,
1H), 4.98 (s, 2H), 4.38 (d, J = 6.9 Hz, 2H), 4.20 – 4.11 (m, 1H), 3.37 (s, 2H), 2.91 (s, 2H), 2.59 (s,
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3H), 2.51 (s, 3H), 2.07 (s, 3H), 1.96 (s, 1H), 1.73 (s, 3H), 1.63 (s, 1H), 1.44 (s, 6H), 0.97 (s, 9H),
0.11 (s, 6H).
Compound 6

Compound 5 (150mg, 0.16 mmoles) was dissolved in 10 ml of DMF and 20% Piperidene in DMF
was added to it at 00C and reaction mixture was allowed to stir for 45 minutes. TLC was done to
check completion of the reaction. After completion, the reaction was concentrated under reduced
pressure and dried under vacuum to give crude 6(100mg, 89%). The compound 6 was used in the
next step without purification.
Compound 8:

Add 7(100 mg, 0.26 mmoles) and HATU (117mg, 0.30 mmoles) and dissolve in 10 ml of DMF
(dry) at 00C and stir for 30 mins. Next add C (50 mg, 0.30 mmoles) to the above mixture and then
add DIEPA (0.08 ml, 0.64 mmoles) dropwise. The reaction mixture was allowed to stir at room
temperature for 12 h. DMF is removed under reduced pressure and then the compound is purified
by column chromatography. Pure compound 3(91 mg, 71%) elutes at DCM: MeOH (90: 10).

169

1H

NMR (400 MHz, CDCl3) δ 7.78 (s, 1H), 7.57 (d, J = 8.7 Hz, 2H), 7.40 (d, J = 7.3 Hz, 2H),

7.36 – 7.31 (m, 6H), 6.02 (d, J = 8.7 Hz, 1H), 4.79 (d, J = 8.6 Hz, 1H), 4.58 – 4.50 (m, 1H), 4.41
– 4.10 (m, 4H), 3.78 (s, 4H), 3.31 – 3.14 (m, 2H), 3.05 (dd, J = 13.7, 6.6 Hz, 1H), 2.20 – 2.10 (m,
1H), 1.93 (dd, J = 10.1, 4.6 Hz, 4H), 1.29 (d, J = 7.2 Hz, 1H).
Compound 9

Compound 8 (120 mg, 0.14 mmoles) was dissolved in 10 ml of a mixture of 10% HCl in ACN and
refluxed for 5h at 750C. TLC was done to check completion of the reaction. After completion, the
reaction was concentrated under reduced pressure and dried under vacuum. The compound 9 was
used in the next step without purification.
Compound 10

Add 9 (80mg, 0.14 mmoles) and HATU (67 mg, 0.17mmoles) and dissolve in 10 ml of DMF (dry)
at 00C and stir for 30 mins. Next add 6 (70mg, 0.18 mmoles) to the above mixture and then add
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DIEPA (3 eq) dropwise. The reaction mixture was allowed to stir at room temperature for 12 h.
DMF is removed under reduced pressure and then the compound is purified by column
chromatography. Pure compound elutes at DCM: MeOH (90:10) to give 10 (35mg, 65%).
NMR (400 MHz, CDCl3) δ 7.75 (d, J = 7.4 Hz, 2H), 7.61 (dd, J = 29.3, 7.7 Hz, 4H), 7.40 – 7.32
(m, 3H), 7.25 (s, 4H), 6.91 – 6.75 (m, 5H), 5.93 (s, 2H), 5.80 (d, J = 7.5 Hz, 1H), 5.02 (s, 1H),
4.85 (s, 2H), 4.38 (d, J = 6.9 Hz, 2H), 4.20 – 4.11 (m, 1H), 3.37 (s, 2H), 2.91 (s, 2H), 2.59 (s, 3H),
2.51 (s, 3H), 2.07 (s, 6H), 1.80 (m, 3H), 1.73 (s, 3H), 1.63 (s, 1H), 1.48 (s, 6H), 0.97 (s, 9H), 0.13
(s, 6H).
Phe-Pro-Arg-PABA-catechol:

Compound 10: (15 mg, 0.02 mmoles) was dissolved in 10 ml of DMF and 20% Piperidene
in DMF was added to it at 00C and reaction mixture was allowed to stir for 45 minutes. TLC was
done to check completion of the reaction. After completion, the reaction was concentrated under
reduced pressure and dried under vacuum. The compound was used in the next step without
purification. The dried compound was dissolved in a mixture of 5 ml of TFA: Isopropyl silane:
H2O (92.5: 2.5:5) and allowed to stir at 00C for 3h. TLC was done to check completion of the
reaction. After completion, the reaction was concentrated under reduced pressure and dried under
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vacuum. The compound was used in the next step without purification. The dried compound was
then dissolved in MeOH (dry) and then NaOMe (0.5 eq) was added to it at room temperature and
reaction mixture was allowed to stir for 2h. TLC was done to check completion of the reaction.
The compound was purified using HPLC to get pure compound 10 (5mg, 65%).
1H

NMR (400 MHz, MeOD) δ 8.00 (s, 1H), 7.91 (d, J = 7.6 Hz, 2H), 7.74 (dd, J = 5.6, 3.0 Hz,

3H), 7.64 (dd, J = 5.7, 3.3 Hz, 2H), 7.50 (d, J = 7.3 Hz, 2H), 7.44 (t, J = 7.1 Hz, 2H), 6.76 (dd, J
= 5.8, 3.6 Hz, 1H), 6.66 (dd, J = 5.9, 3.6 Hz, 1H), 4.51 (t, J = 5.2 Hz, 1H), 4.27 – 4.20 (m, 3H),
3.85 (d, J = 5.5 Hz, 2H), 3.66 (d, J = 3.0 Hz, 2H), 3.15 (d, J = 5.7 Hz, 7H), 3.01 (s, 2H), 2.88 (s,
2H), 1.80 (d, J = 5.4 Hz, 8H), 1.72 (d, J = 4.8 Hz, 5H), 0.94 – 0.90 (m, 11H).
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HPLC purification:
HPLC elution. The elution solvents were pumped through the column at a flow rate of 1.5
ml/min using a Waters X Bridge Prep C18 5um column. Solution A was H20/0.1% TFA, solution
B was CH3 CN/ 0.1% TFA at a max pressure of 400 mbar. Before each HPLC run the column was
equilibrated with water containing 0.1% TFA (H20/0.1% TFA) at a flow rate of 1.5 ml/min until
the absorbance of the column effluent was constant, which usually took -30 min. The compound
was eluted at a gradient where the starting polarity is 100% A to 95% B in 15 mins. The desired
compound elutes at 11mins. At the end of each HPLC run, the column was flushed for 15 min with
100% acetonitrile to remove any residual TFA. The column was then stored in 100% acetonitrile.

Phe-Pro-Arg-PABA-catechol

Figure 46. HPLC trace for Phe-Pro-Arg-PABA-Catechol.
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4.10 Summary and Future work
In summary, we identified a need for the detection of thrombin in point of care setting and
have successfully designed and synthesized and characterized a substrate for Thrombin detection.
This substrate can be used to directly detect and quantify the amount of thrombin in blood using a
repurposed glucose meter in a POC setting. Using this approach, it would be possible to monitor
and accurately detect the level of thrombin in blood and modulate the level of anti-coagulants
prescribed to a patient. For the new direct oral anti-coagulant (DOAC), there are currently no FDA
approved test to regulate and monitor the level of drugs prescribed. Future work on this project
will be towards developing assays that can be used to monitor the levels of these DOAC drugs
using the synthesized substrate in a POC setting.
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APPENDICES
Appendix A. NMR spectra
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Appendix B. Raw data from biological assays
Plaque Assays:
Dilution of viruses (pfu/ml):

10-4

10-5

10-6
Plaques formed by the virus

Figure 47. Plaque Assay for Influenza virus A/Brisbane/57/2009.
The assay was done in duplicate. Each well consisted of 4.5X 106 cells and the cells were
seeded 24 h prior to performing the assay to obtain around 80% cell confluency. Each cell was
then treated with 450 µL of viral culture with different dilutions (10-4, 10-5, 10-6 pfu/ml of virus)
for an hour with shaking every 15 mins. After an hour of incubation with the virus, each well was
washed twice and then media supplemented with 0.2ug/ml of TPCK treated Trypsin was added
and the cells were allowed to grow for 3 days before checking for plaques.
The number of plaques was calculated using the following formulae
Pfu/ml= (no of plaques/ d x V)
Where, d= dilution of virus
V=volume of diluted virus added to each well.
After the plaque assay for Influenza virus A/Brisbane/57/2009 strain, the pfu/ml was calculated
using the above formula as pfu/ml=1.207 X 107
The titer values of the different Influenza viral strain obtained from Plaque assays.
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Catalogue Influenza
No
Virus
NR-15268 A/New York/18/2009
NR-3177 A/Aichi/2/1968
NR-21667 A/New Jersey/8/76
NR-12283 A/Brisbane/10/2007
NR-13658 A/California/04/2009
NR-41800 A/Wisconsin/67/2005
NR-31657 A/Brisbane/59/2007
NR-3223 A/Texas/36/91
NR-12281 A/Solomon Islands/03/2006

Strain
H1N1
H3N2
H1N1
H3N2
H1N1
H3N2
H1N1
H1N1
H1N1

(pfu/ml)
1.5 X 10^8
1.8 X 10^8
2.5 X 10^7
6.75 X 10^7
1.2 X 10^7
1.5 X 10^7
7.0 X 10^7
2.5 X 10^7
6.5X 10^6

Growth curves for E. coli:

E.coli Growth curve

1.20
1.00

OD600

0.80
0.60
0.40
0.20
0.00
0

5

10

15

20

25

Time (h)
E.coli growth curve:
Time (h) OD600
1
0.11
4
0.1623
8
0.43
12
0.812
16
0.92
24
0.987

AVG
STDEV
0.121
0.1155 0.007778
0.164 0.16315 0.001202
0.443
0.4365 0.009192
0.83
0.821 0.012728
0.939
0.9295 0.013435
0.989
0.988 0.001414

The E. coli B (ATCC 11303) samples were grown in Luria-Bertani (LB) broth for 24 h at 370C,
supplemented with a final concentration of 1 mM isopropyl β -D-thiogalactopyranoside (IPTG)
for the induction of β-galactosidase enzyme. The OD values were taken every 4 hours to get the
growth curve for E.coli. The cells were harvested by centrifuging them at 2500 rpm for 5 min
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and re-suspended in sterile PBS buffer. 1% Triton was added to the E. coli cells to lyse and
release the β - galactosidase enzyme.
Limit of detection of E. coli. with GP; All assays were done in triplicates.
E.coli
time-15 min
pfu/ml Glucose Meter
Average
Reading
Glucose
(Triplicates)
Meter
p valuer
Reading
STD
control
10^5
97,98,89 94.66667 37.66667
4.932883
57
10^4
76,79,73
76
19 0.008668
3
10^3
65,68,67 66.66667 9.666667 0.017565 1.527525
10^2
62,61,63
62
5 0.015902
1
10^1
57,60,61 59.33333 2.333333 0.143248 2.081666
10^0
57,59,58
58
1 0.393854
1
E.coli
time-30 min
pfu/ml Glucose Meter
Average
ReadingGlucose
(Triplicates)
Meter
p valuer
Reading
STD
control
10^5
101,105,103
103
46
2
57
10^4
83,86,89
86
29 0.002163
3
10^3
67,72,73
70.66667 13.66667 0.003847 3.21455
10^2
66,62,63 63.66667 6.666667 0.042153 2.081666
10^1
64,60,61 61.66667 4.666667 0.304559 2.081666
10^0
59,61,60
60
3 0.303342
1
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Detection of A/Aichi/2/1968 and S. pneumoniae with SP(OMe)2 and SP respectively.
Detection of 10^4 pfu/ ml Aichi (A/2/1968/H3N2)
Glucose Meter Reading
Time(mins)Average ( Δ Glucose Standard
Meter Reading
Dev
0 59.66667 2.666667 1.154701
15 66.66667 9.666667 1.527525
30 69.66667 12.66667 2.081666
60 77.33333 20.33333 0.57735

Detection of S. pneumonia 10^6 CFU/ml
Glucose Meter Reading
Time(mins)Average ( Δ Glucose Standard
Meter Reading
Dev
0 137.6667
0 2.081666
15
139 1.333333
3
30
138 0.333333
2
60
140 2.333333
2

\
Limit of detection of A/Aichi/2/1968 strain with SP(OMe)2; All the assays were done in
triplicates.
Aichi/2/1968
15 mins
pfu/ml
10^4
10^3
10^2
10^1
10^0

Glucose Meter
p value
Reading
Glucose
(Triplicates)
Meter
Average
Reading
Δ STD
glucose meter
control
66,67,68
67
10
1.5
57
64,63,64
0.0137
63
6
1.0
62,61,62
0.0132
62
5
0.6
62,61,61
0.5185
62
5
0.6
61,61,64
0.5813
62
5
1.7

pfu/ml
10^4
10^3
10^2
10^1
10^0

time-30 min
Glucose Meter
p value
Reading
Glucose
(Triplicates)
Meter
Average
Reading
Δ STD
glucose meter
control
77,78,77
77
20
0.6
57
68,71,68 0.008536
69
12
2.1
63,62,63 0.01625
63
6
0.6
61,60,63
0.2667
61
4
1.5
61,60,59
0.2846
60
3
1.0
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Limit of detection of A/Solomon Islands/3/2006 strain with SP(OMe)2; All the assays were
done in triplicates
Solomon Islands
time-15 min
pfu/ml Glucose Meter
p value
Reading
Glucose
(Triplicates)
Meter
Average
Reading
Δ STD
glucose meter
control
10^6
95, 90, 94
93
36 2.645751
57
10^5
84,88,88 0.036288 86.66667 29.66667 2.309401
10^4
80,84,83 0.073918
81
24 1.732051
10^3
77,69,73 0.036967 79.66667 22.66667 0.57735
10^2
63,64,62 0.042455 69.66667 12.66667 2.081666
10^1
60,61,63 0.200173 68.33333 11.33333 1.527525
10^0
57,60,65 0.809315
67
10
1
concentration of Virus
time-30 min
pfu/ml Glucose Meter
p-value
Reading
Glucose
(Triplicates)
Meter
Average
Reading
Δ STD
glucose meter
control
10^6
100, 102,98
100
43
2
57
10^5
86,89,88 0.001412 87.66667 30.66667 1.527525
10^4
83,84,83 0.027122 83.33333 26.33333 0.57735
10^3
75,73,77 0.013255 81.33333 24.33333 2.309401
10^2
70,66,72 0.064171
75
18
2
10^1
61,63,65 0.048108 71.66667 14.66667 1.154701
10^0
64,61,60 0.468594
70
13
1
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